TRANSGENIC PLANTS CO-EXPRESSING A FUNCTIONAL HUMAN 2-5A SYSTEM

Abstract: Novel transgenic plants having the ability to express a functional 2-5A system, i.e., a 2-5A synthetase which produces 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A) in response to double-stranded RNA (dsRNA), and a 2-5A-dependent (RNase L), are disclosed. The novel transgenic plants expressing the functional 2-5A system, such as novel transgenic tobacco plants, are immune to and resistant against viral infection. When the novel transgenic tobacco plants are exposed to three different types of plant viruses, i.e., TMV, TEV and AIMV, such viral exposure leads to necrotic local lesions in such transgenic tobacco plants instead of typical systemic infections.

Description: TRANSGENIC PLANTS CO-EXPRESSING A FUNCTIONAL HUMAN 2-5A SYSTEM Related Applications This application for U.S. patent is a continuation-in-part of U.S. patent application Serial No. 08/198,973 filed on February 18, 1994, which is a continuation-in-part of U.S. patent application Serial No. 08/028,086 filed on March 8, 1993. Field of the Invention The present invention relates to isolated 2- 5A-dependent RNases having the ability to bind 2-5A and/or cleave single stranded RNA when bound to 2-5A, encoding sequences therefor, recombinant nucleotide molecules, recombinant vectors, recombinant cells, antiviral transgenic plants which express, for example, antiviral animal amino acid sequences which have activity similar or identical to 2-5A-dependent RNase, 2-5A synthetase and/or PKR, and antiviral transgenic tobacco plants which show resistance to, for example, the tobacco etch virus (TEV) , the tobacco mosaic virus (TMV) and the alfalfa mosaic virus (AIMV.) . Backσround Control of RNA degradation is a critical cell function, and gene expression is often regulated at the level of RNA stability. See, e.g., Sha, G. and Kamen R. , Cell. 46:659-667 (1986). Nevertheless, relatively little is known about the biochemical pathways that mediate RNA degradation in mammalian or plant systems. For instance, most if not all of the ribonucleases responsible for mRNA turnover in mammalian or plant cells remain unidentified. This was reviewed in Brawerman, G. , Cell. 57:9-10 (1989). Presently, the 2-5A system is believed to be the only well-characterized RNA degradation pathway from higher animals including man. See FIG. 1. See also, e.g., Kerr, I.M. and Brown, R.E. , Prod. Natl. Acad. Sci. USA. 75:256-260 (1978) and Cayley, P.J. et al.: Biophvs Res. Commun.. 108:1243-1250 (1982)^ reviewed in Sen, G.C. and Lengyel, P., J. Biol. Chem.. 267:5017-5020 (1992). The activity of the 2-5A system is believed to be mediated by an endoribonuclease known as 2-5A- dependent RNase. See Clemens, M.J. and Williams, B.R.G., Cell. 13:565-572 (1978). 2-5A-dependent RNase is a unique enzyme in that it requires 2-5A, unusual oligoadenylates with 2' ,5' phosphodiester linkages, p n (A2'p) n A, for ribonuclease activity. See Kerr, I.M. and Brown, R.E., Prod. Natl. Acad. Sci. USA. 75:256-260 (1978). 2-5A is produced from ATP by -a family of synthetases in reactions requiring double-stranded RNA (dsRNA) . See FIG. 1. See also Hovanessian, A.G. et al., Nature. 256:537-539 (1977); Marie, I. and Hovanessian, A.G., J. Bio. Chem.. 267:9933-9939 (1992). 2-5A is unstable in cells and in cell-free systems due to the combined action of 2' ,5'-phosphodiesterase and 5'-phosphatase. See Williams, B.R.G. et al.; Eur. J. Biochem.. 92:455-562 (1978); and Johnson, M.I. and Hearl, W.G., J. Biol. Chem.. 262:8377-8382 (1987). The interaction of 2-5A-dependent RNase and 2-5A(K d = 4 x 10"" M) , Silverman, R.H. et al., Biol. Chem.. 263:7336- 7341 (1988), is highly specific. See Knight, M. et al., Nature. 288:189-192 (1980). 2-5A-dependent RNase is believed to have no detectable RNase activity until it is converted to its active state by binding to 2-5A. See Silverman, R.H., Anal. Biochem.. 144:450-460 (1985). Activated 2-5A-dependent RNase cleaves single-stranded regions of RNA 3' of UpNp, with preference for UU and UA sequences. See Wreschner, D.H. et al., Nature, 289:414-417 (1981a); and Floyd-Smith, G. et al., Science. 212:1020-1032 (1981). Analysis of inactive 2- 5A-dependent RNase from mouse liver revealed it to be a single polypeptide of approximately 80 kDa. See Silverman, R.H. et al., Biol. Chem.. 263:7336-7341 (1988). Although full scope and biological significance of the 2-5A system remains unknown, studies on the molecular mechanisms of interferon action have provided at least some of the functions. Interferons , or Y are believed to induce the accumulation of both 2-5A-dependent RNase, Jacobsen, H. et al., Virology. 125:496-501 (1983A) and Floyd-Smith, G. , J Cellular Biochem.. 38:12-21 (1988), and 2-5A synthetases, Hovanessian, A.G. et al., Nature, 268:537- 539 (1977), reviewed in Sen, G.C. and Lengyel, P., J. Biol. Chem.. 267:5017-5020 (1992). Furthermore, several investigations have implicated the 2-5A system in the mechanism by which interferon inhibits the replication of picornaviruses. Indeed, 2-5A per se and highly specific 2-5A mediated rRNA cleavage products were induced in interferon-treated, encephalomyocarditis virus (EMCV)-infected cells. See Williams, B.R.G., ature, 282:582-586 (1979); Wreschner, D.H. et al., Nucleic Acids Res.. 9ιl571-1581 (1981b); and Silverman, R.H. et al., Eur. J. Biochem.. 124:131-138 (1982a). In addition, expression of 2-5A synthetase cDNA inhibited the replication of picornaviruses, Chebath, J. , Nature. 330:587-588 (1987) and Rysiecki, E.F. et al., J ^ Interferon Res.. 9:649-657 (1989), and the introduction of a 2-5A analogue inhibitor of 2-5A-dependent RNase into cells reduced the interferon-mediated inhibition of EMCV replication. See Watling, D. et al., EMBO J.. 4:431-436 (1985). Further, 2-5A-dependent RNase levels were correlated with the anti-EMCV activity of interferon, Kumar, R. et al., J. Virol.. 62:3175-3181 (1988), and EMCV-derived dsRNA both bound to and activated 2-5A synthetase in interferon-treated, infected cells. See Bribaudo, G. et al., J. Virol.. 65:1948-1757 (1991). The 2-5A system, however, almost certainly provides functions beyond the antipicornavirus activity of interferons. For instance, introduction of 2-5A into cells, Hovanessian, A.G. and Wood, J.N. , Virology. 101:81-90 (1980), or expression of 2-5A synthetase cDNA, Rysiecki, G. et al., J. Interferon Res.. 9:649-657 (1989), inhibits cell growth rates. Moreover, 2-5A- dependent RNase levels are elevated in growth arrested cells, Jacobsen, H. et al., Proc. Natl. Acad. Sci. USA, 80:4954-4958 (1983b), and 2-5A synthetase, Stark, G. et al., Nature. 278:471-473 (1979), and 2-5A-dependent RNase levels are induced during cell differentiation. See, e.g., Krause, D. et al., Eur. J. Biochem.. 146:611- 618 (1985). Therefore, interesting correlations exist between 2-5A-dependent RNase and the fundamental control of cell growth and differentiation suggesting that the 2-5A system may function in general RNA metabolism. The ubiquitous presence of the 2-5A system in reptiles, avians and mammalians certainly supports a wider role for the pathway. See, for example, Cayley, P.J. et al., Biochem. Biophys. Res. Commun.. 108:1243-1250 (1982). While it is presently believed that the 2-5A system is the only well-characterized RNA degradation pathway from higher animals, the dsRNA-dependent protein kinase enzyme, known as PKR, is also thought to have antiviral effects in higher animals. Like the 2-5A synthetase enzyme, it is believed that PKR is stimulated by dsRNA. It is believed that activated PKR phosphorylates the alpha subunit of translation factor eIF 2 -alpha, which indirectly inhibits protein synthesis initiation. It is believed that interferons α, and Y induce the accumulation of PKR. See Hovanessian et al.: J. Interferon Res.. 9:641-647 (1989). Like the 2-5A system, the PKR system is also likely to provide functions beyond the antipicornavirus activity of interferons. See Meurs, E.F. et al. : J. Virology. 66:5805-5814 (1992). For example, expression of mutant forms of PKR in NIH 3T3 cells resulted in tumor formation when injected into nude mice. See Meurs, E.F. et al. : Proc. Natl. Acad. Sci USA. 90:232- 236 (1993). In short, the 2-5A system and the PKR system inhibit viral protein synthesis. This is believed to be accomplished by the 2-5A system by degrading mRNA and rRNA whereas the PKR system is believed to accomplish this by indirectly inhibiting protein synthesis initiation. Viral plant diseases are pandemic and their severity varies from mild symptoms to plant death. The majority of plant viruses are believed to have single stranded RNA genomes. Moreover, it is currently believed that plants are void of the three enzymes discussed above, i.e., PKR, 2-5A synthetase and 2-5A- dependent RNase. See Cayley, P.J. et al. : Biochem. Biophys. Res. Commu .. 108:1243-1250 (1982) and Devach, Y. et al.: Biochemistry. 24:593-599 (1985); but see Crum, C. etal.: J. Biol. Chem.. 263:13440-13443 (1988); Hiddinga, H.J. et al. : Science. 241:451-453 (1988); Sela, I.: TIBS, pp. 31-33 (Feb. 1981); and Devach, Y. et al.: Science. 216:1415-1416. The interferon family of cytokines are believed to induce an antiviral state in cells of higher vertebrates. J. Vilcek, G.C. Sen, In Virology, B. Fields, ed. (Raven, New York, 1995). Virus infected cells produce and secrete interferons and β, which are believed to signal uninfected cells that a virus infection has occurred. Interferons are thought to bind to specific cell surface receptors, activating Jak-STAT signal transduction pathways which induce interferon- stimulated genes. Darnell, J.E. et al.: Science. 264:1415 (1994). The proteins encoded by these genes are believed to be responsible for the biological effects of interferons, including the antiviral responses. The 2-5A system, see Kerr, t.M. et al.: Proc. Natl. Acad. Sci. USA. 75:256 (1978), is one such interferon-induced, antiviral pathway present in cells of reptiles, avians and mammals. Cayley et al. : Biochem. Biophys. Res. Commun.. 108:1243 (1982). Two types of enzymes are believed to be essential for a functional 2-5A system: 1) any one of several 2-5A synthetases, which require dsRNA to produce 2-5A, a series of 5 '-phosphorylated, 2 ',5 '-linked oligoadenylates, A.G. Hovanessian, A.G. et al.: Nature. 268:537 (19.77), and Marie, I. et al.: J. Biol. Chem.. 267:9933 (1992); and 2) the 2-5A-dependent Rnase L. Clemens, M.J. et al.: Cell. 13:565 (1978), Slattery et al.: Proc. Natl. Acad. Sci. USA. 76:4778 (1978), and Zhou, A. et al.: Cell. 72:753 (1993). 2-5A is thought to activate Rnase L which cleaves viral and cellular single-stranded RNAs, predominantly after UpNp sequences. Floyd-Smith, G.E. et al.: Science, 212:1020 (1981); and Wreschner, D.H. et al.: Nature, 289:414 (1981). Because virus-infected cells often contain dsRNA activators of 2-5A synthetase, see, e.g., Gribaudo G. et al.: J. Virol.. 65:1748 (1991), for instance as replicative intermediates of RNA viruses, RNA degradation by Rnase L is believed to frequently occur in interferon-treated, virus-infected cells. See Wreschner, D.H. et al.: Nucleic Acids Res.. 9:1571 (1981); and Silverman, R.H. et al.: Eur. J. Biochem.. 124:131 (1982). It is believed that the 2-5A system inhibits replication of the picornaviruses, encephalomyocarditis virus and mengo virus in interferon-treated mammalian cells. Chebath, J. et al. : Nature, 330:587 (1987); Rysiecki, G. et al. : J. Interferon Res.. 9:649 (1989); Coccia, E.M. et al., Virology. 179:228 (1990); and Hassel, B.A. et al. : EMBO J ^ , 12:3297 (1993). RNase L, assayed by 2-5A binding activity, was not detected in tobacco, Nicotiana glutinosa and N. tabacum . See Cayley et al. : Bioche . Biophys. Res. Commun.. 108:1243 (1982). Furthermore, 2-5A synthetase was not detected in such plants, and 2-5A synthetase was not detected in control, tobacco mosaic virus (TMV)- infected, interferon-treated or poly (I) : poly (C)- treated plants. Plants therefore appear to lack a 2-5A system or an equivalent of the mammalian 2-5A system. Previously, expression in potato of rat 2-5A synthetase mRNA, without co-expression of RNase L. , was correlated with possible partial resistance to potato virus X (PVX) in some, but not all transgenic plants. See Truve, E. et al.: Bio/Technologv. 11:1048 (1993). The biochemical basis for both this perceived effect and for a possible anti-TMV effect of 2' ,5'-oligoadenylate in non-transgenic N. glutinosa leaf disks has not been established. See Y. Devash, et al. : Science. 216: (1982). Although plant oligoadenylates are-believed to exist, they appear to differ from 2-5A, see, e.g., Y. Devash et al. : Biochem.. 24:593 (1985) . It is therefore presently believed that plants do not produce or express 2-5A synthetase and RNase L. Notwithstanding the importance of 2-5A- dependent RNase to the 2-5A system, 2-5A-dependent RNase enzymes having ribonuclease function have not been isolated, purified or sequenced heretofore. Consequently, there is a demand for isolated, active 2- 5A-dependent RNases and their complete amino acid sequences, as well as a demand for encoding sequences for active 2-5A-dependent RNases. There is also a demand for transgenic plants which are immune or resistant to viruses, such as transgenic tobacco plants that are immune or resistant to viruses such as the picornaviruses, tobacco mosaic virus (TMV), tobacco etch virus(TEV) and alfalfa mosaic virus (AIMV). Summary of the Invention In brief, the present invention alleviates and overcomes certain of the above-mentioned problems and shortcomings of the present state of the art through the discovery of novel, isolated 2-5A-dependent RNases and encoding sequences therefor. Broadly speaking, the novel 2-5A-dependent RNases of the instant invention are involved in the fundamental control of single stranded RNA decay in animal cells, such as mammals, and are also present in animal cells, such as avian and reptilian cells. More particularly, the novel 2-5A dependent RNases of the present invention have the ability to degrade single stranded RNA, mainly 3' of UpUp or UpAp sequences, after they are activated by binding to 5'- phosphorylated,2' ,5'-linked oligoadenylates (hereinafter "2-5A". As a result, it is believed that the novel 2-5A dependent RNase are useful in connection with inhibition of cell growth rates, viral replication and in connection with interferon treatment of viral infection and cancer. As used herein, the term "2-5A-dependent RNase(s) " is used in a broad sense and is meant to include any amino acid sequence which includes a 2-5A binding domain and/or ribonuclease function when the 2- 5A-dependent RNase is activated by 2-5A. The term 2-5A- dependent RNase also includes the term "RNase L" and is used interchangeably with the term "2-5A-dependent RNase. " The novel 2-5A dependent RNases of the present invention are protein enzyme having molecular weights on the order of between about 74 KDa ( urine) and about 84 KDa (human), as determined by gel electrophoresis migration and/or prediction from their respective encoding nucleotide sequences. For example, a human 2- 5A-dependent RNase of the instant invention has a molecular weight of about &3,539 Da as det-ermined from the amino acid sequence predicted from the encoding sequence therefor, whereas the murine 2-5A-dependent RNase has a molecular weight of about 74 KDa as determined by gel electrophoresis migration and from prediction of the amino acid sequence from the encoding sequence. While an about 74 KDa molecular weight is reported herein for a murine 2-5A-dependent RNase, it should nevertheless be appreciated that the reported molecular weight is for an incomplete murine 2-5A- dependent RNase. It is nevertheless believed that once completely sequenced, i.e., when an about 84 amino acid end region is identified, the molecular weight of a complete murine 2-5A-dependent RNase will be similar to that of human, i.e., about 84 KDa. It should also be readily apparent to those versed in this art, however, that since gel electrophoresis migration has been employed to determine molecular weight of a murine 2-5A-dependent RNase, the 74 KDa molecular weight is only an estimate based upon relative migration. The amino acid sequence for human 2-5A- dependent RNase protein is depicted in FIG. 3 and Table 1. The encoding sequence for the human 2-5A-dependent RNase protein is also set forth in Table 1. The mRNA for human 2-5A-dependent RNase is about 5.0 Kb in size. The virtually complete amino acid sequence for the murine 2-5A-dependent RNase protein and the encoding sequence therefor is depicted in Table 2. The mRNA for murine 2-5A-dependent RNase is about 5.7 Kb in size. Analysis of the amino acid sequences f the 2- 5A-dependent RNases of the present invention have revealed several characteristics unique to the 2-5A- dependent RNases. For example, it has been, discovered that the novel 2-5A dependent RNases of the instant invention include the following unique domains which span between the amino terminus and the caroxy terminus. For instance, it has been discovered that there are at least four and possibly as many as nine or more ankyrin repeats, of which three lie closest to the amino terminus. However, while four ankyrin repeats have been discovered, it is believed that there may be additional ankyrin repeats that may total, for instance, about eight or more when the amino acid sequences of the 2-5A- dependent RNases of the present invention are further analyzed. It is believed that these ankyrin repeats may possibly function in protein-protein interaction. Ankyrin repeat 1 generally lies between amino acids designated as 58-90 in Tables 1 and 2. Ankyrin repeat 2 generally lies between amino acids designated as 91- 123 in Tables 1 and 2. Ankyrin repeat 3 generally lies between amino acids designated as 124-156 in Tables 1 and 2. Ankyrin repeat 4 generally lies between amino acids designated as 238 and 270 in Tables 1 and 2. See also FIGS. 10A and 10B. It has also been discovered that the novel 2- 5A dependent RNases include a cysteine rich region (which has homology to zinc fingers) that lies closer to the carboxy terminus than the amino terminus which may possibly function in RNA recognition or in formation of protein dimers. The cysteine rich region is believed to include about 5 or 6 cysteine residues which generally lie between amino acids designated as 395-444 in the human sequence as reported in Table 1 and FIG. 4, or between amino acids designated as 401-436 in the murine sequence as reported in Table 2 and FIG. 4. Still further, it has been discovered that the novel 2-5A dependent RNases include a duplicated phosphate binding (2 P-loops) motif which lies generally within the ankyrin repeat motifs. It is believed that the two P-loops are in the same orientation and constitute the binding domain necessary for binding 2- 5A. It is further believed that each P-loop motif includes a lysine residue which.is essential for maximum 2-5A binding activity. The lysine residues are designated as 240 and 274 in Tables 1 and 2. It has been further discovered that the 2-5A- dependent RNase proteins contain an amino acid region which follows the cysteine rich region that is believed to be homologous to protein kinases. Within this region, there is believed to be separate domains designated as domains VI and VII which generally lie between amino acid residues designated as 470-504 in Tables 1 and 2. More particularly, as to the human sequence of 2-5A-dependent RNase, domain VI generally lies between amino acid residues designated as 501-504, as reported in Table 1 and FIG. 4. As to the murine sequence of the 2-5A-dependent RNase, domain VI generally lies between amino acids designated as 470-489 and domain VII generally lies between amino acid residues designated as 499-502, as reported in Table 2 and FIG. 4. It has also been discovered that there is limited homology between the amino acid sequences for the 2-5A-dependent RNases of the present invention and RNase E, encoded by the altered mRNA stability (ams)/rne gene of E. Coli. Uniquely, the limited homology is generally conserved between the murine and human amino acid sequences for 2-5A-dependent RNases and generally lies between a 200 amino acid region. More particularly, for the human sequence, (the amion acid region spans amino acid residues designated as 160-349 in Table 1 and FIGS. 9A and 9B. With respect to the murine sequence, the amino acid region spans amino acid residues designated as 160-348 in Table 2 and FIGS. 9A and 9B. It has been further discovered and is believed that almost the entire, if not complete, amino acid sequences of the novel 2-5A-dependent RNase-proteins of the instant invention are necessary for ribonuclease function. For example, it is believed that, when an about 84 amino acid region at the carboxy terminus is present in the human 2-5A-dependent RNase, the human 2- 5A-dependent RNase has ribonuclease function in the presence of 2-5A. In contrast, when the murine 2-5A- dependent RNase lacks the about 84 amino acid region at the carboxy terminus, it lacks ribonuclease function. With respect to the binding activity of a murine 2-5A-dependent RNase protein to 2-5A, it has been discovered that, when one P-loop is deleted from the repeated P-loop motif of a murine 2-5A-dependent RNase protein, nearly all 2-5A binding activity is lost, and that when both P-loops are deleted, virtually complete activity is lost. However, it has been found that, even though the carboxy terminus portion of the amino acid sequence of a murine 2-5A-dependent RNase protein following the repeated P-loop motif has been deleted, partial 2-5A binding activity is maintained. It has been further discovered that when lysine residues 240 and 274 are replaced with asparagine residues in both P-loop motifs, significant 2-5A binding activity of a murine 2-5A-dependent RNase protein is lost. It has been further discovered, however, that when either lysine residue 240 or 274 is replaced in either P-loop motif, only partial 2-5A binding activity is lost. It is therefore believed that the-presence of both P-loop motifs in the amino acid sequences for the 2-5A dependent RNases of the present invention plays an important role in 2-5A binding activity.. It is further believed that the presence of lysine residues 240 and 274 in each P-loop motif plays an important role for enhanced 2-5A binding activity. It is also believed that the presence of virtually the entire amino acid sequence of the 2-5A-dependent RNases of the present invention provides for even further enhanced 2-5A binding activity, as well as provides for ribonuclease function. In addition, the present invention relates to the cloning of murine and human 2-5A-dependent RNases and novel murine and human clones. Recombinant and naturally occurring forms of 2-5A-dependent RNase displayed virtually identical 2-5A binding properties and ribonuclease specificities. The present invention further contemplates the use of the novel isolated, 2-5A-dependent RNases and encoding sequences therefor, as well as analogs and active fragments thereof, for use, for instance, 1. ) in gene therapy for human and animal diseases including viral disease and cancer, 2.) as genetic markers for human disease due to perhaps cancer or viral infection, 3. ) to develop plants and animals resistant to certain viruses, and 4. ) as enzymes in connection with research and development, such as for studying the -structure of RNA. In one manner to accomplish the above, and as contemplated by the present invention, the encoding sequences of the instant invention may be utilized in ex vivo therapy, i.e., to develop recombinant cells using encoding sequence of the present invention using techniques known to those versed in this art. In another manner which may be employed to accomplish the above, the encoding sequences of the present invention may be combined with an appropriate promoter to form a recombinant molecule and inserted into a suitable vector for introduction into an animal, plant, or other lower life forms also using techniques known to those skilled in this art. Of course, other suitable methods of means known to those versed in this art may be selected to accomplish the above-stated objectives or other objectives for which the novel 2-5A-dependent RNases and encoding sequences of the present invention are suited. The present invention also contemplates novel transgenic plants, as indicated above, which are resistant to viruses such as the picornaviruses. Generally speaking, the transgenic plants of the present invention include any inserted nucleotide sequence encoding any type of antiviral amino acid sequence, including proteins. Preferably, the antiviral nucleotide sequences introduced into plants in accordance with the present invention are animal antiviral genes, such as those genes which are stimulated in response to interferon production and/or treatment. These include, for example, those animal antiviral genes that encode 2-5A-synthetase, 2-5A- dependent RNase, and PKR. These interferon-regulated proteins, 2-5A-synthetase, 2-5A-dependent RNase and PKR (the dsRNA-dependent protein kinase) have recognized antiviral effects in higher animals and are believed to have antiviral effects in the transgenic plants of the present invention. PKR is stimulated by dsRNA to phosphorylate translation factor eIF2 which indirectly inhibits protein synthesis initiation. On the other hand, 2-5A synthetase is activated by dsRNA resulting in the production of "2-5A, " p x A(2'p5'A) y wherein x = about 1 to about 3 and y ≥ about 2, from ATP. The 2-5A then activates an endoribonuclease entitled 2-5A dependent RNase (also known as RNase L or nuclease F) . The activated ribonuclease degrades mRNA and rRNA thus inhibiting protein synthesis. These above-described pathways are particularly effective at inhibiting viruses in animals with single stranded RNA genomes that replicate through dsRNA intermediates, such as the picornaviruses, and are believed to be effective at inhibiting similar types of viruses that infect plants. This belief is premised upon the understanding that most single stranded RNA plant viruses produce double stranded structures during replication by their viral replicases, see-Dawson, W.O. et al.: Acad. Press. 38:307-342 (1990), and that plant viruses are similar to animal viruses in structure, composition and mechanism of replication in cells. In addition, even viral so-called single-stranded RNA may contain secondary structures which could activated PKR and 2-5A synthetase leading to widespread plant protection against plant viruses. It is believed that co-expression of 2-5A-dependent RNase and 2-5A- synthetase, will lead to the destruction of viral mRNA and viral genomic RNA thereby protecting the transgenic plants of the present invention from viruses. Moreover, it is believed that expression of PKR by the transgenic plants of the present invention will inhibit viral protein synthesis leading to inhibition of virus replication and protection of the transgenic plants. The present invention is therefore premised in part upon the belief that plant virus RNAs activate 2-5A- synthetase and PKR in the transgenic plants of the instant invention leading to immunity against virus infection. Furthermore, expression of 2-5A synthetase alone or 2-5A-dependent RNase alone or PKR alone may protect plants against viruses, perhaps by binding to viral RNA, such as viral replicative intermediates thereby blocking viral replication. Moreover, expression of only the dsRNA binding domains of PKR and/or of 2-5A-synthetase may similarly protect the transgenic plants of the present invention against viral infection. It should therefore be appreciated by those versed in this art that novel transgenic plants which are resistant to viral infection can now be produced in accordance with the present invention. It is believed that the effectiveness of the anti-viral protection can be enhanced or even maximized when at least the three- above animal antiviral genes are inserted into plants to form exemplary transgenic plants of the present invention, since the animal antiviral proteins encode by these three animal antiviral genes interfere with different stages of the viral life cycles. Moreover, these animal antiviral proteins or amino acid sequences are believed likely to be safe to give or introduce into animals, including humans, since these antiviral proteins or amino acid sequences are naturally occurring in humans as well as in other mammals, avians and reptiles. While the present invention is described herein with reference to the particular sequences disclosed, it should nevertheless be understood by those skilled in this art that the present invention contemplates variations to the amino acid and/or nucleotide sequences which do not destroy 2-5A synthetase activity, PKR activity and/or 2-5A-dependent ribonuclease activity. Therefore, the present invention contemplates any analogs, parts or fragments of 2-5A- dependent RNase, 2-5A synthetase, and PKR which are active, such as any active part, and any encoding sequences therefor. In other words, the present invention includes, among other things, any amino acid sequence, any nucleotide sequence and any transgenic plant which have the ability to accomplish the objectives of the instant invention. For example, the instant invention includes any amino acid sequence which has antiviral activity and any nucleotide sequence which encodes therefor and those transgenic plants that express such nucleotide sequences. More specifically, the present invention includes, for instance: 1.) any animal amino acid sequence which has the ability to inhibit or interfere with viral replication such as those amino acid sequences that have activity similar or identical to PKR activity, 2-5A synthetase activity and/or 2-5A ribonuclease activity, and any nucleotide sequence which encodes for an amino acid sequence having any such activity; and 2.) any transgenic plant having any animal antiviral nucleotide sequence which encodes any such amino acid sequence which has any such antiviral activity. In accordance with a further feature contemplated by the present invention, novel transgenic plants, such as transgenic tobacco plants, having the ability to express a functional 2-5A system for conferring to such transgenic plants immunity to or resistance against viral infection have been surprisingly discovered. More particularly, transgenic tobacco plants having the ability to express functional 2-5A-dependent RNase (RNase L) and functional 2-5A synthetase to confer resistance against, e.g., the tobacco mosaic virus (TMV), the tobacco etch virus (TEV) and the alfalfa mosaic virus (AIMV) have been discovered. It has been surprisingly discovered that these unique transgenic tobacco plants are more resistant and immune to infection by TMV, TEV and AIMV than similar plants, which are not transgenic and with no ability to express such a 2-5A system. Expression of the 2-5A system in plants in accordance with the present invention appears to have several apparent advantages compared to alternative plant antiviral strategies utilized heretofore. The most common approach involves pathogen-derived resistance, Sanford, J.C. et al. : J. Theor. Biol.. 113:395 (1985), in which plants are transformed to express certain viral-coded proteins or antisense RNAs, Wilson, T.M.A. et al. : Proc. Natl. Acad. Sci. USA. 90:3134 (1993); and Hull, R. et al. : Crit. Rev. Plant Sci.. 11:17 (1992). A potential limitation of this approach has been virus recombination that may occur in the plants resulting in possibly a more virulent virus, expansion of the host range of a virus or vector specificity. See Greene, A.E. et al. : Science. 263:1423 (1994); White, K.A. et al.: Proc. Natl. Acad. Sci. USA. 91:3642 (1994); and Tepfer, M. et al. : Bio/Technology. 11:1125 (1993). These risks, in general, are not considered to be high. See Falk, B.W. et al. : Science. 263:1395 (1994). However, even in instances of substantial resistance to virus infection, protection is usually limited to the virus from which the protein or antisense RNA is derived, or to closely related strains. In contrast, the transgenic plants containing the functional 2-5A system of the present invention are predicated upon the realization that immunity to and resistance against any plant virus that produces dsRNA in the infected cell may be provided. Most plant viruses, including those in the economically important potyvirus group, are positive sense, single-stranded RNA viruses which produce a dsRNA intermediate during their replicative process. Furthermore, because plant viruses are naive to a functional 2-5A system, it is believed that these viruses are likely to be even more vulnerable to it than viruses of higher vertebrates. It is therefore believed that expression of a functional 2-5A system in transgenic plants may uniquely provide a broad range of resistance against viral infections. Accordingly, the transgenic plant strategy according to the present invention provides a unique and advtangeous approach for protecting crops and other plants against virus infections in the field. The above features and advantages of the present invention will be better understood with reference to the accompanying FIGS. , Detailed Description and Examples. It should also be understood that the particular methods, amino acid sequences, encoding sequences, constructs, vectors, recombinant cells, and antiviral transgenic plants illustrating the invention are exemplary only and not to be regarded as limitations of the invention. Brief Description of the FIGS. Reference is now made to the accompanying FIGS, in which is shown illustrative embodiments of the present invention from which its novel features and advantages will be apparent. FIG. 1 is the 2-5A system: a ribonuclease pathway which is believed to function in the molecular mechanism of interferon action. 5'-phosphatase, p'tase; 2'-5'-phosphodiesterase, 2'-PDE. FIGS. 2A and 2B are a comparison of 2-5A binding activity of recombinant and naturally occurring forms of murine 2-5A-dependent RNase. FIG. 2A is a specific affinity of truncated murine 2-5A-dependent RNase for 2-5A. UV covalent crosslinking of the 32 P-2-5A probe (lanes 1-7) to protein is performed after translation reactions in wheat germ extract (5 μl ) with murine 2-5A-dependent RNase mRNA (from clone ZBl) (lanes 1-3) or without added RNA (lane 4) or in extract of interferon treated mouse L cells (100 μg of protein) (lanes 5-7). Reactions are without added competitor (lanes 1, 4, and 5) or in the presence of either timer core. (A2'p) 2 A, (100 nM) (lanes 2 and 6) or timer 2-5A, p 3 (A2'p) 2 A (100 nM) (lanes 3 and 7) . Lanes 8 and 9 are produced by incubating the wheat germ extract with 35 S-methionine in the absence or presence of 2-5A-dependent RNase mRNA, respectively. FIG. 2B are identical chymotrypsin cleavage products and are obtained from recombinant and naturally occurring form of 2-5A-dependent RNase. Partial chymotrypsin digests (arrows) are performed on truncated 2-5A-dependent RNase (clone ZBl) produced in wheat germ extract ("Recombinant" ) and murine L cell 2-5A-dependent RNase ("Naturally Occurring") after crosslinking to the 2-5A probe and purification from gels. FIGS. 3A and 3B are clonings of the complete coding sequence for human 2-5A-dependent RNase. FIG. 3A is the construction of a human 2-5A- dependent RNase clone. The initial human 2-5A-dependent RNase clone. The initial human 2-5A-dependent RNase cDNA cone, HZB1, is isolated from an adult human kidney cDNA library in λgtlO using radiolabeled murine 2-5A- dependent RNase cDNA (clone ZBl) as probe. See Example. Radiolabeled HZB1 DNA is used to isolate a partially overlapping cDNA clone, HZB22, which is fused to HZB1 DNA at the Ncol site to form clone ZC1. The 5'-region of the coding sequence is obtained from a genomic Sad fragment isolated using a radiolabeled HZB22 DNA fragment as probe. Fusion of the genomic SACI fragment with ZC1 at the indicated Sad site produces clone ZC3. The coding sequence with some flanking sequences is then subcloned as a Hindlll fragment into pBluescript (KS(+) (Strategene) resulting in clone ZC5. The restriction map for the composite clone, ZC5, is shown. Clone HZB1 includes nucleotides designated as 658-2223 in Table I which encode for amino acids designated as 220-741 in Table I. Clone HZB22 includes a nucleotide sequence which encodes for amino acids designated as 62-397 in Table I. Clone ZC1 includes a nucleotide sequences which encode for amino acids designated as 1-741 in Table I. FIG. 3B is a nucleotide sequence and predicted amino acid sequence of human 2-5A-dependent RNase with flanking nucleotide sequences. The numbers to the right indicate the positions of nucleotides and amino acid residues. FIG. 4 is alignment of the predicted amino acid sequences for murine and human forms of 2-5A- dependent RNase.. The positions of the repeated P-loop motifs, the cysteine (Cys)-rich regions with homology to zinc fingers, and the regions of homology to protein kinase domains VI and VII are indicated. Amino acid residues which are important components of the indicated domains are represented in bold type and are italicized. Identical amino acid residues in murine and human 2-5A- dependent RNase are indicated with colon ( : ) symbols adjacent therebetween. FIGS. 5A and 5B are 2-5A binding properties and ribonuclease activity of recombinant human 2-5A- dependent RNase produced in vitro. FIG. 5A is specific affinity of recombinant human 2-5A-dependent RNase for 2-5A. Crosslinking of the 2-5A probe (lanes 1-7) to protein is performed after translation reaction in wheat germ extract (5 λl) with human 2-5A-dependent RNase mRNA (lanes 1-3) or without added RNA (lane 4) or in extract of human interferon a treated (1000 units per ml for 16 h) human HeLa cells (350 μg of protein) (lanes 5-7). Reactions were without added competitor (lanes 1, 4, and 5) or in the presence of either timer core, (A2'p) 2 A, (100 nM) (lanes 2 and 6) or timer 2-5A, p 3 (A2'p) 2 A (100 nM) (lanes 3 and 7). Incubations with 35 S-methionine are shown in lanes 8 to 12. Lane 8 is with wheat germ extract and human 2-5A- dependent RNase mRNA. Reticulocyte lysate preadsorbed to 2-5A-cellulose is incubated with human 2-5A-dependent RNase mRNA in the absence (lane 9) or presence (lane 10) of cycloheximide, or in the absence of added mRNA (lane 11). Lane 12 shows human 2-5A-dependent RNase which is produced in the nonadsorbed, crude reticulocyte lysate. The positions and relative molecular masses (in kDa) of the marker proteins are indicated. FIG. 5B is reticulocyte lysate pretreated to remove endogenous 2-5A-dependent RNase and is incubated in the absence of added mRNA (■), in the presence of human 2-5A-dependent RNase mRNAwithout inhibitor (O, D) or in the presence of both 2-5A-dependent RNase mRNA and cycloheximide (50 μg per ml (•) . See Example I. Subsequently, the recombinant 2-5A-dependent RNase (or controls) is adsorbed to 2-5A-cellulose and ribonuclease assays are performed after extensive washing of the matrix to reduce general nuclease activity. Radiolabeled substrate RNA was either poly(U) (O, •, ■) or poly(C) (O) . FIGS. 6A, 6B and 6C show levels of 2-5A- dependent RNase mRNA which are induced by interferon treatment of murine L929 cells even in the presence of cycloheximide. FIG. 6A is a northern blot prepared with poly(A) + RNA (4 μg per lane) that is isolated from murine L929 cells treated with murine interferon (α + ) (1000 units per ml) and/or cycloheximide (50 μg per ml) for different durations (indicated) which is probed with radiolabeled murine 2-5A-dependent RNase cDNA. Interferon, IFN; cycloheximide, CHI. FIG. 6B shows levels of 2-5A-dependent RNase which are estimated from the autoradiogram shown in panel (a) with a video camera and QuickCapture and Image computer programs. FIG. 6C shows levels of glyceraldehyde-3- phosphate dehydrogenase (GAPDH) mRNA as determined in the same blot shown in panel (A) . FIGS. 7A and 7B are the truncated, recombinant murine 2-5A-dependent RNase, clone ZBl, and murine L cell 2-5A-dependent RNase having identical 2-5A binding activities localized to a repeated P-loop motif. FIG. 7A shows incubations of truncated 2-5A- dependent RNase, clone ZBl, ("Recombinant") which is produced in wheat germ extract (upper panel) or of murine L cell 2-5A-dependent RNase (labeled "Naturally Occurring," lower panel) with the 32 P-2-5A probe, (2.4 nM) , are in the absence of presence of unlabeled 2',5'- phosphodiester linked oligonucleotides (as indicated) followed by uv covalent crosslinking. Autoradiograms of the dried SDS/10% polyacrylamide gels are shown. Concentrations of the oligonucleotide competitors are indicated. It is inosine. FIG. 7B shows a truncated series of murine 2- 5A-dependent RNase mutants (ZBl to ZB15) which is produced in wheat germ extract which are assayed for 2- 5A binding activity by a filter binding method. See Example and Knight et al. 1980). The positions of the P-loop motifs and the lengths of the translation products are indicated. Clone ZBl encodes for amino acids designated as 1-656 in Table 2, except for the last 5 amino acid residues which are Lys, Pro, Leu, Ser, and Gly. Clone ZB2 encodes for amino acids designated as 1-619 in Table 2 . Clone ZB3 encodes for amino acids designated as 1-515 in Table 2. Clone ZB5 encodes for amino acids designated as 1-474 in Table 2. Clone ZB9 encodes for amino acids designated as 1-403 in Table 2. Clone ZB10 encodes for amino acids designated as 1-365 in Table 2. Clone ZB13 encodes for amino acids designated as 1-294 in Table 2. Clone ZB14 encodes for amino acids designated as 1265 in Table 2. Clone ZB15 encodes for amino acids designated as 1-218 in Table 2. FIGS. 8A and 8B are substitution mutations of the lysine residues in the P-loop motifs of 2-5A- dependent RNase. FIG. 8A shows the truncated murine 2-5A- dependent RNase, clone ZBl, and lysine to asparagine substitution mutants of clone ZBl, which are synthesized in wheat germ extract. In (A) unlabeled translation products are covalently crosslinked to the bromine- substituted, 32 P-labeled 2-5A probe, Br-2-5A-[ 32 P]pCp. See Nolan-Sordan et al., 1990. FIG. 8B shows the mRNA species which are translated in the presence of 35 -S-methionine in separate reactions. Autoradiograms of the dried, SDS/polyacrylamide gels are shown. The order and positions of the translation products (labelled ("RNase") and the relative molecular masses (in kDa) of the protein markers are indicated. FIGS. 9A and 9B are a comparison of the amino acid sequences of RNase E ad 2-5A-dependent RNase. FIG. 9A shows identical and conservative matches which are shown between E. coli RNase E and the murine and human forms of 2DR. FIG. 9B is a model for the structure and function of 2DR. Abbreviations: P-loop motifs, a repeated sequence with homology to P-loops; Cys x , a cysteine-rich region with homology to certain zinc fingers; PK, homology to protein kinase domains VI and VII. FIGS. 10A and 10B are a comparison of the amino acid sequences of the ankyrin repeats in the human and murine 2-5A-dependent RNase proteins. FIG. 10A shows murine and human forms of 2-5A- dependent RNases containing four ankyrin repeats. Homology between the ankyrin consensus sequence and the murine and human forms of 2-5A-dependent RNase are indicated, y/, hydrophobic amino acids. -33- FIG. 10B is a model showing the relative positions of the four ankyrin repeats in 2-5A-dependent RNase in comparison to the position of the proposed 2-5A binding domain (t) (the repeated P-loop motif); Cys x , the cysteine-rich region; PK, the protein kinase homology region, and the carboxy-terminal region required for RNase activity. FIG. 11 shows the role of 2-5A-dependent RNase in the anti-viral response of cells to interferon treatment. Interferon binds to specific cell surface receptors resulting in the generation of a signal which activates a set of genes in the cell nucleus. The genes for 2-5A synthetase are thus activated producing inactive, native 2-5A synthetase. Interferon treatment of the cell also activates the 2-5A-dependent RNase gene (not shown in the FIGS.) Subsequently, the interferon- treated cells is infected by a virus. The virus produces double stranded RNA (dsRNA) during its replicative cycle. The viral dsRNA then activates the 2-5A synthetase resulting in the production of 2-5A. The 2-5A then activates the 2-5A-dependent RNase to degrade the viral RNA thus destroying the virus itself. FIG. 12 depicts a physical map of T: based binary vector pAM943 which is about 12 Kbp. Abbreviations: B L , left border; AMT, promotor of adenyl methyl transferase gene from Chlorella virus; 35S, promoter for 35S RNA from Cauliflower mosaic virus; TER, RNA termination signal; Ovi V and Ori K origins of DNA replication. FIG. 13 depicts physical maps of portions of certain recombinant plasmid constructs containing cDNAs encoding mammalian antiviral proteins and showing the important DNA elements in between right border and left border of T-DNAs that re transferred to plant genomes. FIG. 13A depicts a certain portion of plasmid pAM943:PK68; FIG. 13B depicts a certain portion of plasmid pAM943:muPK68; FIG. 13C depicts a certain portion of plasmid pAM943:Synthetase; FIG. 13D depicts a certain portion of plasmid pAM943:2-5A-dep. RNase (sense); FIG. 13D/a depicts a certain portion of plasmid pAM943:2-5A-dep. RNase and FIG. 13E depicts pAM822:2-5A dep. RNase (antisense). Abbreviations: B L , left border; B R , right border; Kan r , kanamycin resistance; Hygro r , hygromycin resistance; AMT, promoter of adenyl methyl transferase gene from Chlorella virus; 35S, promoter for 35S RNA from Cauliflower mosaic virus; PKR, cDNA to human PKR; muPKR, cDNA to a lysine (amino acid #296) to arginine mutant form of PKR; Synthetase, cDNA to human PKR; muPKR, cDNA to a lysine (amino acid #296) to arginine mutant form of PKR; Synthetase, cDNA to a lower molecular weight form of human 2-5A-synthetase; 2-5Adep. RNase, cDNA to human 2-5A-dependent RNase; TER, RNA termination signal. FIG. 14 shows a physical map of Ti based binary vector pAM822 which is about 14.6 Kbp. Abbreviations: B L , left border; B R , right border, Kan r , kanamycin resistance; Hygro r , hygromycin resistance; Tet r , tetracycline resistance; AMT, promoter of adenyl methyl transferase gene from Chlorella virus; 35S, promoter for 35S RNA from Cauliflower mosaic virus; TER, RNA termination signal; Ovi V, origin of DNA replication. FIG. 15 shows expression of human 2-5A- synthetase DNA cDNA intransgenic tobacco plants as determined by measuring mRNA levels in a Northern blot. Construct C (pAM943:Synthetase) was introduced into the plants. Total RNA was prepared from the leaves of control (labeled "C") and transgenic plants using RNASTAT-60 (Tel-Test B., Inc.). Thirty μg of RNA was treated with glyoxal and separated in a 1.5% agarose gel. After electrophoresis RNA was transferred to Magnagraph (MSI) Nylon membrane and probed with human 2-5A-synthetase cDNA labeled with [α- P]dCTP by random priming. Autoradiograms were made from the dried blots. FIG. 16 shows expression of mutant and wild type forms of human PKR cDNA in transgenic tobacco plants as determined by measuring mRNA levels in a Northern blot. Constructs A (pAM943:PK68) and B (pAM943:muPK68) encoding wild type and mutant (lysine at position 296 to arginine) forms of PKR, respectively, were introduced into the plants. Total RNA was prepared from the leaves of control (labeled "C") and transgenic plants using RNASTAT-60 (Tel-Test B., Inc.. Thirty μg of RNA was treated with glyoxal and separated in a 1.5% agarose gel. After electrophoresis RNA was transferred to Magnagraph (MSI) Nylon membrane and probed with human PKR cDNA labeled with [α- 32 P]dCTP by random priming. Autoradiograms were made from the dried blots. FIG. 17 shows a presence of 2-5A-dependent RNase cDNA in transgenic plants as determined on a Southern blot. Genomic DNA was isolated from leaves of transgenic plants containing construct D/a (pAM943:2-5A- dep.RNase, antisense) using CTAB (cetyItrimethylammonium bromide) following the method of Rogers and Bendich (1988, Plant Molecular Biology Manual, A6, pp. 1-10, Kluwar Academic Publisher, Dordrecht) . Ten μg of genomic DNA was digested with Hindlll for 5 h at 37"C and fractionated in a 1% agarose gel followed by transfer to Magnagraph (nylon transfer membrane, Micron Separations, Inc.) using a capillary transfer method. The cDNA for 2-5A-dependent RNase (from plasmid pZC5) was labeled by random priming with [α- 32 P]dCTP (3,000 Ci/mmole) using a Prime-a-gene kit from (Promega) according to the protocol supplied by the company. The labeled 2-5A-dependent RNase cDNA (Specific activity of 1.0 X 10 9 " c.p.m. per μg DNA) was washed and an autoradiogram was made from the dried membrane. The sizes (in kilobases) and the positions of the DNA markers are indicated. The band indicated as "2-5A-dep. RNase cDNA" (see arrow) was absent in Southern blots of control plants (data not shown) . FIG. 18 depicts a cDNA coding sequence for human p68 kinase mRNA (PKR) . FIG. 19 depicts a translation product of the complete coding sequence for human p68 kinase mRNA (PKR) of FIG. 18. FIG. 20 depicts a coding sequence for human 2-5A synthetase cDNA. FIG. 21 depicts a translation product of the coding sequence for human 2-5A-synthetase of FIG. 20. FIG. 22. Verification of transgenic tobacco plants. (A), Southern blot of transgenic plants. Total genomic DNA is digested with Hind III, is electrophoresed on 1% agarose gel, is transferred to a membrane and hybridized with 32 P-labeled random primed fragments generated from the 2-5A synthetase or RNase L cDNAs. Numbers at right are size markers in kbp. (B), Northern blot analysis of the transgenic plants. Total cellular RNA is isolated and is electrophoresed on a 1% formaldehyde gel, is transferred to a membrane and is hybridized with the same probe as in (A) . Lane 1, control tobacco plant; Lanes 2-5 transgenic plants expressing both 2-5A synthetase and RNase L; Lane 6, transgenic plant expressing 2-5A synthetase only; Lane 7, transgenic plant expressing RNase L only. SYN 2-5A synthetase; RL, RNase L. (C), A partial map of the expression plasmid is shown. FIG. 23. Immunodetection of RNase L protein in transgenic plants. Total protein extracts from the transgenic plants are fractionated by SDS/PAGE and blotted onto a nitrocellulose membrane and probed with a monoclonal antibody reagent to recombinant human RNase L protein, which are expressed in and isolated from insect cells. Dong, B. et al.: J. Biol. Chem.. 269:14153 (1994). Numbers at the right are protein size markers in kDa. RN human RNase L protein (200 ng) ; TC, protein extract from control tobacco plant; T1-T5, protein extracts from transgenic tobacco plants; Tl, transgenic plants expressing 2-5A synthetase only, T2, transgenic plant expressing RNase L only, T3-T5, plants expressing both 2-5A synthetase and RNase L. FIG. 24. 2-5A induce degradation of rRNA in transgenic plants expressing RNase L protein. Leaves are injected with about 2.5 μM 2-5A, total RNA is extracted after 3 hr and probed with 32 P-labeled 18S cDNA. Lanes 1-2, control plant, lanes 3 and 4, plant expressing only 2-5A synthetase (Syn); lane 5, plant expressing only RNase L (RL); lanes 6-7, plants expressing both 2-5A. synthetase and RNase L (Syn+RL) . FIG. 25. Transgenic plants produce functional, human recombinant 2-5A synthetase. Extracts of plants containing cDNA to both human RNase L and 2-5A synthetase (lanes 8-11), of control plants that are transformed with vector alone (lanes 12-15), and of interferon treated human HeLa cells (lanes 16 and 17) are assayed for 2-5A synthetase activity. 2-5A synthetase activity in extracts of transgenic plants is determined by a functional assay for 2-5A. Plants extracts are prepared by homogenizing leaves in NP40 lysis buffer containing: about 0.5% (v/v) Non-idet P-40, about 90 mM KCl, about 5 mM magnesium acetate, about 20 mM Tris-HCl, pH about 7.5, about 5 mM 2-mercaptoethanol, and about 10 μg per ml leupeptin. The total cell lysates are centrifuged at about 10,000 X g for about 10 min at about 4°C, the supernatants are collected and the protein concentration is determined as described in Bradford, M. et al. : Anal. Biochem.. 72:248 (1976). Extracts of interferon-treated (about 200 units per ml human interferon alpha for about 18 hr) human HeLa cells is prepared by the same method, except cells are disrupted by vortex mixing. 2-5A synthetase assays are performed by incubating about 200 μg (protein) extract per assay adjusted to about 65 μls with NP40 lysis buffer, with about 65 μl (per assay) of about 20 mM Tris-HCl, pH about 7.5, about 50 mM KCl, about 5 mM magnesium acetate, about 4 mM magnesium chloride, about 5 mM 2-mercaptoethanol, about 10% (v/v) glycerol. About 2 mM ATP, about 20 μg per ml poly (I): poly (C) for about 24 hr at about 30°C. Reactions are terminated, and proteins are denatured and removed, by heating reaction mixtures to about 100 * C for about 5 min followed by centrifugation at about 10,000 X g for about 10 min. Supernatants are removed and concentrated in a speed-vac (Savant) to about 20 μl. 2-5A is then assayed by a 2-5A dependent ribonuclease L assay. Concentrated supernatants (about 5 and about 10 μl per plant), or dilutions of authentic 2-5A (pA(2'p5'A) 3 ) , are incubated in a final volume of about 25 μl with about 1 μg of recombinant human RNase L, Dong, B. et al.: J. Biol. Chem.. 269:14153 (1994), in buffer (about 90 mM KCl, about 10 mM magnesium acetate, about 20 mM Tris-HCl, pH about 7.5, about 8 mM 2-mercaptoethanol, and about 10 μg per ml leupeptin) containing about 0.2 mM of poly(U) -( 32 P)-pCp prepared, as described in Silverman, R.H. et al. : Anal. Biochem.. 144:450 (1985) and incubated at about 30° C for about 2 hr. Reactions are terminated with about 7.5 μl stop buffer, boiled for about 5 min, centrifuged briefly, and about 3 μl is loaded to 6% polyacrylamide/urea gels. After electrophoresis, X-ray film is exposed to the gel. 2-5A is monitored by its ability to activate RNase L, which are expressed and isolated from insect cells, Dong, B. et al.: J. Biol. Chem.. 269:14153 (1994), to cleave poly (U) to discrete products (arrows). Lanes 1-7 show activation of RNase L by authentic pA(2'p5'A) 3 . An autoradiogram of the sequencing gel is shown. FIG. 26. Virus-inoculated leaves showing local lesions. Leaves from transgenic or control plants are mechanically inoculated with either TEV, TMV or AIMV. Transgenic plants are grown in a greenhouse. Leaves from these plants are cut at the petiole and placed in petri dishes on moist filter papers. Leaves that are maintained in petri dishes for the incubation period remain in good physiological condition. The leaves are inoculated with an about 1:200, 1:1000 and 1:150 dilution of freshly prepared extracts from tobacco leaves systemically infected with tobacco etch virus (TEV, severe strain, ATCC#PV69), TMV, common strain), and alfalfa mosaic virus (AIMV, Nebraska strain) respectively. Six of six control plants become systemically infected when inoculated with sap diluted 1:10,000, 1:100,000, and 1:15,000, respectively. Following inoculation with virus, the leaves are rinsed with water, and petri dishes are sealed with stretched parafilm and placed in an incubator at about 22° C for about 7 days under about 18 hr light. Panels a,c,e, plants expressing both 2-5A synthetase and RNase L; panel g, plant expressing 2-5A synthetase alone; panel h, plant expressing RNase L alone. Control plants, panels b,d and f, are transgenic for the vector-alone construct. FIG. 27 illustrates (A) southern blot of genomic DNA and (B) northern blot of total RNA of control plants (lanes 1) and two plants that were transgenic for human 2-5A-synthetase probed with human 2-5A synthetase cDNA (lanes 2 and 3). FIG. 28 illustrates southern blot of genomic DNA from control plant (lane 1) and three plants that are transgenic for human RNase L (lanes 2-4) probed with human RNase L cDNA. FIG. 29 illustrates detection of RNase L after covalent crosslinking to a 32 P-labeled 2-5A probe. Extracts of control plants (lanes 1 and 2) , of plants transgenic for human RNase L cDNA (2-5A-dependent RNase) (lanes 3-12) or of human MCF-7 cells (lanes 13 and 14) is incubated with 32 P-labeled 2-5A probe under ultraviolet light to induce crosslinking with RNase L. Specificity of crosslinking is determined with an excess of unlabeled 2-5A (as indicated) . The positions and molecular masses (in kDa) of the.protein markers and the position of RNase L (arrow) are indicated on the autoradiogram of the dried SDS/polyacrylamide gel. FIG. 30 illustrates that RNase L in cut leaves is activated to cleave rRNA by incubation in a solution containing 2-5A. A northern blot probed with 32 P- labeled cDNA to 18C rRNA is shown. The cut leaves are from a control plant (lanes 1 and 2) or from a plant transgenic for human RNase L cDNA (lanes 3-and 4) . The -43- presence or absence of 2-5A and the position of the 2- 5A-mediated rRNA cleavage products are shown. Detailed Description By way of illustrating and providing a more complete appreciation of the present invention and many of the attendant advantages thereof, the following Detailed Description and Examples are given concerning the novel 2-5A-dependent RNases, encoding sequences therefor, recombinant nucleotide molecules, constructs, vectors, recombinant cells, antiviral transgenic plants and methods. Because 2-5A-dependent RNase is very low in abundance (one five-hundred-thousandth of the total pro€ein in mouse liver, Silverman, R.H. et al., J. Biol. Chem.. 263:7336-7341 (1988)), its cloning requires the development of a sensitive screening method. Murine L929 cells are selected as the source of mRNA due to high basal levels of 2-5A-dependent RNase. A protocol to enhance 2-5A-dependent RNase mRNA levels is developed based on the observation that optimal induction of 2-5A-dependent RNase is obtained by treating cells with both interferon and cycloheximide, then with medium alone. See Example. The cDNA library is screened by an adaptation of techniques developed for cloning DNA binding proteins, Singh, H. et al.. Cell. 52:415-423 (1988); -44- Singh H. et al., BioTechniσues. 7:252-261 (1989), in which a bromine-substituted 32 P-labeled 2-5A analogue ( M 2-5A probe") , Example and Nolan-Sorden, N.L. et al.. Anal. Biochem.. 184:298-304 (1990), replaced a radiolabeled oligodeoxyribonucleotide. A single clone (ZBl) is thus isolated from about three million plaques. The protein expressed from the ZBl clone, transferred from plaques to filter-lifts, shows reactivity to both the 2-5A probe and to a highly purified polyclonal antibody directed against 2-5A-dependent RNase. To obtain recombinant protein for characterization, the cDNA is transcribed and translated in cell-free systems. See Example. 2-5A binding activity is then determined by covalently crosslinking the 2-5A probe to the protein with uv light, for example, Nolan-Sorden, N.L. et al., Anal. Biochem.. 184:298-304 (1990). The recombinant 74 kDa protein produced in a wheat germ extract shows specific affinity for the 2-5A probe. See FIG. 2A, lanes 1 to 3. A core derivative of 2-5A lacking 5'-phosphoryl groups, (A2'p) 2 A, fails to interfere with binding of the protein to the 2-5A probe whereas trimer 205A, p 3 (A2'p) 2 A, completely prevents probe binding. See FIG. 2A, lanes 2 and 3, respectively. There is no detectable 2-5A binding proteins in the wheat germ extract as. shown in the incubation without -45- added RNA, FIG. 2A, lane 4. For comparison, a similar profile of 2-5A binding activity is obtained for the 80 kDa 2-5A-dependent RNase from murine L929 cells, incubated without added oligonucleotide or with (A2'p) 2 A or p 3 (A2'p) 2 A as competitors. See FIG. 2A, lanes 5 to 7. The 35 S-labeled translation product is shown in FIG. 2A, lane 9. In a further comparison, covalent linkage of the 2-5A probe to the about 74 kDa protein and to murine L929 cell 2-5A-dependent RNase followed by partial digestion with chymotrypsin produces an identical pattern of six labeled peptides. See FIG. 2B. Similarly, partial digestion of the two labeled proteins with S. aureus V8 protease also produces identical patterns of labeled cleavage products. These results and the apparent molecular weight of about 74 kDa for the recombinant protein, as compared to about 80 kDa for 2-5A-dependent RNase, see FIG. 2A, suggests that the about 74 kDa protein is a truncated, or partial clone for 2-5A-dependent RNase. To obtain the entire coding sequence for human 2-5A-dependent RNase, a composite DNA containing genomic and cDNA is constructed. See FIG. 3A. The initial cDNA portion of the human 2-5A-dependent RNase clone (HZBl) is obtained by screening a human kidney cDNA library with radiolabeled murine 2-5A-dependent RNase cDNA. See -46- Exa ple. A genomic clone, containing the 5*-part of the coding sequence, is isolated with radiolabeled human 2-5A-dependent RNase cDNA. The nucleotide and predicted amino acid sequences of human 2-5A-dependent RNase are determined, FIG. 3B, resulting an open reading frame encoding a protein of 83,539 Da. A comparison is made between the predicted amino acid sequences of the human and murine forms of 2-5A-dependent RNase in order to identify and evaluate the conserved regions of the proteins. See FIG. 4. The murine cDNA, clone ZBl, contains about 88% of the coding sequence for 2-5A-dependent RNase to which an additional twenty-eight 3'-codons are added from a murine genomic clone. Alignment of the murine and human forms of 2-5A-dependent RNase indicates about 65% identity between the overlapping regions. See FIG. 4. In addition, there is 73% identity between the corresponding nucleotide sequences for murine and human 2-5A-dependent RNase. The apparent translation start codons for both the murine and human 2-5A-dependent RNases, are in an appropriate context for translational initiation, namely ACCATGG and GTCATGG. respectively. See FIG. 3B. See also, for example, Kozak, M. , Cell. 44:283-292 (1986). In addition, both the human and murine 2-5A-dependent RNase sequences contain -47- in-fra e stop codons upstream of the translation start sites. See FIG. 3B. The 2-5A binding properties of the recombinant and naturally occurring forms of human 2-5A-dependent RNase are compared by uv covalent crosslinking to the 2-5A probe. The recombinant human 2-5A-dependent RNase produces in wheat germ extract shows specific affinity for 2-5A. See FIG. 5A, lanes 1 to 3. Radiolabeling of the cloned human 2-5A-dependent RNase with the 2-5A probe is not prevented by (A2'p) 2 A. See FIG. 5A, lanes 1 and 2. In contrast, addition of trimer 2-5A, p 3 (A2'p) 2 A, effectively competes with the 2-5A probe for binding to the recombinant 2-5A-dependent RNase. See lane 3. The same pattern of 2-5A binding activity is obtained with 2-5A-dependent RNase in an extract of interferon-treated human HeLa cells. See FIG. 5A, lanes 5 to 7. The apparent molecular weights of HeLa cell 2-5A-dependent RNase and 35 S-labeled recombinant human 2-5A-dependent RNase produced in reticulocyte lysate are believed to be exactly the same (about 80 kDa). See FIG. 5A, lanes 5 and 9. The recombinant human 2-5A-dependent RNase produced in wheat germ extract migrates slightly faster probably due to pOst-translational modifications. See FIG. 5A, lanes 1, 2 and 8. -48- To demonstrate and characterize the ribonuclease activity of the cloned 2-5A-dependent RNase, translation is performed in a reticulocyte lysate instead of a wheat germ extract due to the substantially greater efficiency of protein synthesis in the former system. See FIG. 5A, compare lanes 9 and 8. Prior to translation, endogenous reticulocyte 2-5A-dependent RNase is removed by adsorbing the lysate to the affinity matrix, 2-5A-cellulose. See Example. See also, Silverman, R.H., Anal. Biochem.. 144:450-460 (1985). The treatment with 2-5A-cellulose effectively removes all measurable endogenous 2-5A-dependent RNase activity from the lysate, as determined by 2-5A-dependent ribonuclease assays, and FIG. 5B. In addition, the adsorption- depletion protocol did not reduce translational efficiency. FIG. 5A, lanes 9 and 12 show the 35 S-translation products produced in the 2-5A-cellulose-pretreated and untreated lysates, respectively. Ribonuclease assays with recombinant 2-5A-dependent RNase are performed after immobilizing and purifying the translation product on the activating affinity matrix, 2-5A-cellulose. It was previously shown that murine L cell 2-5A-dependent RNase bound to 2-5A-cellulose, resulting in ribonuclease activity against poly(U) but not -49- poly(C). See Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985). Furthermore, by washing 2-5A-dependent RNase:2-5A-cellulose prior to adding the substrate the level of general, non-2-5A-dependent RNase, is greatly reduced. See Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985). Incubations of lysate in the absence of added mRNA or in the presence of both human 2-5A-dependent RNase mRNA and cycloheximide resulted in only low levels of poly(U) breakdown. See FIG. 5B. In addition, it is shown that cycloheximide completely prevented 2-5A-dependent RNase synthesis. See FIG. 5A, lane 10. In contrast, translation of the human 2-5A-dependent RNase mRNA, in the absence of inhibitor, results in substantial ribonuclease activity against poly(U) but not against poly(C). See FIG. 5B. The poly(U) is degraded with a half-life of about 10 minutes whereas only 20% of the poly(C) is degraded after one hour of incubation. Binding of recombinant 2-5A-dependent RNase to the affinity matrix was also shown by monitoring the presence of the 35 S-labeled translation product. These results are believed to demonstrate that the recombinant human 2-5A-dependent RNase produced in vitro is a functional and potent ribonuclease. Furthermore, both recombinant and naturally occurring forms of 2-5A-dependent RNase are capable of cleaving -50- poly(U) but not poly(C) . See FIG. 5B. See also Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985) and Floyd-Smith, G. et al., Science. 212:1020-1032 (1981). To determine if 2-5A-dependent RNase mRNA levels are regulated by interferon, a northern blot from murine L929 cells treated with interferon and cycloheximide is probed with the radiolabeled murine. 2-5A-dependent RNase cDNA. See FIG. 6. 2-5A-dependent RNase mRNA levels are enhanced three-fold by interferon (α + β) treatment even in the presence of cycloheximide. See FIGS. 6A and B, compare lanes 1 and 2) . Regulation of 2-5A-dependent RNase mRNA levels by interferon as a function of time is " demonstrated (FIGS. 6A and B, lanes 3 to 6. Maximum 2-5A-dependent RNase mRNA levels are observed after 14 hours of interferon treatment. See FIGS. 6A and B, lane 6. A similar increase in levels of 2-5A-dependent RNase per se is observed after interferon treatment of the cells. Relatively invariant levels of GAPDH mRNA indicates that equivalent levels of RNA are present in every lane of the blot. See FIG. 6C. These results are believed to show that the induction of 2-5A-dependent RNase e pression is a primary response to interferon treatment. The murine and human 2-5A-dependent RNase mRNAs are determined from northern blots to be 5.7 kb -51- and 5.0 kb in length, respectively. See FIG. 6A. The 2-5A-dependent RNase coding sequences, therefore, comprise only about 40% the nucleotide sequences contained in the mRNAs. The 2-5A binding functions of the recombinant and naturally occurring forms of murine 2-5A-dependent RNase are characterized by covalent crosslinking to the 2-5A probe in the presence of unlabeled 2-5A or 2-5A analogues as competitors. See FIG. 7A. Interestingly, although the about 74 kDa truncated 2-5A-dependent RNase is missing about 84 amino acids from its carboxy-terminus, see FIG. 4, it nonetheless possesses a 2-5A binding activity indistinguishable from that of naturally occurring 2-5A-dependent RNase. See FIG. 7A. Trimer 2-5A[p 3 (A2'p) 2 A], at about 20 nM effectively prevents the 2-5A probe from binding to either protein. See FIG. 7A, lane 8. In comparison, a 500-fold higher concentration of (A2'p) 2 A (10 μM) is required to prevent probe binding to both proteins. See lane 13. The dimer species, p 3 A2'pA, is unable to prevent the 2-5A probe from binding to the proteins even at a concentration of lOμM (lane 18) . However, the inosine analogue, P3l2'pA2' A, Imai, J. et al., J. Biol. Chem.. 260:1390-1393 (1985), is able to prevent probe binding to both proteins but only when added at a concentration of about 1.0 uM (lane 22). -52- To further define sequences involved in 2-5A binding, nested 3'-deletions of the murine 2-5A-dependent RNase cDNA, clone ZBl, are constructed, transcribed in vitro, and expressed in a wheat germ extract. See FIG. 7B. The different deletion clones produces comparable amounts of polypeptide as monitored by incorporation of 35 S-methionine. The levels of 2-5A binding activity are determined with the 2-5A probe in both a filter binding assay, Knight, M. et al.. Nature. 288:189-192 (1980), and the uv crosslinking assay, Nolan-Sorden, N.L. et al., Anal. Biochem.. 184:298-304 (1990), with similar results. See FIG. 7B. Expression of clone ZBll, encoding amino acid residues 1 to 342, results in " a loss of only about 26% of the 2-5A binding activity as compared to clone ZBl (amino acids 1 to 656) . See FIG. 7B. Clones intermediate in length between ZBl and ZBll all result in significant levels of 2-5A binding activity. In contrast, protein produced from ZB13 (amino acids 1 to 294) results in only about 38.3% of the 2-5A binding activity of clone ZBl, suggesting that a region important for the 2-5A binding function is affected. Indeed, clone ZB14 produced a protein encoding amino acids 1 to 265 which is nearly inactive in the 2-5A binding assay (only 1.9% of th activity of clone ZBl). Interestingly, the significant decrease in 2-5A -53- binding activity observed with ZB14 occurs with the deletion of one of two P-loop motifs; nucleotide binding domains in many proteins. See FIGS. 4 and 7B. See also Saraste, M. et al., TIBS. 14:430-434 (1990) . Deletion of both P-loop motifs in clone ZB15 results in protein (amino acids 1 to 218) which is completely lacking in 2-5A binding activity. See FIG. 7B. To probe the involvement of the consensus lysine residues in the P-loop motifs in 2-5A binding activity, site-directed mut genesis is performed on the truncated form of murine 2-5A-dependent RNase encoded by clone ZBl. Previously, it is reported that substitution mutations of the conserved lysine residues in P-loop motifs of eucaryotic initiation factor 4A and for Bacillus anthracis adenylyl cyclase results in a loss of ATP binding and catalytic activities, respectively. See Rozen et al., Mol. Cell. Biol.. 9:4061-4063 (1989) and Xia, Z. and Storm, D.R. , J. Biol. Chem.. 265:6517-6520 (1990). In the former study the invariant lysine residue is mutated to asparagine. See Rozen et al., Mol. Cell. Biol.. 9:4061-4063 (1989). We substituted, individually and together, the consensus lysines with asparagines at positions 240 and 274 in the two P-loop motifs of 2-5A-dependent RNase. See FIG. 8 and the Example. Analysis of the effects of these -54- mutations on 2-5A binding activity is determined by covalently crosslinking the 32 P-2-5A probe to the in vitro translation products under uv light. See FIG. 8A. See also Nolan-Sorden, N.L. et al., Anal. Biochem.. 184:298-304 (1990). Similar levels of proteins are synthesized from the different mRNA species as shown in separate reactions containing 35 S-methionine. See FIG. 8B. The three mutant forms of 2-5A-dependent RNase shows reduced binding to the 2-5A probe. See FIG. 8A, lanes 2 to 4. Clone ZBl(Lys 40 ->Asn) , FIG. 8A, lane 2, expresses a mutant 2-5A-dependent RNase with a substantially reduced affinity for 2-5A; about 48.4% of the activity of clone ZBl as determined by phosphorimager analysis (Molecular Dynamics) of the dried gel. A more modest reduction in 2-5A binding activity, to 79% of the control value, is obtained from clone ZBl(Lys 274 ->Asn) . See FIG. 8A, lane 3. In contrast, 2-5A binding activity from clone ZBl(Lys 240 ' 274 -)Asn) , FIG. 8A, lane 4, in which both conserved lysine residues are replaced with asparagine residues, is reduced to only 12.2% of the activity of clone ZBl (averaged from three separate experiments) . These results suggest that the lysine residues at positions 240 and 274 function within the context of a repeated P-loop motif in the binding of 2-5A to 2-5A-dependent RNase. -55- The molecular cloning and expression of 2-5A-dependent RNase, the terminal factor in the 2-5A system and a key enzyme in the molecular mechanisms of interferon action is described. See FIG. 1. The recombinant proteins produced in vitro are demonstrated to possess 2-5A binding properties identical to naturally occurring forms of murine and human 2-5A-dependent RNase. See FIGS. 2, 5A, and 7. In addition, linkage of a 32 P-2-5A analogue to a truncated murine 2-5A-dependent RNase and to murine L cell 2-5A-dependent RNase followed by partial proteolysis reveals identical patterns of labeled peptides. See FIG. 2B. Furthermore, the full-length recombinant human 2-5A-dependent RNase isolated on the " activating, affinity matrix, 2-5A-cellulose, shows potent ribonuclease activity towards poly(U) but none against poly(C) . See FIG. 5B. Similarly, it is previously demonstrated that murine L cell 2-5A-dependent RNase was activated by 2-5A-cellulose resulting in the cleavage of poly(U) , but not of poly(C) . See Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985). The full-length human 2-5A-dependent RNase, which is produced in reticulocyte lysate, had the same apparent molecular weight as did naturally occurring 2-5A-dependent RNase. See FIG. 5A. However, the actual molecular mass of human 2-5A-dependent RNase is determined from -56- the predicted amino acid sequence, FIG. 3B, to be about 83,539 Da. Previously, it was reported that interferon enhances levels of 2-5A-dependent RNase by between two- to twenty-fold depending on the cell type. See Silverman, R.H. et al., Eur. J. Biochem.. 126:333-341 (1982b) and Jacobsen, H. et al., Virology. 125:496-501 (1983a). Results presented herein suggest that the gene for 2-5A-dependent RNase may be an interferon-sti ulated gene. See FIG. 6. Levels of 2-5A-dependent RNase mRNA in murine L929 cells are elevated as a function of time of interferon (α + (J) treatment by a factor of about three. Furthermore, the induction appeared to be a primary response to interferon treatment because it is observed in the presence of cycloheximide. Therefore, interferon is believed to regulate the 2-5A pathway by elevating levels of both 2-5A synthetases, Hovanessian, A.G. et al.. Nature. 268:537-539 (1977), and 2-5A-dependent RNase, Jacobsen, H. et al., Virology, 125:496-501 (1983a). See. FIGS. 1, 6 and 11. The cloning of 2-5A-dependent RNase reveals several features of the protein. The 2-5A binding domain is of particular interest because it is the ability of 2-5A-dependent RNase to be activated by 2-5A that sets it apart from other nucleases. By expressing nested 3'-deletions of murine -57- 2-5A-dependent RNase, a region between amino acids residues 218 and 294 which is believed to be critical for 2-5A binding activity is identified. See FIG. 7B. Interestingly, the identified region contains a repeated P-loop motif, one from residues 229 to 241 and another from residues 253 to 275. See FIG. 4 and Table 2 • When the latter P-loop motif (amino acids 253-275) is partially deleted, there is a precipitous decline in 2-5A binding activity. See clone ZB14 in FIG. 7B. The homology with P-loops is believed to be highly conserved between the human and murine forms of 2-5A-dependent RNase; thus underscoring the belief of the importance of this region for 2-5A binding activity. See FIG. 4. The similarity to P-loops consists of the tripeptides, glycine-lysine- threonine, preceded by glycine-rich sequences. In this regard, the unusual feature of 2-5A-dependent RNase is that the P-loop motif is repeated and are in the same orientation. Adenylyl cyclase from Bacillus anthracis also contains a duplicated P-loop motif, however, the two sequences are in opposite orientation and are overlapping. See Xia, Z. and Storm, D.R. , J. Biol. Chem.. 265:6517-6520 (1990). The relative importance of the conserved P-loop lysines (at positions 240 and 274) are evaluated by site-directed mutagenesis of the murine -58- 2-5A-dependent RNase, clone ZBl. Although individual substitution mutations of the two lysines significantly reduced 2-5A binding activity, replacing both of the lysines with asparagine residues in the same mutant RNase severely represses 2-5A binding. See FIG. 8. Perhaps the trimer 2-5A requirement for activation of most forms of 2-5A-dependent RNase could be explained if the first and third adenylyl residues of 2-5A interact with the separate P-loop sequences inducing conformational changes in 2-5A-dependent RNase. In this regard, dimer 2-5A neither binds 2-5A-dependent RNase efficiently nor does it activate 2-5A-dependent RNase, FIG. 7A; Kerr, I.M. and Brown, R.E. , Prod. Natl. Acad. Sci. U.S.A.. 75:265-260 (1978) and Knight, M. et al., ature. 288:189-192 (1980), perhaps because it is too short to span the two P-loop motifs. Alternately, the residual 2-5A binding activity observed in the point mutants, ZBl(Lys 240 -)Asn) and ZBl(Lys 27 -)Asn) , and the very low affinity of the double mutant, ZBl(Lys 240 ' 274 ->Asn) for 2-5A, could indicate that the two P-loop motifs are parts of separate 2-5A binding domains. Homology with protein kinase domains VI and VII is also identified in 2-5A-dependent RNase. See FIG. 4. See also Hanks, S.K. et al., Science. -59- 241:42-52 (1988). Although domain VI is believed to be involved in ATP binding, this region in 2-5A-dependent RNase is believed not to be important for 2-5A binding because its deletion caused only a minimal reduction in affinity for 2-5A. See FIG. 7B. However, a modest (two-fold) stimulatory effect of ATP on 2-5A-dependent RNase activity has been reported. See Wreschner, D.H. et al., Eur. J. Biochem.. 124:261-268 (1982) and Krause, D. et al., J. Biol. Chem.. 261:6836-6839 (1986). The latter report indicated that ATP was not required for 2-5A-dependent RNase activity but may act to stabilize the enzyme. Therefore, the region of homology with protein kinases could perhaps bind ATP resulting in stimulation of ribonuclease activity through stabilization of the enzyme. A consensus zinc finger domain, reviewed in Evans, R.M. and Hollenberg, S.M., Cell. 52:1-3 (1988) , consisting of six cysteine residues with the structure CX 4 CX 3 CX 17 CX 3 CX 3 C (amino acid residues 401-436 in Table 2 ) is identified in the murine form of 2-5A-dependent RNase. See FIG. 4. The homologous region in the human form of 2-5A-depenent RNase is CX 11 CX 25 CX 3 CX 6 C (amino acid numbers 395 to 444 in Table 1 ) . Because zinc fingers are nucleic acid binding domains, the cysteine-rich region in 2-5A-dependent RNase could be involved in binding to -60- the RNA substrate. Alternatively, the cysteine-rich domain in 2-5A-dependent RNase could mediate formation of 2-5A-dependent RNase dimers. Analysis of crude preparations of 2-5A-dependent RNase suggest that 2-5A-dependent RNase may form dimers in concentrated but not in dilute extracts. See Slattery, E. et al. , Proc. Natl. Acad. Sci. U.S.A.. 76:4778-4782 (1979) and Wreschner, D.H. et al., Eur. J. Biochem.. 124:261-268 (1982). Comparison between the amino acid sequences of other ribonucleases with 2-5A-dependent RNase identifies some limited homology with RNase E, an endoribonuclease from E. coli. See FIG. 9A. See also Apirion D. and Lassar, A.B. , J. Biol. Chem.. 253 " :1738-1742 (1978) and Claverie-Marti , F. et al., J. Biol. Chem. 266:2843-2851 (1991). The homology with RNase E is relatively conserved between the human and murine forms of 2-5A-dependent RNase and spans a region of about 200 amino acid residues. Within these regions there are 24 and 32% identical plus conservative matches, with some gaps, between RNase E and the human and murine forms of 2-5A-dependent RNase, respectively. See FIG. 9A. The me gene which encodes RNase E and the altered mRNA stability (ams) gene, Ono, M. and Kumano, M., J_ A . Mol. Biol.. 129:343-357 (1979), map to the same genetic locus. See Mudd E.A. et al., Mol. -61- Microbiol.. 4:2127-2135 (1990); Babitzke, P. and Kushner, S.R., Proc. Natl. Acad. Sci. U.S.A.. 88:1-5 (1991) and Taraseviciene, L. et al., Mol. Microbiol.. 5:851-855 (1991). RNase E is required for both efficient mRNA turnover and rRNA processing in E. coli. See Mudd E.A. et al., Mol. Microbiol.. 4:2127-2135 (1990) and Babitzke, P. and Kushner, S.R. , Proc. Natl. Acad. Sci. U.S.A.. 88:1-5 (1991). The cleavage specificities of 2-5A-dependent RNase and RNase E are similar in that 2-5A-dependent RNase cleaves mainly after UU or UA, Wreschner, D.H. et al., Nature. 289:414-417 (1981a) and Floyd-Smith, G. et al.. Science. 212:1020-1032 (1981), and RNase E usually cleaves within the central AUU sequence of (G or " A)AUU(A or U) , Ehretsmann, C.P. et al., Genes & Development. 6:149-159 (1992). The location of the RNase E homology and other identified features in 2-5A-dependent RNase are shown. See FIG. 9B. These findings raise the possibility that RNase E may be the ancestral precursor of 2-5A-dependent RNase. In this regard, there are indications of 2',5'-oligoadenylates in E. coli. See Brown, R.E. and Kerr, I.M., Process in Clinical and Biological Research. 202:3-10 (1985) and Trujillo, M.A. et al., Eur. J. Biochem.. 169:167-173 (1987). However, the evolutionary distribution of a complete 2-5A system (i.e. 2-5A synthetase and 2-5A-dependent RNase) is -62- reported to begin only with reptiles or possibly amphibia. See Cayley, P.J. et al., Biochem. Biophys. Res. Commun.. 108:1243-1250 (1982). Endoribonucleases play a controlling role in RNA metabolism by catalyzing the rate-limiting steps in RNA decay. See Brawerman, G., Cell. 57:9-10 (1989) . 2-5A-dependent RNase is a uniquely regulated endoribonuclease which mediates effects of interferon against picornaviruses. It functions by binding 2-5A and subsequently degrades both viral and cellular RNA. See Wreschner, D.H. et al.. Nucleic Acids Res.. 9:1571-1581 (1981b). In addition, the 2-5A system may be involved in the antiproliferative effects of interferon and in the fundamental control of RNA stability. Cellular levels of 2-5A-dependent RNase and/or 2-5A-synthetase are regulated during interferon-treatment, Hovanessian, A.G. et al.. ature. 268:537-539 (1977) and Jacobsen, H. et al.. Virology. 125:496-501 (1983a), cell growth arrest. Stark, G. et al., Nature. 278:471-473 (1979) and Jacobsen, H. et al., Proc. Natl. Acad. Sci. U.S.A.. 80:4954-4958 (1983b), cell differentiation, Krause, D. et al., Eur. J. Biochem.. 146:611-618 (1985), changing hormone status, e.g.. Stark, G. et al., Nature. 278:471-473 (1979), and liver regeneration, Etienne-Smekens, M. et al., Proc. Natl. Acad. Sci. U.S.A.. 80:4609-4613. (1983) . However, basal levels -63- of 2-5A-dependent RNase and 2-5A synthetase are present in most if not all mammalian cells. The existence of multiple forms of 2-5A synthetase with different intracellular locations, Hovanessian, A.G. et al., EMBO J.. 6:1273-1280 (1987), could indicate diverse functions for the 2-5A system. Similarly, the ubiquitous presence of the 2-5A system in higher animals suggests an important function for 2-5A-dependent RNase, Cayley, P.J. et al., Biochem. Biophys. Res. Commun.. 108:1243-1250 (1982). For instance, 2-5A-dependent RNase cleaves rRNA at specific sites in intact ribosomes, Wreschner, D.H. et al., Nucleic Acids Res.. 9:1571-1581 (1981b) and Silverman, R.H. et al., J. Virol.. 46:1051-1055 (1983) , possibly affecting translation rates. The transient nature of 2-5A, Williams, B.R.G. et al., Eur. J. Biochem.. 92:455-562 (1978) , and its growth inhibitory effect after introduction into cells, Hovanessian, A.G. and Wood, J.N. , virology. 101:81-89 (1980) , indicate that the 2-5A system is a tightly regulated pathway. EXAMPLE I The source of mRNA for preparing the cDNA library is murine L929 cells grown in EMEM (Whittaker, Inc.) and supplemented with about 10% FBS (Gibco-BRL) , and antibiotics. The cells are treated with about 50 μg per ml of cycloheximide and 1000 -64- units per ml of murine interferon (α + β) (1.3 X 10 7 units per mg protein: Lee Biomolecular) for about 2.5 hours to increase levels of 2-5A-dependent RNase mRNA. Total RNA was then isolated, e.g. Chomczynski, P. and Sacchi, N. , Anal. Biochem.. 162:156-159 (1987) , from which poly(A) + RNA is prepared by oligo(dT)-cellulose chromatography as described. See Sambroo , J. et al. , Cold Spring Harbor Laboratory Press (1989). Synthesis of the first strand of cDNA is done by using reverse transcriptase as described (Superscript; BRL) except that 5-methyl-dCTP is substituted for dCTP and an XhoI-oligo-dT adapter-primer (Stratagene) is used. Synthesis of the second strand of cDNA and ligation of EcoRI linker was as described (Stratagene) . The cDNA is digested with EcoRI and Xhol and unidirectionally cloned into predigested λZAPII vector (Stratagene) . The library is packaged by using Giagpack Gold extract and titered on PLK-F bacteria. The cDNA library is screened directly without prior amplification at a density of about 25,000 phage per 150 mm plate. Phage are grown for 3.5 hours at about 42°C until plaques are visible. Nitrocellulose filters saturated in IPTG (10 mM) and then dried, are overlaid on the plates and growth was continued for an additional 4 to 6 hours at 37 β C. The filters are processed by a modification of the -65- methods of Singh, H. et al.. Cell. 52:415-423 (1988) and Singh, H. et al., BioTechniσues. 7:252-261 (1989) . Filters are washed in ice-cold binding buffer (about 20 mM Tris-HCl, about pH 7.5, about 20 mM magnesium acetate, about 50 mM potassium chloride, about 1 mM EDTA, about 50 mM β-mercaptoethanol, about 0.1 mM PMSF, about 5% glycerol) containing about 6 M guanidine-HCl for about 20 min. The solution containing the filters is then diluted two-fold with binding buffer and washing on ice is continued for about an additional 5 minutes; serial two-fold dilutions were continued until the guanidine concentration was about 187. mM. The filters are then washed twice with binding buffer, and incubated with binding buffer containing about 5% nonfat milk for one hour at about room temperature. The filters are then washed twice with binding buffer and incubated in binding buffer (supplemented with about 0.25% nonfat dry milk and about 0.02% sodium azide) containing p(A2'p) 2 (br 8 A2'p) 2 A3'-[32P]Cp (the "2-5A probe"), Nolan-Sorden, N.L. et al., Anal. Biochem.. 184:298-304 (1990), at about 2 X 10 5 counts per minute per ml (about 3,000 Ci per mmole) at about 4°C with shaking for about 24 hours. The filters are washed twice with binding buffer and then twice with water before air drying and exposing to film. - 66- Murine L929 cells are treated with about 1000 units per ml interferon (α + β) with or without about 50 μg per ml of cycloheximide and the total RNA is then isolated as described. See Chomczynski, P. and Sacchi, N., Anal. Biochem.. 162:156-159 (1987). Poly(A) + RNA is prepared by oligo(dT)-cellulose chromatography, as described τ in Sambrook, J. et al., Cold Spring Harbor Laboratory Press (1989) , and is separated on glyoxal agarose gels and transferred to Nytran membranes. RNA is immobilized on the membrane by uv crosslinking (Stratalinker, Stratagene). The murine 2-5A-dependent RNase cDNA is 32 P-labeled by random priming and then hybridized to the filter [about 50% formamide, about 10% dextran sulphate, Denftardt's solution about 1% SDS, 6X SSPE, Sambrook, J. et al. , Cold Spring 'Harbor Laboratory Press (1989) , about 250 μg per ml salmon sperm DNA] at about 42°C. The Human 2-5A-dependent RNase cDNA clone, HZBl, is isolated from an adult human kidney cDNA library in λgtlO with radiolabeled (random primed) murine 2-5A-dependent RNase cDNA (clone ZBl) as probe, Sambrook, J. et al.. Cold Soring Harbor Laboratory Press (1989) . Clone HBZ22 is isolated using radiolabeled HZBl DNA as probe. The genomic human 2-5A-dependent RNase clone is isolated from a human placenta cosmid library in vector pVE15 -67- (Stratagene) with a radiolabeled fragment of HZB22 DNA as probe. The murine genomic 2-5A-dependent RNase clone is isolated from a mouse 129SV genomic library in vector λFIXII (Stratagene) with a radiolabeled fragment of 2-5A-BP cDNA (clone ZBl) as probe. Subcloning of DNA is in Bluescript vectors (Stratagene) . Transcription of plasmids with phage RNA polymerases is in the presence of mGppppG as described (Promega) except that reaction mixtures are supplemented with 15% dimethyl sulfoxide and incubations are at about 37°C for about 90 minutes. RNA is purified through Sephadex G50 spun-columns and ethanol precipitated prior to translation. Protein synthesis was performed, as described (Promega) , at about 30°C for about one hour in micrococcal nuclease-pretreated rabbit reticulocyte lysate or in an extract of wheat germ at about room temperature for about one hour and then at about 40°C for about 12 hours. Translation reactions contain about 50 μM zinc sulfate. Endogenous 2-5A-dependent RNase in the reticulocyte lysated is removed by adsorption to about 30 μM of p 2 (A2'p) 3 A covalently attached to cellulose (2-5A-cellulose) , prepared as described in Wells, J.A. et al., J. Biol. Chem.. 259:1363-1370 (1984) and Silverman, R.H. and Krause, D. , I.R.L. Press. Oxford. England, pp. 149-193 (1987) , for about -68- one hour on ice as described. See Silverman, R.H., Anal. Biochem.. 144:450-460 (1985). The 2-5A-dependent RNase:2-5A-cellulose complex is removed by twice centrifuging at about 400 x g for about 5 minutes at about 2°C. The supernatant completely lacking in measurable levels of 2-5A-dependent RNase. See FIG. 5. The set of nested 3'-deletions of the truncated murine 2-5A-dependent RNase cDNA, ZBl, is generated with exonuclease III/S1 nuclease digestion followed by filling-in with Klenow DNA Polymerase using the "Erase-A-Base" system (Promega) . The synthesis of the 2-5A probe, p(A2'p) 2 (br B A2'p) 2 A[32P]Cp, and its crosslinking to 2-5A-dependent RNase is performed exactly as described. See Nolan-Sorden, N.L. et al.. Anal. Biochem.. 184:298-304 (1990). Briefly, the 2-5A probe, about 0.7 to 2.5 nM at 3,0009 Ci/mmole, is incubated for about one hour on ice with cell extract prepared as described, Silverman, R.H. and Krause, D. , I.R.L. Press. Oxford. England. pp. 149-193 (1987) , in the absence or presence of unlabeled oligonucleotide competitors. Covalent crosslinking is done under a uv lamp (308 nm) for one hour on ice and the proteins are separated on SDS/10% polyacryla ide gels. Filter assays for 2-5A binding activity using the 2r5A probe for about one hour on -69- ice, as described in Knight, M. et al., Nature. 288:189-192 (1980). Protease digestions are performed on gel-purified proteins in a gel, as described by Cleveland, D.W. et al., J. Biol. Chem.. 252:1102-1106 (1977) . The ribonuclease assay with 2-5A-cellulose is performed, as described by Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985). Briefly, lysates are adsorbed to about 30 μM of 2-5A-cellulose on ice for about two hours. The matrix is then washed three times by centrifuging and resuspending in buffer A. See Silverman, R.H. , Anal. Biochem.. 144:450-460 (1985) . The matrix is then incubated with poly(U)-[ 32 P]Cp or poly(C)-[ 32 P]Cp (both at about 16 μM in nucleotide equivalents) at about 30°C and the levels of acid-precipitable radioactive RNA are determined by filtration on glass-fiber filters. The Sanger dideoxy sequencing method is used to determine the DNA sequences (Sequenase, United States Biomedical) . The lysines in the truncated murine 2-5A-dependent RNase, clone ZBl, at positions 240 and 274 are mutated, individually and together, to asparagine residues. Mutants ZBl(Lys 274 -)Asn) and the double mutant, ZBl(Lys 2 0 ' 274 ->Asn) , are obtained with mutant oligonucleotides after subcloning ZBl -70- cDNA into pALTER-1 as described (Promega) . Mutant ZBl(Lys 240 -)Asn) is obtained after polymerase chain reaction amplification of a segment of ZBl with an upstream primer containing a unique Hindi site attached to the mutant sequence and a second primer downstream of a unique Bglll site. The Hindi- and BGHI-digested polymerase chain reaction product and similarly-digested clone ZBl are then ligated. The specific mutations are: for codon 240, AAA-)AAC and for codon 274, AAG-)AAC. Mutants are confirmed by DNA sequencing. EXAMPLE II Seeds of tobacco (Nicotiana abacum cv. Wisconsin) and Ti based binary vectors pAM9 3 and pAM822 were obtained from Dr. Amit Mitra, Department of Plant Pathology, University of Nebraska, Lincoln, Nebraska. The Aroobacteriu tumefaciens LBA 04 and the E. coli strains K802 and MM294 were purchased from Clonetech, Palo Alto, California and Stragene, LaJolla, California. The plant tissue culture medium Murashige and Skoog'ε ready mix (MS media) was purchased from Sigma Chemical Company, St. Louis, Missouri. The human cDNAs for PKR, the lysine ■ » arginine mutant PKR, and 2-5A synthetase were obtained from Dr. B.R.G. Williams, Department of Cancer Biology, The Cleveland Clinic Foundation. See, for example, Meurs, E. et al.: Cell. 62:379-390 - 71- (1990) ; Chong , K.L. et al . : EMBO J . . 11-.1553-1562 (1992); Rysieki, G. et al.: J. Interferon Res.. 9:649-657 (1989); Benech, P. et al.: EMBO J.. 4:2249-2256 (1985); and Saunders, M.E. et al.: EMBO J t . 4:1761-1768 (1985). The human cDNA for 2-5A dependent RNase, as shown in FIG. 3A, was cloned in Dr. R.H. Silverman's laboratory in the Department of Cancer Biology and is the property of The Cleveland Clinic Foundation. See, Zhou, A. et al.: Cell. 72:753-765 (1993). The expression vector pAM943 is used to obtain Argobacterium-mediated transfer of T DNA containing the cDNAs and kanamycin resistance marker gene. The physical map of the plasmid vector pAM943 shows its elements. See FIG. 12. The plasmid pAM943 contains a dual promoter consisting of the adenyl methyl transferase (AMT) gene promoter of Chlorella virus and the wild type 35S promoter of Cauliflower mosaic virus. The vector also contains the gene for kanamycin resistance to select the transformed plants. Initially, the cDNAs are subcloned in pAM943 and amplified in E. coli strains K802 or MM294 using tetracycline resistance as the selectable marker. The Argobacterium cells are transformed with the recombinant pAM943 plasmids and selected by growth in medium containing about 5 μg/ml of tetracycline, -72- about 10 μg/ml of kanamycin and about 25 μg/ml of streptomyci . To subclone cDNAs for PKR (PK68) , a lysine •* arginine mutant PKR (muPk68; the mutant PKR protein binds to dsRNA but has no kinase activity and will thus function as a control) , and a low molecular weight form of 2-5A-synthetase (synthetase) , the plasmids pKS(+)PKR, pKS(+)muPKR, and pKS(+)synthetase are digested first with Xbal and than with Clal restriction endonucleases, the cDNA fragments are purified from low melting point agarose gels and subcloned in sense orientation at Xbal and Clal sites of pAM943. See FIG. 13. The recombinant plasmids, e.g., construct A, pAM943:PK68, construct B, pAM9 " 43:muPK68, and contruct C, pAM943:synthetase, which correspond to the constructs depicted in FIG. 13A-C, respectively, are used to transform Argobacteriu tu efaciens LBA4404. The resultant bacteria, identified as AG68, AGmu68 and AGsyn, respectively, are used for tobacco leaf disc transformations. Production of the recombinant plasmids, i.e., construct A, pAM943:PK68, construct B, pAM943:muPK68, and construct C pAM943:synthetase, is described in greater detail hereinafter. To subclone cDNA for 2-5A-dependent RNase, the plasmid pKS(+)2C5 DNA is digested with Hindlll enzyme and subcloned in the Hindlll site of pAM9 3 in -73- both orientations, see FIG. 13, and the recombinant plasmids, construct D, pAM943:2-5A-dep. RNase sense and construct D/a, pAM943:2-5A-dep. RNase antisense, both of which correspond to constructs D and D/a, respectively, in FIG. 13D and D/a, are used to transform Argobacterium to obtain the bacteria called AG2DR sense and AG2DR antisense, respectively. Production of the recombinant plasmids, i.e., construct D, pAM943:2-5A-dep. RNase sense, construct D/a, pAM943:2-5A-dep. RNase antisense, and construct E, pAM822:2-5A dep. RNase antisense, is also described in greater detail hereinafter. The competent Argobacterium cells are prepared and transformation follows the method of, for " example, An, G. et al.: Plant Molecular Biology Manual. AD:1-19 (1988). The presence of recombinant plasmids in the transformed Argobacterium cells is confirmed by preparing plasmid DNA and by performing PCR using specific complementary oligonucleotides and by observing restriction enzyme digests. The physical map of plasmid pAM822, one of the vectors used to deliver the reverse orientation cDNA for 2-5A dependent RNase into plant cells by electropcration, is also shown. See FIGS. 13E and 14. To subclone cDNA for 2-5A-dependent RNase into pAM822 the entire coding region of 2-5A-dependent RNase was PCR amplified using two oligonucleotide -74- primers containing BamHT restriction sites before ATG (start codon) and after TGA (stop codon) . The product was digested with BamHI and subcloned at Bglll site of pAM822 vector. The cDNA used for 2-5A-dependent RNase is in plasmid pZC5 referenced in Zhou et al. Cell 72, 753-765 (1994), the human form of the cDNA. The sequence is also disclosed herein. The plasmid pAM822 contains a second selectable marker gene, the hygromycin resistance gene, permitting the construction of plants containing both 2-5A-synthetase and 2-5A-dependent RNase cDNAs. Insertion of pAM822:2-5Adep. RNase (Fig. 13E) , containing 2-5A-dependent RNase cDNA, into kanamycin-resistant, transgenic tobacco leaf discs containing 2-5A-synthetase cDNA is thus performed. Tobacco plants are grown aseptically in Murashige and Skoog's medium, known as MS medium, containing about 3% sucrose (MSO medium) and about 0.8% agar in plastic boxes (Phytatray) at about 28*C under cycles consisting of about 16 hr of light and about 8 hr of dark in a growth chamber. Leaves bigger than about 2" long are cut into about 2 to 3 cm 2 pieces under the MSO medium and 6-8 leaf pieces are placed in a 6 cm Petri dish containing about 2 ml of MSO medium and holes are made in the leaf pieces with a sterile pointed forcep. Overnight cultures of AG68, AGmu68, AGSyn, .AG2DR sense and AG2DR antisense -75- are grown in LB (L broth) containing about 50 μM of acetosyringone and appropriate antibiotics at about 28*C in a waterbath. One hundred microliter of overnight culture is added to each of the Petri dishes containing leaf pieces. Incubation is at about 28*C under diffuse light in the growth chamber for about 2 days. Leaf pieces are washed extensively with MSO medium and transferred to solid agar for selection in shoot regeneration medium [MSO; about -0.5 mg/1 BAP (benzylaminopurine) ; about 200 μg/ml kanamycin; about 200 μg/ml carbenicillin; and about 100 μg/ml of cefotaxine] , under diffuse light at about 28*C in the growth chamber. Within about 3 weeks, regeneration of plantlets is observed. When the " plantlets are about 2-3cm long they are transferred to root-inducing, hormone-free MSO solid agar medium containing about 200 μg/ml kanamycin and about 200 μg/ml carbenicillin. The transgenic plants expressing 2-5A synthetase are substantially transformed to introduce the cDNA for 2-5A-dependent RNase (with pAM943:2-5Adep.RNase sense, construct D; FIG. 13D) . Alternatively, the vector pAM822 (FIG. 14) containing the 2-5A-dependent RNase cDNA in sense orientation and the hygromycin resistance gene is used to transform 2-5A-synthetase containing plants. This allows selection in hygromycin containing MSO media. Tissue culture and regeneration of plants are -76- done as described above. Transgenic plants are grown to produce flowers and seeds to demonstrate the transfer of the antiviral genes or nucleotide sequences to subsequent generations. Although specific plasmid constructs are described herein, the present invention is intended to include any plant vector including those with inducible promoters. Expression of PKR, mutant PKR, 2-5A-synthetase, and 2-5A-dependent RNase in plants that are 4" to 5" tall are tested in protein extracts of leaves (supernatant of 10,000 x g centrifugation) . Results of Northern and Southern blot assays and functional binding assays for 2-5A-dependent RNase are reported in Tables I-V. See also FIG. 15 wherein expression of human 2-5A synthetase cDNA in transgenic tobacco plants as determined by measuring the mRNA levels in a Northern blot is shown. FIG. 16, on the other hand, shows expression of mutant and wild type forms of human PKR cDNA in transgenic tobacco plants as determined by measuring mRNA levels in a Northern blot. FIG. 17 depicts presence of 2-5A-dependent RNase cDNA in transgenic tobacco plants as determined on a Southern blot. TABLE I Transgenic Tobacco Plants Expressing Wild Type and Mutant Forms of Human PKR cDNA (plasmid pAM943:PK68) FIG. 13A (plasmid pAM943:muPK68) FIG. 13B Transgenic: Plant: Southern Blot: Northern Blot: (clone #) (presence of DNA) (expression of mRNA) N.T. + N.T. + + + + + + + N.T. + N.T. N.T. + + N.T. N.T. TABLE II Transgenic Tobacco Plants Expressing Human 2-5A-Synthetase cDNA (Plasmid pAM943:synthetase - FIG. 13C) TABLE III Transgenic Tobacco Plants Containing Sense or Antisense Orientation Human 2-5A-Dependent RNase cDNA (plasmid pAM943:2-5A-dep. RNase sense - FIG. 13D) (plasmid pAM943:2-5A-dep. RNase antisense - FIG. 13D/a) N.T. , Not Tested. -80- TABLE III Transgenic Tobacco Plants Containing Sense or Antisense Orientation Human 2-5A-Dependent RNase cDNA (plasmid pAM943:2-5A-dep. RNase sense - FIG. 13D) (plasmid pAM943:2-5A-dep. RNase antisense - FIG. 13D/a) TABLE IV Transgenic Tobacco Plants Containing Both Human 2-5A-Synthetase and Human 2-5A-Dependent RNase cDNA (plasmid pAM943:synthetase - FIG. 13C) (plasmid pAM943:2-5A-dep. RNase sense - FIG. 13D) N.T!, Not Tested. -82- Assays of dsRNA-dependent autophosphoryl- ation of PKR, 2-5A synthetase activated with dsRNA, and 2-5A-dependent RNase by UV-crosslinking to radioactive 2-5A, see Nolan-Sorden et al.: Analytical Biochemists. (184) :298-304 (1990), may be performed on the leaf extracts. The levels of the proteins may also be determined by Western blot analysis using the antibodies against PKR, 2-5A-synthetase and 2-5A-dependent RNase. To demonstrate the expression of 2-5A-dependent RNase in transgenic plants containing construct D, pAM943:2-5A-dep. RNase sense, as depicted in FIG. 13D, functional assays that measure binding of radiolabeled 2-5A analog to 2-5A-dependent RNase are performed. See Tables III and V. Results show the presence of 2-5A-dependent RNase in transgenic plants Zl, Z2, Z3, Z5 and Z6. It is believed that the highest levels of human, recombinant 2-5A dependent RNase are in plant Z5. See Table V. TABLE V Functional Expression of 2-5A-Deρendent RNase in Transgenic Tobacco Plants ad Determined by a 2-5A Binding Assay (plasmid pAM943:2-5A-dep. RNase sense - FIG. 13D) Plant; 2-5A Binding Activity: Zl 662 Z2 1,618 Z3 1,545 Z5 2,575 Z6 1,547 Z7 31 a Tobacco plants contain construct D, pAM943:2-5Adep. RNase (sense) . 2-5A binding assays are performed by the filter binding method of Knight, M. et al. Nature (288) :189-192 (1980) with modifications. A 32 P-labeled and bromine substituted 2-5A analog, p(A2'p) 2 (br 8 A2'p) 2 A3'- 32 p]Cp, about 15,000 counts per min per assay, at about 3,000 Ci per mmole, Nolan-Sorden, N.L. , et al. Anal. Biochem.. (184) :298-304 (1990), is incubated with plant extracts, containing about 100 micrograms of protein per assay, or ice for about 4 h. The reaction mixtures are thei transferred to nitrocellulose filteres which are washec twice in distilled water and dried and the amount of 2-52 probe bound to the 2-5A-dependent RNase on the filters it measured by scintillation counting, Silverman, R.H. anc Krause, D. , In, Clemens, M.J. , Morris, A.G., and Gearing A.J.H., (eds.), Lymphokines and Interferons - A Practical Approach. I.R.L. Press, Oxford, pp. 149-193 (1987). Dat< is presented as counts per min of labeled 2-5A bound tc 2-5A-dependent RNase expressed in the transgenic plants Background radioactivity from extracts of control plants 705 counts per min, consisting of nonspecific binding o 2-5A, is subtracted from these data. -84- To further confirm that the transgenic plants containing 2-5A-dependent RNase cDNA express functional 2-5A-dependent RNase protein or an amino acid sequence, an affinity labeling method is performed (data not shown) . In this method, 2-5A-binding activity is determined on a Western blot with a bromine-substituted, 32 P-labeled 2-5A analog (the ••probe") , as described in Nolan-Sorden, N.L. et al.: Anal. Biochem.. 184:298-304 (1990). More particularly, leaves are collected from transgenic plants containing 2-5A-dependent RNase cDNA and they are homogenized in NP40 lysis buffer, see Silverman, R.H. and Krause, D. (1987) .In, Clemens, M.J. , Morris, A.G., and Gearing, A.J.H., (eds.), Lymphokines and Interferons - A Practical Approach. I.R.I. , Press, Oxford, pp. 149-193, supplemented with about 5mM ascorbic acid, about 1 mM cysteine, about 2 μg per ml leupeptin, about 100 μ per ml phenylmethyleulfonyl fluoride, and about 2 μg per ml pepstatin. Extracts are clarified by centrifugation at about 10,000 x g for about 10 min. Supernatants of the extracts, about 100 μg of protein per assay, are separated by SDS/10% polyacrylamide gel electrophoresis, followed by transfer of the proteins to Immobilon-P membrane filters (Millipore Corp., Bedford, MA). The filter is then incubated with about 4 X 10 5 c.p.m. per ml of 32 P-labeled 2-5A probe for about 24 h at about 4'C, -85- according to Zhou, A. et al.: Cell 73:753-765 (1993). The autoradiogra s of the washed and dried filters show the presence of functional human 2-5A-dependent RNase visible to about 80 kDa bands, in plants Z3, Z5, and Z6 (data not shown). Antiviral activity of the plants are determined by rubbing celite powder coated with Tobacco mosaic virus (ATCC) and Tobacco Etch virus (from Dr. Amit Mitra, Nebraska) . The plants are monitored for symptoms of viral infection on leaves from control and transgenic plants and are documented in photographs. The plasmids described and the transformed Argobacterium strains can be used to transform any other plants into virus-resistant plants. Exemplary of plants that may be transformed in accordance with the present invention include vegetable plants like corn, potato, carrot, lettuce, cabbage, broccoli, cauliflower, bean, squash, pumpkin, pepper, onion, tomato, pea, beet, celery, cucumber, turnip and radish plants, fruit plants like banana, apple, pear, plum , apricot, peach, nectarine, cherry, key lime, orange, lemon, lime, grapefruit, grape, berry, and melon plants, grain plants like wheat, barley, rice, oat and rye plants, grass, flowers, trees, shrubs and weeds such as laboratory weeds like Arabidopsis. It should therefore be understood that the present -86- invention includes any plant into which any nucleotide sequence encoding an amino acid having antiviral activity has been introduced to form transgenic plants having immunity or resistance against viral infection. Construction of pAM943:PKR fConstruct and PAM943;MUPKR (construct B) The plasmids pKS(+)PKR and pKS(+)muPKR, encoding wild type PKR and a lysine to arginine at codon 296 mutant form of PKR, respectively, present in E. coli cells (obtained from Dr. B.R.G. Williams, Cleveland Clinic, Cleveland, Ohio) are prepared by standard methods. See, for example, Katze, M.G. et al.: Mol. Cell Biol.. 11:5497-5505 (1991) for generation of muPKR, lysine - 296 •* • arginine mutant (K296R) , by site specific mutagenesis as described. The PKR nucleotide sequence utilized to construct plasmids pKS(+)PKR and pKS(+)muPKR is depicted in FIG. 18. To determine the ability of a plant translation apparatus to synthesize PKR protein, capped PKR mRNA is produced from linearized pKS(+)PKR by in vitro transcription. The RNA is then translated in wheat germ extract (obtained from Promega Corp., Madison, W.I.) in the presence of 35 S-methionine. Synthesis of the 35 S-labeled PKR is detected in an autoradiogram of the dried, SDS/polyacryla ide gel. -87- The cDNAs encoding PKR and muPKR are excised from plasmids pKS(+)PKR and pKS(+)muPKR by digesting with Kpnl and Xbal. The resulting DNA fragments containing the entire coding sequences for PKR and muPKR are purified from a low melting point agarose gel. To generate cDNAs containing at the 5' end Xbal and at the 3' end Clal sites, the PKR cDNA and muPKR cDNA are then digested with Clal and purified. The resulting digested PKR cDNA and muPKR cDNA are then force cloned into Xbal and Clal digested pAM943 by DNA ligation. The resulting plasmids, FIG. 13, constructs A and B, are used to transform Argobacterium tumefaciens strain LBA4404 (Clonetech, Plao Alto, CA) . Recombinant plasmids are prepared from transformed Argobacterium tumefaciens bacteria by standard methods and the presence of PKR and muPKR cDNA is confirmed by PCR analysis and restriction enzyme digests of the isolated plasmids. Construction of pAM943:Synthetase (construct C) The plasmid ptac-15 containing the human cDNA illustrated in FIG. 20 for a small form of 2-5A-synthetase (producing a 1.8 kb mRNA) (obtained from Dr. B.R.G. Williams, Cleveland Clinic, Cleveland, Ohio) is prepared by standard methods and is digested with BamHI and EcoRI. The synthetase cDNA is purified from a low melting point agarose gel by standard methods, and is then subcloned into -88- plasmid pKS(+) (Strategene, La Jolla, CA) in BamHI and EcoRI sites. The resulting recombinant plasmid DNA (pKS(+)synthetase) is digested with Xbal and Clal and the 2-5A synthetase cDNA is purified from a low melting point agarose gel and is then subcloned into Xbal and Clal digested pAM9 3 to produce construct C (FIG. 13) . Recombinant plasmids are prepared from transformed Argobacterium tumefaciens bacteria by standard methods and the presence of 2-5A-synthetase cDNA is confirmed by PCR analysis and by restriction enzyme digests of the isolated plasmids. Construction of pAM943:2-5Adep.RNase sense (construct D) and pAM943:2-5Adep.RNase antisense (construct D/aϊ The plasmid pKS(+)ZC5 encoding a complete coding sequence for human 2-5A-dependent RNase is digested with Hindlll. The 2.5kbp cDNA for 2-5A-dependent RNase is purified in a low melting point agarose gel and is then subcloned in Hindlll digested pAM9 3 in both sense (forward) and antisense (reverse) orientations to produce pAM943:2-5Adep.RNase sense (construct D) and pAM943:2-5Adep.RNase antisense (construct D/a), as depicted in FIG. 13D and D/a, respectively. Transformed Argobacterium are determined to contain the 2-5A-dependent RNase cDNA by restriction enzyme digests and by PCR analysis. - 89- Construction of pAM822:2-5Adep. Nase antisense (construct E) Polymerase chain reactions (PCR) are performed on plasmid pKS(+)ZC5 encoding human 2-5A-dependent RNase to generate Hindlll and BamHI sites on the two ends of the cDNA and to reduce 5' and 3' untranslated sequences. The PCR primers used are: ID SEQ NO:7: 2DR-5 5'-TCATGCTCGAGAAGCTTGGATCCACCATGGAGAGCAGGGAT- 3' ; and ID SEQ NO:8: H2DR-4 5'-GATACTCGAGAAGCTTGCATCCTCATCAGCACCCAGGGCTGG -3'. The PCR product (about 2.25 kbp) is purified on a low melting point agarose gel and is then digested with Hindlll and is then subcloned into Hindlll digested plasmid pKS(+). The resulting plasmid, pKS:pZC5 is digested with BamHI and the 2-5A-dependent RNase cDNA fragment is purified and cloned into Bglll digested pAM822. Recombinants isolated in the reverse (antisense) orientation give pAM822:2-5Adep.RNase antisense (construct E) . See FIG. 13E. -90- As to the nucleotide sequences disclosed herein, A means adenine; C means cytosine; G means guanine; T means thymine; and U means uracil. With respect to the disclosed amino acid sequences, A means ala or alanine; R means arg or arginine; N means asn or asparagine; D means asp or aspartic acid; C means cys or cysteine; E means glu or glutamic acid; Q means gin or glutamine; G means gly or glycine; H means his or histidine; I means ile or isoleucine; L means leu or leucine; K means lys or Lysine; M means met or methionine; F means phe or phenylalanine; P means pro or proline; S means ser or serine; T means thr or threonine; W means trp or tryptophan; Y means tyr or tyrosine; and V means val or valine. The following listed materials are on deposit under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, USA, and have been assigned the following Accession Numbers. •this seed contains construct D, shown in Fig. 13, which is pAM943:2-5Adep.RNase **this seed contains construct C, shown in Fig. 13, which is pAM943:Synthetase -91- TABLE 1 pirpa-n 2-5A-depedent RNase SEQ ID NO:1• , SEQ ID NO:2: , SEQ ID NO:3: and SEQ ID NO:4 -103 aatcccaacttacactcaaagct tctttgattaagtgctaggagataaatttgcattttctca aggaaaaggctaaaagtggtagcaggtggcatttaccgtc ATG GAG AGC AGG GAT CAT AAC AAC CCC CAG 30 Met Glu Ser Arg Asp His Asn Asn Pro Gin 10 GAG GGA CCC ACG TCC TCC AGC GGT AGA AGG 60 Glu Gly Pro Thr Ser Ser Ser Gly Arg Arg 20 GCT GCA GTG GAA GAC AAT CAC TTG CTG ATT 90 Ala Ala Val Glu Asp Asn His Leu Leu lie 30 AAA GCT GTT CAA AAC GAA GAT GTT GAC CTG 120 Lys Ala Val Gin Asn Glu Asp Val Asp Leu 40 GTC CAG CAA TTG CTG GAA GGT GGA GCC AAT 150 Val Gin Gin Leu Leu Glu Gly Gly Ala Asn 50 GTT AAT TTC CAG GAA GAG GAA GGG GGC TGG 180 Val Asn Phe Gin Glu Glu Glu Gly Gly Trp 60 ACA-CCT CTG CAT AAC GCA GTA CAA ATG AGC 210 Thr Pro Leu His Asn Ala Val Gin Met Ser 70 AGG GAG GAC ATT GTG GAA CTT CTG CTT CGT 240 Arg Glu Asp lie Val Glu Leu Leu Leu Arg 80 CAT GGT GCT GAC CCT GTT CTG AGG AAG AAG 270 His Gly Ala Asp Pro Val Leu Arg Lys Lys 90 (CCT)* AAT GGG GCC ACG CTT TTT ATC CTC GCA GCG 300 Asn Gly Ala Thr Leu Phe lie Leu Ala Ala 100 (Pro)* ATT GCG GGG AGC GTG AAG CTG CTG AAA CTT 330 lie Ala Gly Ser Val Lys Leu Leu Lys Leu 110 TTC CTT TCT AAA GGA GCA GAT GTC AAT GAG 360 Phe Leu Ser Lys Gly Ala Asp Val Asn Glu 120 TGT GAT TTT TAT GGC TTC ACA GCC TTC ATG 390 Cys Asp Phe Tyr Gly Phe Thr Ala Phe Met 130 GAA GCC GCT GTG TAT GGT AAG GTC AAA GCC 420 Glu Ala Ala Val Tyr Gly Lys Val Lys Ala 140 -92* CTA AAA TTC CTT TAT AAG AGA GGA GCA AAT 450 Leu Lys Phe Leu Tyr Lys Arg Gly Ala Asn 150 GTG AAT TTG AGG CGA AAG ACA AAG GAG GAT 480 Val Asn Leu Arg Arg Lys Thr Lys Glu Asp 160 CAA GAG CGG CTG AGG AAA GGA GGG GCC ACA 510 Gin Glu Arg Leu Arg Lys Gly Gly Ala Thr 170 GCT CTC ATG GAC GCT GCT GAA AAA GGA CAC 540 Ala Leu Met Asp Ala Ala Glu Lys Gly His 180 GTA GAG GTC TTG AAG ATT CTC CTT GAT GAG 570 Val Glu Val Leu Lys lie Leu Leu Asp Glu 190 ATG GGG GCA GAT GTA AAC GCC TGT GAC AAT 600 Met Gly Ala Asp Val Asn Ala Cys Asp Asn 200 ATG GGC AGA AAT GCC TTG ATC CAT GCT CTC 630 Met Gly Arg Asn Ala Leu lie His Ala Leu 210 CTG AGC TCT GAC GAT AGT GAT GTG GAG GCT 660 Leu Ser Ser Asp Asp Ser Asp Val Glu Ala 220 ATT ACG CAT CTG CTG CTG GAC CAT GGG GCT 690 lie Thr His Leu Leu Leu Asp His Gly Ala 230 GAT GTC AAT GTG AGG GGA GAA AGA GGG AAG 720 Asp "Val Asn Val Arg Gly Glu Arg Gly Lys 240 ACT CCC CTG ATC CTG GCA GTG GAG AAG AAG 750 Thr Pro Leu lie Leu Ala Val Glu Lys Lys 250 CAC TTG GGT TTG GTG CAG AGG CTT CTG GAG 780 His Leu Gly Leu Val Gin Arg Leu Leu Glu 260 CAA GAG CAC ATA GAG ATT AAT GAC ACA GAC 810 Gin Glu His lie Glu lie Asn Asp Thr Asp 270 AGT GAT GGC AAA ACA GCA CTG CTG CTT GCT 840 Ser Asp Gly Lys Thr Ala Leu Leu Leu Ala 280 GTT GAA CTC AAA CTG AAG AAA ATC GCC GAG 870 Val Glu Leu Lys Leu Lys Lys lie Ala Glu 290 TTG CTG TGC AAA CGT GGA GCC AGT ACA GAT 900 Leu Leu Cys Lys Arg Gly Ala Ser Thr Asp 300 TGT GGG GAT CTT GTT ATG ACA GCG AGG CGG 930 Cys Gly Asp Leu Val Met Thr Ala Arg Arg 310 AAT TAT GAC CAT TCC CTT GTG AAG GTT CTT 960 Asn Tyr Asp His Ser Leu Val Lys Val Leu 320 -93- CTC TCT CAT GGA GCC AAA GAA GAT TTT CAC 990 Leu Ser His Gly Ala Lys Glu Asp Phe His 330 CCT CCT GCT GAA GAC TGG AAG CCT CAG AGC 1020 Pro Pro Ala Glu Asp Trp Lys Pro Gin Ser 340 TCA CAC TGG GGG GCA GCC CTG AAG GAT CTC 1050 Ser His Trp Gly Ala Ala Leu Lys Asp Leu 350 CAC AGA ATA TAC CGC CCT ATG ATT GGC AAA 1080 His Arg lie Tyr Arg Pro Met lie Gly Lys 360 CTC AAG TTC TTT ATT GAT GAA AAA TAC AAA 1110 Leu Lys Phe Phe lie Asp Glu Lys Tyr Lys 370 ATT GCT GAT ACT TCA GAA GGA GGC ATC TAC 1140 lie Ala Asp Thr Ser Glu Gly Gly lie Tyr 380 CTG GGG TTC TAT GAG AAG CAA GAA GTA GCT 1170 Leu Gly Phe Tyr Glu Lys Gin Glu Val Ala 390 GTG AAG ACG TTC TGT GAG GGC AGC CCA CGT 1200 Val Lys Thr Phe Cys Glu Gly Ser Pro Arg 400 GCA CAG CGG GAA GTC TCT TGT CTG CAA AGC 1230 Ala Gin Arg Glu Val Ser Cys Leu Gin Ser 410 AGC CGA GAG AAC AGT CAC TTG GTG ACA TTC 1260 Ser "Arg Glu Asn Ser His Leu Val Thr Phe 420 TAT GGG AGT GAG AGC CAC AGG GGC CAC TTG 1290 Tyr Gly Ser Glu Ser His Arg Gly His Leu 430 TTT GTG TGT GTC ACC CTC TGT GAG CAG ACT 1320 Phe Val Cys Val Thr Leu Cys Glu Gin Thr 440 CTG GAA GCG TGT TTG GAT GTG CAC AGA GGG 1350 Leu Glu Ala Cys Leu Asp Val His Arg Gly 450 GAA GAT GTG GAA AAT GAG GAA GAT GAA TTT 1380 Glu Asp Val Glu Asn Glu Glu Asp Glu Phe 460 GCC CGA AAT GTC CTG TCA TCT ATA TTT AAG 1410 Ala Arg Asn Val Leu Ser Ser lie Phe Lys 470 GCT GTT CAA GAA CTA CAC TTG TCC TGT GGA 1440 Ala Val Gin Glu Leu His Leu Ser Cys Gly 480 TAC ACC CAC CAG GAT CTG CAA CCA CAA AAC 1470 Tyr Thr His Gin Asp Leu Gin Pro Gin Asn 490 ATC TTA ATA GAT TCT AAG AAA GCT GCT CAC 1500 lie Leu lie Asp Ser Lys Lys Ala Ala His 500 .94- CTG GCA GAT TTT GAT AAG AGC ATC AAG TGG 1530 Leu Ala Asp Phe Asp Lys Ser lie Lys Trp 510 GCT GGA GAT CCA CAG GAA GTC AAG AGA GAT 1560 Ala Gly Asp Pro Gin Glu Val Lys Arg Asp 520 CTA GAG GAC CTT GGA CGG CTG GTC CTC TAT 1590 Leu Glu Asp Leu Gly Arg Leu Val Leu Tyr 530 GTG GTA AAG AAG GGA AGC ATC TCA TTT GAG 1620 Val Val Lys Lys Gly Ser He Ser Phe Glu 540 GAT CTG AAA GCT CAA AGT AAT GAA GAG GTG 1650 Asp Leu Lys Ala Gin Ser Asn Glu Glu Val 550 GTT CAA CTT TCT CCA GAT GAG GAA ACT AAG 1680 Val Gin Leu Ser Pro Asp Glu Glu Thr Lys 560 GAC CTC ATT CAT CGT CTC TTC CAT CCT GGG 1710 Asp Leu He His Arg Leu Phe His Pro Gly 570 GAA CAT GTG AGG GAC TGT CTG AGT GAC CTG 1740 Glu His Val Arg Asp Cys Leu Ser Asp Leu 580 CTG GGT CAT CCC TTC TTT TGG.ACT TGG GAG 1770 Leu Gly His Pro Phe Phe Trp Thr Trp Glu 590 AGC CGC TAT AGG ACG CTT CGG AAT GTG GGA 1800 Ser Αrg Tyr Arg Thr Leu Arg Asn Val Gly 600 AAT GAA TCC GAC ATC AAA ACA CGA AAA TCT 1830 Asn Glu Ser Asp He Lys Thr Arg Lys Ser 610 GAA AGT GAG ATC CTC AGA CTA CTG CAA CCT 1860 Glu Ser Glu He Leu Arg Leu Leu Gin Pro 620 GGG CCT TCT GAA CAT TCC AAA AGT TTT GAC 1890 Gly Pro Ser Glu His Ser Lys Ser Phe Asp 630 AAG TGG ACG ACT AAG ATT AAT GAA TGT GTT 1920 Lys Trp Thr Thr Lys He Asn Glu Cys Val 640 ATG AAA AAA ATG AAT AAG TTT TAT GAA AAA 1950 Met Lys Lys Met Asn Lys Phe Tyr Glu Lys 650 AGA GGC AAT TTC TAC CAG AAC ACT GTG GGT 1980 Arg Gly Asn Phe Tyr Gin Asn Thr Val Gly 660 GAT CTG CTA AAG TTC ATC CGG AAT TTG GGA 1210 Asp Leu Leu Lys Phe He Arg Asn Leu Gly 670 GAA CAC ATT GAT GAA GAA AAG CAT AAA AAG 2040 Glu His He Asp Glu Glu Lys His Lys Lys 680 -95- ATG AAA TTA AAA ATT GGA GAC CCT TCC CTG 2070 Met Lys Leu Lys He Gly Asp Pro Ser Leu 690 TAT TTT CAG AAG ACA TTT CCA GAT CTG GTG 2100 Tyr Phe Gin Lys Thr Phe Pro Asp Leu Val 700 ATC TAT GTC TAC ACA AAA CTA CAG AAC ACA 2130 He Tyr Val Tyr Thr Lys Leu Gin Asn Thr 710 GAA TAT AGA AAG CAT TTC CCC CAA ACC CAC 2160 Glu Tyr Arg Lys His Phe Pro Gin Thr His 720 AGT CCA AAC AAA CCT CAG TGT GAT GGA GCT 2190 Ser Pro Asn Lys Pro Gin Cys Asp Gly Ala 730 GGT GGG GCC AGT GGG TTG GCC AGC CCT GGG 2220 Gly Gly Ala Ser Gly Leu Ala Ser Pro Gly 740 TGC 2223 tgatggactgatttgctggagttcagggaactact 2258 Cys 741 tattagctgtagagtccttggcaaatcacaacat 2292 tctgggccttttaactcaccaggttgcttgtgagggat 2330 gagttgcatagctgatatgtcagtccctggcatcgtg 2367 tattccatatgtctataacaaaagcaatatatacccag 2405 actacactagtccataagctttacccactaactggga 2442 ggacattctgctaagattccttttgtcaattgcaccaa 2480 aagaatgagtgccttgacccctaatgctgcatatgtt 2517 acaattctctcacttaattttcccaatgatcttgcaaa 2555 acagggattatcatccccatttaagaactgaggaacc 2592 tgagactcagagagtgtgagctactggcccaagattat 2630 tcaatttatacctagcactttataaatttatgtggtg 2667 ttattggtacctctcatttgggcaccttaaaacttaac 2705 tatcttccagggctcttccagatgaggcccaaaacat 2742 atataggggttccaggaatctcattcattcattcagta 2780 tttattgagcatctagtataag ctgggcactggatg 2817 catgaatt 2825 *It is believed that the original codon number 95, i.e. CTT encoding the amino acid number 95, i.e. leucine, is correct, however the alternative codon in parenthesis shown above codon number 95, i.e. CCT encoding the alternative amino acid in parenthesis shown below amino acid number 95, i.e. proline may also exist at this position (see page 81) . SEQ ID NO:1: represents the DNA encoding sequence for the human 2-5A-dependent RNase protein. SEQ ID NO:2: represents the amino acid sequence encoded by the DNA sequence designated SEQ ID NO:1: . SEQ ID NO:3: represents the DNA sequence, represented by SEQ ID NO:l:, having the alternative codon number 95, CCT. SEQ ID NO:4: represents the amino acid sequence encoded by SEQ ID NO:3: , having the alternative amino acid number 95, proline. - 96- TABLE 2 Murine 2-5 -deoendent RNase (partial^ SEQ ID NO:5: and SEQ ID NO:6: -163 attcggcacgaggaaggtgccaattactagctcccttctttattcgtgta ctgatgagatgtcagaagacagaacataatcagcccaatccctactccaa gactctcattgtgtcccaaagaaacacacgtgtgcatttcccaaggaaaa ggcattgaggacc ATG GAG ACC CCG GAT TAT 18 Met Glu Thr Pro Asp Tyr 6 AAC ACA CCT CAG GGT GGA ACC CCA TCA GCG 48 Asn Thr Pro Gin Gly Gly Thr Pro Ser Ala 16 GGA AGT CAG AGG ACC GTT GTC GAA GAT GAT 78 Gly Ser Gin Arg Thr Val Val Glu Asp Asp 26 TCT TCG TTG ATC AAA GCT GTT CAG AAG GGA 108 Ser Ser Leu He Lys Ala Val Gin Lys Gly 36 GAT GTT GTC AGG GTC CAG CAA TTG TTA GAA 138 Asp Val Val Arg Val Gin Gin Leu Leu Glu 46 AAA " GGG GCT GAT GCC AAT GCC TGT GAA GAC 168 Lys Gly Ala Asp Ala Asn Ala Cys Glu Asp 56 ACC TGG GGC TGG ACA CCT TTG CAC AAC GCA 198 Thr Trp Gly Trp Thr Pro Leu His Asn Ala 66 GTG CAA GCT GGC AGG GTA GAC ATT GTG AAC 228 Val Gin Ala Gly Arg Val Asp He Val Asn 76 CTC CTG CTT AGT CAT GGT GCT GAC CCT CAT 258 Leu Leu Leu Ser His Gly Ala Asp Pro His 86 CGG AGG AAG AAG AAT GGG GCC ACC CCC TTC 288 Arg Arg Lys Lys Asn Gly Ala Thr Pro Phe 96 ATC ATT GCT GGG ATC CAG GGA GAT GTG AAA 318 He He Ala Gly He Gin Gly Asp Val Lys 106 CTG CTC GAG ATT CTC CTC TCT TGT GGT GCA 348 Leu Leu Glu He Leu Leu Ser Cys Gly Ala 116 GAC GTC AAT GAG TGT GAC GAG AAC GGA TTC 378 Asp Val Asn Glu Cys Asp Glu Asn Gly Phe 126 -97- ACG GCT TTC ATG GAA GCT GCT GAG CGT GGT 408 Thr Ala Phe Met Glu Ala Ala Glu Arg Gly 136 AAC GCT GAA GCC TTA AGA TTC CTT TTT GCT 438 Asn Ala Glu Ala Leu Arg Phe Leu Phe Ala 146 AAG GGA GCC AAT GTG AAT TTG CGA CGA CAG 468 Lys Gly Ala Asn Val Asn Leu Arg Arg Gin 156 ACA ACG AAG GAC AAA AGG CGA TTG AAG CAA 498 Thr Thr Lys Asp Lys Arg Arg Leu Lys Gin 166 GGA GGC GCC ACA GCT CTC ATG AGC GCT GCT 528 Gly Gly Ala Thr Ala Leu Met Ser Ala Ala 176 GAG AAG GGC CAC CTG GAA GTC CTG AGA ATT 558 Glu Lys Gly His Leu Glu Val Leu Arg He 186 CTC CTC AAT GAC ATG AAG GCA GAA GTC GAT 588 Leu Leu Asn Asp Met Lys Ala Glu Val Asp 196 GCT CGG GAC AAC ATG GGC AGA AAT GCC CTG 618 Ala Arg Asp Asn Met Gly Arg Asn Ala Leu 206 ATC CGT ACT CTG CTG AAC TGG GAT TGT GAA 648 He Arg Thr Leu Leu Asn Trp Asp Cys Glu 216 AAT GTG GAG GAG ATT ACT TCA ATC CTG ATT 678 Asn " Val Glu Glu He Thr Ser He Leu He 226 CAG CAC GGG GCT GAT GTT AAC GTG AGA GGA 708 Gin His Gly Ala Asp Val Asn Val Arg Gly 236 GAA AGA GGG AAA ACA CCC CTC ATC GCA GCA 738 Glu Arg Gly Lys Thr Pro Leu He Ala Ala 246 GTG GAG AGG AAG CAC ACA GGC TTG GTG CAG 768 Val Glu Arg Lys His Thr Gly Leu Val Gin 256 ATG CTC CTG AGT CGG GAA GGC ATA AAC ATA 798 Met Leu Leu Ser Arg Glu Gly He Asn He 266 GAT GCC AGG GAT AAC GAG GGC AAG ACA GCT 828 Asp Ala Arg Asp Asn Glu Gly Lys Thr Ala 276 CTG CTA ATT GCT GTT GAT AAA CAA CTG AAG 858 Leu Leu He Ala Val Asp Lys Gin Leu Lys 286 GAA ATT GTC CAG TTG CTT CTT GAA AAG GGA 888 Glu He Val Gin Leu Leu Leu Glu Lys Gly 296 GCT GAT AAG TGT GAC GAT CTT GTT TGG ATA 918 Ala Asp Lys Cys Asp Asp Leu Val Trp He 306 ■ 98- GCC AGG AGG AAT CAT GAC TAT CAC CTT GTA 948 Ala Arg Arg Asn His Asp Tyr His Leu Val 316 AAG CTT CTC CTC CCT TAT GTA GCT AAT CCT 978 Lys Leu Leu Leu Pro Tyr Val Ala Asn Pro 326 GAC ACC GAC CCT CCT GCT GGA GAC TGG TCG 1008 Asp Thr Asp Pro Pro Ala Gly Asp Trp Ser 336 CCT CAC AGT TCA CGT TGG GGG ACA GCC TTG 1038 Pro His Ser Ser Arg Trp Gly Thr Ala Leu 346 AAA AGC CTC CAC AGT ATG ACT CGA CCC ATG 1068 Lys Ser Leu His Ser Met Thr Arg Pro Met 356 ATT GGC AAA CTC AAG ATC TTC ATT CAT GAT 1098 He Gly Lys Leu Lys He Phe He His Asp 366 GAC TAT AAA ATT GCT GGC ACT TCC GAA GGG 1128 Asp Tyr Lys He Ala Gly Thr Ser Glu Gly 376 GCT GTC TAC CTA GGG ATC TAT GAC AAT CGA 1158 Ala Val Tyr Leu Gly He Tyr Asp Asn Arg 386 GAA GTG GCT GTG AAG GTC TTC CGT GAG AAT 1188 Glu Val Ala Val Lys Val Phe Arg Glu Asn 396 AGC CCA CGT GGA TGT AAG GAA GTC TCT TGT 1218 Ser " Pro Arg Gly Cys Lys Glu Val Ser Cys 406 CTG CGG GAC TGC GGT GAC CAC AGT AAC TTA 1248 Leu Arg Asp Cys Gly Asp His Ser Asn Leu 416 GTG GCT TTC TAT GGA AGA GAG GAC GAT AAG 1278 Val Ala Phe Tyr Gly Arg Glu Asp Asp Lys 426 GGC TGT TTA TAT GTG TGT GTG TCC CTG TGT 1308 Gly Cys Leu Tyr Val Cys Val Ser Leu Cys 436 GAG TGG ACA CTG GAA GAG TTC CTG AGG TTG 1338 Glu Trp Thr Leu Glu Glu Phe Leu Arg Leu 446 CCC AGA GAG GAA CCT GTG GAG AAC GGG GAA 1368 Pro Arg Glu Glu Pro Val Glu Asn Gly Glu 456 GAT AAG TTT GCC CAC AGC ATC CTA TTA TCT 1398 Asp Lys Phe Ala His Ser He Leu Leu Ser 466 ATA TTT GAG GGT GTT CAA AAA CTA CAC TTG 1428 He Phe Glu Gly Val Gin Lys Leu His Leu 476 CAT GGA TAT TCC CAT CAG GAC CTG CAA CCA 1458 His Gly Tyr Ser His Gin Asp Leu Gin Pro 486 -99- CAA AAC ATC TTA ATA GAT TCC AAG AAA GCT 1488 Gin Asn He Leu He Asp Ser Lys Lys Ala 496 GTC CGG CTG GCA GAT TTT GAT CAG AGC ATC 1518 Val Arg Leu Ala Asp Phe Asp Gin Ser He 506 CGA TGG ATG GGA GAG TCA CAG ATG GTC AGG 1548 Arg Trp Met Gly Glu Ser Gin Met Val Arg 516 AGA GAC TTG GAG GAT CTT GGA CGG CTG GTT 1578 Arg Asp Leu Glu Asp Leu Gly Arg Leu Val 526 CTC TAC GTG GTA ATG AAA GGT GAG ATC CCC 1608 Leu Tyr Val Val Met Lys Gly Glu He Pro 536 TTT GAG ACA CTA AAG ACT CAG AAT GAT GAA 1638 Phe Glu Thr Leu Lys Thr Gin Asn Asp Glu 546 GTG CTG CTT ACA ATG TCT CCA GAT GAG GAG 1668 Val Leu Leu Thr Met Ser Pro Asp Glu Glu 556 ACT AAG GAC CTC ATT CAT TGC CTG TTT TCT 1698 Thr Lys Asp Leu He His Cyc Leu Phe Ser 566 CCT GGA GAA AAT GTC AAG AAC TGC CTG GTA 1728 Pro Gly Glu Asn Val Lys Asn Cys Leu Val 576 GAC CTG CTT GGC CAT CCT TTC TTT TGG ACT 1758 Asp " Leu Leu Gly His Pro Phe Phe Trp Thr 586 TGG GAG AAC CGC TAT AGA ACA CTC CGG AAT 1788 Trp Glu Asn Arg Tyr Arg Thr Leu Arg Asn 596 GTG GGA AAT GAA TCT GAC ATC AAA GTA CGG 1818 Val Gly Asn Glu Ser Asp He Lys Val Arg 606 AAA TGT AAA AGT GAT CTT CTC AGA CTA CTG 1848 Lys Cys Lys Ser Asp Leu Leu Arg Leu Leu 616 CAG CAT CAG ACA CTT GAG CCT CCC AGA AGC 1878 Gin His Gin Thr Leu Glu Pro Pro Arg Ser 626 TTT GAC CAG TGG ACA TCT AAG ATC GAC AAA 1908 Phe Asp Gin Trp Thr Ser Lys He Asp Lys 636 AAT GTT ATG GAT GAA ATG AAT CAT TTC TAC 1938 Asn Val Met Asp Glu Met Asn His Phe Tyr 646 GAA AAG AGA AAA AAA AAC CCT TAT CAG GAT 1968 Glu Lys Arg Lys Lys Asn Pro Tyr Gin Asp 656 ACT GTA GGT GAT CTG CTG AAG TTT ATT CGG 1998 Thr Val Gly Asp Leu Leu Lys Phe He Arg 666 AAT ATA G GC GAA CAC ATC AAT GAG GAA AAA 2 028 j£n lie Gly G lu His He Asn Glu Glu Lys 676 2037 AAG CGG GGG 679 Lys Arg Gly SEQ ID NO:5 : represents the DNA sequence encod i n Murine 2-5A-dependent RNase (partial). SEQ ID NO.o. represents the amino acid sequence encoded by SEQ ID NO:5: . EXAMPLE III The Ti based binary vector, plasmid pAM943 (Mitra, A. et al. : Plant Mol Biol. 26:85-93 (1994)) containing a dual promoter consisting of the upstream region of the gene for adenyl methyl transferase (AMT) of Chlorella virus and the minimum length of 35S promoter is used as the cloning vector for this study. See FIG. 13. The vector also contains the gene for kanamycin resistance for selection of the transformed plants. Bacterial strains used are the Agrobacterium tumefaciens strain, LBA4404 and the Escherichia coli strain MM294 (Clonetech) . The human cDNA encoding a low molecular weight form of 2-5A synthetase is a gift from Drs. B.R.G. Williams (Cleveland, Ohio) and Dirk Gewert (London, England) and the cDNA for human RNase L is previously reported in Zhou, A. et al. : Cell. 72:753-765 (1993) . The plant tissue culture medium, Murashige and Skoog's ready mix (MS media), is from Sigma Co. Seeds of Nicotiana tabacum cv. Wisconsin 38 are grown aseptically in MS in 0.8% agarose medium supplemented with 3% sucrose (MSO medium) in plastic boxes in a growth chamber at about 25'C under cycles consisting of about 16 hours of light and about eight hours of dark cycle. The Xbal-Clal fragment of human cDNA for 2-5A synthetase is directionally cloned at Xbal-, Clal sites of pAM943. See FIG. 13C. The human cDNA for RNase L is subcloned at the Hindlll site of pAM943 and the recombinant plasmid with the cDNA in sense orientation is selected. See FIG. 13D. The plasmids are grown in MM294 strain of E . coli and then introduced into Agrrobaσterium tumefaciens LBA4404 as described in An, G. et al. : Binary Vectors. In: SB Selvin, RA Schilperoort and DPS Ver a (eds), Plant Molecular Biology Manual. Martinus Nijhoff, Dordrecht, The Netherland, pp. A-3:l-19 (1988). AgrroJbacterium cells transformed with either pAM943:Synthetase or pAM943:2- 5Adep.RNase are grown in LB medium containing tetracycline (5 μg per ml), kanamycin (10 μg per ml) and streptomycin (25 μg per ml). Tobacco leaf discs are transformed following an AgrroJbacterium-leaf disc co- culture method. See, An, G. et al. : Binary Vectors. In: SB Selvin, RA Schilperoort and DPS Verma (eds), Plant Molecular Biology Manual, Martinus Nijhoff, Dordrecht, The Netherland, pp. A-3:l-19 (1988). The leaf discs are washed extensively with MSO medium and incubated on MSO solid agar selection and shoot regeneration medium containing BAP(benzylaminopurine) (0.5 mg per 1), kanamycin (200 μg per ml), carbenicillin (200 μg per ml) and cefotaxeme (200 μ per ml) in parafilm-covered Petri dishes under diffuse light at 25°C in a growth chamber. The regenerated plantlets are transferred to MSO solid agar selection and hormone free medium and later monitored for the presence of the cDNAs. For southern blots, DNA from leaves of control and transformed plants are prepared as described in Robert, S.O. et al. : Extraction of DNA from plant tissues, In: SB Gelvin, RA Schilperoort and DPS Verma (eds) , Plant Molecular Biology Manual, Martinus Nijhoff, Dordrecht, The Netherland, pp. A6:l-10 (1988). After digestion of Hindlll, the DNA fragments are separated in 1% agarose gel and transferred to Nytran membranes (Scheilcher & Schuell) . For northern blots, total RNA is extracted from the leaves using RNA-State 60 reagent (Tel-Test, B. Inc.). Glyoxal treated RNA is fractionated in agarose gels and transferred to Nytran filters. The cDNAs are 32 P-labeled using a multiprime DNA labelling kit (Promega) and used as probes. 2-5A synthetase expressed in the leaves of transgenic tobacco plants are isolated on the activating affinity matrix, poly(I) :poly(C)-cellulose as described in Silverman, R.H. et al. : Analysis of anti-viral mechanisms: Interferon-regulated 2' ,5'-oligoadenylate and protein kinase systems, In: MJ Clemens, AG Morris, Gearing, AFH (eds) , Lymphokines and Interferons: A Practical Approach, pp. 149-193, Oxford: IRL Press (1987) . Incubation with ATP allows the synthesis of 2- 5A measured in a competition binding assay in which unlabeled 2-5A produced in the incubations competes with a radiolabeled 2-5A analog for binding to mouse liver RNase L on nitrocellulose discs. See, Knight, M. et al.: Nature, 288:189-192 (1980). Standard curves are prepared with known amounts of unlabeled 2-5A added as competitor. To measure RNase L levels in the extracts of the leaves, cross-linking is performed of a bromine- substituted and 32P-labeled 2-5A probe, (A2'p) 2 (br 8 A2'p) 2 A3'-[ 32 P]Cp, to RNase L under ultraviolet light. See, Nolan-Sorden, N.L. et al.: Anal Biochem. 184:298-304 (1990). Extracts of leaves from control and transgenic plants and from the human breast cancer cell line, MCF7, are prepared as described in Silverman, R.H. et al. : Analysis of anti-viral mechanisms: Interferon- regulated 2' ,5'-oligoadenylate and protein kinase systems, In: MJ Clemens, AG Morrs, Gearing, AFH (eds), Lymphokines and Interferons: A Practical Approach, pp. 149-193, Oxford: IRL Press (1987). Assays are in presence or absence of unlabeled p 3 (A2'p) 2 A, (lOOnM) . The mixtures are exposed to ultraviolet light for about one hour on ice, proteins are separated on SDS- polyacrylamide (10%) gels, and the dried gels are used to expose X-ray film. Leaves from control and transgenic plants are cut and allowed to take up 2-5A [1 μM of p 3 (A2'p) 3 A] through the petiole for about seven hours at room temperature under fluorescent light. Total RNA is prepared and used to prepare northern blots. THe RNA in the blots is hybridized to a 32 P labeled human 18S rRNA cDNA probe (the cDNA is provided by Dr. John Thaden, Baltimore) . Transgenic plants expressing 2-5A synthetase or RNase L are grown in a temperature controlled greenhouse. Six-week old plants are inoculated with a 1:500 or 1:5000 dilution of freshly prepared extracts from tobacco leaves systemically infected with tobacco etch virus (TEV, severe strain, ATCC#PV69) and tobacco mosaic virus (TMV, common strain), respectively. Virus titer in the systemically-infected upper leaves are determined by ELISA 21 days after inoculation. Rabbit polyclonal antibodies are used against either TMV coat protein (CP) or TEV cylindrical inclusion protein (CI). Standard curves are constructed using TMV CP or TEV CI proteins. To produce transgenic tobacco plants, cDNAs for a small form of human 2-5A synthetase and for the human RNase L are individually subcloned into the plant express plasmid, pAM943. See FIG. 13 (Mitra, A. et al.: Plant Mol Biol. 26:85-93 (1994)). In this vector, transcription of the inserted cDNA is driven by a bipartite promoter consisting of the adenyl methyl transferase (AMT) of Chlorella virus fused with the 35S promoter of Cauliflower mosaic virus (FIG. 13). Plants are regenerated from leaf discs transformed separately with AgroJbaσterium containing either of the two cDNAs following selection with kanamycin. Southern blots are performed on the total genomic DNA isolated from the plants nd digested with Hindlll to establish that integration of the cDNAs has occurred. The transformed plants show the presence of 2-5A synthetase cDNA or RNase L cDNA at the expected sizes whereas the control plants are negative. See FIGS. 27A and 28, ' • ' respectively. To demonstrate that the 2-5A synthetase cDNA is transcribed in the transgenic plants, northern blots are performed on the total RNA isolated from these plants. See FIG. 27B. A major transcript of about 2.5 kb is clearly seen in the synthetase expressing plants. See FIG. 27B, lanes 2 and 3 are from representative plants. No cross-hybridizing RNA species are detected in the control plant. See FIG. 27B, lane 1. To determine if 2-5A synthetase activity is present in these plants, enzyme assays are performed on crude extracts of the leafs. See Table V below. The 2-5A synthetase is isolated on the activating affinity matrix, poly(I) :poly(C)-cellulose. See, for example, Silverman, R.H. et al.: Analysis of anti-viral mechanisms: Interferon-regulated 2' ,5'-oligoadenylate and protein kinase systems, In: MJ Clemens, AG Morrs, Gearing, AFH (eds), Lymphokines and Interferons: A Practical Approach, pp. 149-193, Oxford-: IRL Press (1987). Production of 2-5A oligomers from ATP is measured in a highly specific radiobinding assay (Knight, M. et al.: Nature. 288:189-192 (1980). Results showed significant 2-5A synthetase activity only in the transgenic plants. See Table V. Expression of RNase L is detected using a bromine substituted, 32 P-labeled 2-5A probe. See, Nolan-Sorden, N.L. et al. : Anal Biochem. 184:298-304 (1990). Covalent crosslinking of the 2-5A probe to RNase L is achieved using UV light. See, Nolan-Sorden, N.L. et al. : Anal Biochem. 184:298-304 (1990) . The 83.5 kDa RNase L is clearly detected in the transgenic plants, but is absent in the control plants. See FIG. 29. Specificity of the binding of the 2-5A probe to the RNase L is demonstrated by incubating the plant extract with an excess of unlabeled 2-5A. See FIG. 29. Competition between the unlabeled 2-5A and the 2-5A probe prevents the radiolabeling of the RNase L. RNase L from human MCF-7 cells is shown for comparison. See FIG. 29, lanes 13 and 14. To monitor uptake of 2-5A, leaves are cut at the base of the petiole and then placed in a solution of 32 P-labeled 2-5A probe for about three hours at room temperature under light. The petiole was cut further and autoradiograms were made from the lamina. Uptake and translocation of the 2-5A probe is readily apparent through veins to all parts of lamina (data now shown) . Catalytic activity of RNase L in the intact leaves is determined after allowing unlabeled 2-5A, p 3 A(2'p5'A) 3 (1 μM) , to be taken up by cut leaves for seven hours. Total RNA is extracted and northern blots are prepared and then probed with 32 P-labeled cDNA to 18S rRNA. Results show that 2-5A induce degradation of the 18S rRNA to discrete cleavage products in the RNase L expressing plants, but not in the control plant. See FIG. 30. Previous studies report a similar degradation of 18S rRNA induced in mammalian cells by activation of RNase L. See, Wreschner, D.H. et al.: Nucl Acids Res. 9:1571-1581 (1981) . These results appear to demonstrate that both human 2-5A synthetase and RNase L may be expressed as functionally active proteins in plants. To monitor viral resistance, individual leaves from control and transgenic plants are inoculated using diluted extracts prepared from TEV-infected leaves or TMV-infected leaves. All inoculated plants, both control and transgenic, show typical symptoms within one week indicating systemic viral infection. Virus concentrations are determined 21 days after inoculation by ELISA using standard curves constructed from purified viruses. Representative data from these experiments are shown in Table VI below. Results show no significant difference in viral yields in the transgenic plants compared with the control plants. Virus amounts are expressed as μg of viral antigen per g of fresh tissue. A minimum of three leaves are assayed from each plant. ELISAs are repeated two times and each sample is determined in duplicate. Control: virus assays on leaves of plants transformed with the vector alone. Zero time samples consisting of extract of inoculated leaves rinsed with water and immediately processed for ELISAs, gives values of 0.8 and 1 .4 for TEV and TMV in these assays, respectively. In this Example III, neither 2-5A synthetase activity (Table V) nor RNase L activity, as measured either by 2-5A binding, see FIG. 29, or by 2-5A- dependent ribonuclease activities, see FIG. 30, is detectable in leaves of control Nicotiana tabacum plants. Devash et al. also reported an absence of any protein that can bind 2-5A in tobacco plants. See, Devash, Y. et al.: J Biol Chem. 259:3482-3486 (1984). Southern and norther blots probed with human 2-5A synthetase cDNA or RNase L cDNA are also negative. See FIGS. 27 and 28. These results appear to support the report of Cayley, P.J. et al.: Biochem Biophys Res Commun. 108:1243-1250 (1982), .which shows an absence of 2-5A synthetase activity or 2-5A binding activity (a measure of RNase L) in Nicotiana glutinosa and Nicotiana tabacum cv. xanthi-nc. In addition, no 2-5A synthetase is detected and no 2-5A is detected in control, TMV- infected, interferon-treated or poly(I) :poly(C)-treated plants. See, Cayley, P.J. et al.: Biochem Biophys Res Commun. 108:1243-1250 (1982). Definitive evidence for the existence of a 2-5A pathway requires, as a minimum, both an enzyme capable of synthetizing 2-5A [defined as p x A(2'p5'A)y where x=l to 3; y≥2] and a ribonuclease activity that is dormant until activated by 2-5A. Any studies heretofore that establish these minimal criteria for plants has not been uncovered. Therefore, either a 2-5A system exists in plants, but is -sufficiently -in¬ different from that in higher vertebrates that it has thus far escaped detection or that the 2-5A system does not exist in plants. In this regard, oligoadenylates that are substantially different from 2-5A have been found in tobacco plants (Devash, Y. et al. : J Biol Chem, 259:3482-3486 (1984)) and 2',5'-oligoadenylates have been reported to inhibit plant cell-free protein synthesis (Truve, E. et al.: Arch Virol. 9S:41-50 (1994)), TMV replication (Devash, Y. et al. : Science. 216:1415-1416 (1982); Devash, Y. et al. : J Biol Chem. 259:3482-3486 (1984); and Devach, Y. et al. : Meth Enz. 119:759-761 (1986)) or to induce of cytokine activities and stress proteins in plants (Kulaeva, O.N. et al.: Plant Mol Biol. 20:383-393 (1992). Human 2-5A synthetase and RNase L in separate transgenic plants are expressed. Stable introduction of the cDNAs into the plant genome is confirmed in Southern blots, see FIGS. 27A and 28, and expression is determined by northern blotting and by functional enzyme assays. Expression of RNase L is obtained by both specific 2-5A binding assay, producing an 83 kDa labeled protein, see FIG. 29, and by 2-5A dependent breakdown of rRNA in intact leaves, see FIG. 30. The absence of rRNA cleavage in the RNase L + plants without addition of 2-5A indicates that the enzyme is in its dormant state until activation occurs. These findings also suggest an absence of 2-5A per se in the plants; thus confirming other reports. See, for example, Cayley, P.J. et al. : Biochem Biophys Res Commun, 108:1243-1250 (1982); and Devash, Y. et al.: J Biol Chem. 259:3482-3486 (1984). These findings appear to support the feasibility of transferring a complete functional 2-5A system, i.e., RNase L plus 2-5A-synthetase to plants. See Example IV. All of the transgenic plants appear to grow well and produce flowers. Co-expression of both 2-5A synthetase and RNase L, is believed to provide a broad range of protection against plant viruses because activation of 2-5A synthetase require dsRNA structure without any sequence specificity and many types of viruses produce dsRNA during the replicative cycles. See Example IV. Previously, Truve, E. et al.: Bio/Technology. 11:1048-1052 (1993); and Truve, E. et al.: Arch Virol. 9S:41-50 (1994), reported that expression in plants of rat 2-5A-synthetase alone (i.e. , without coexpression of RNase L) provided some antiviral activities. In contrast, in this Example III, inhibition of TMV or TEV replication is not observed in tobacco plants expressing 2-5A-synthetase alone or RNase L alone (see Table VI) . The results of this Example III are consistent with the present belief that both 2-5A synthetase and RNase L are necessary in a functional 2- 5A system. EXAMPLE IV A binary plant transformation/expression vector, Hoekema A. et al.: Nature, 303:179 (1983), designated as pAM2280 and contains both the 2-5A synthetase and RNase L cDNAs is driven by the cauliflower mosaic virus 35S promoter, see Sanders, P. et al.: Nucl. Acids Res.. 15:1534 (1987) and the chlorella virus adenine methyltransferase gene promoter, Mitra, A. et al. : Plant Mol. Bio.. 26:85 (1994), respectively, is constructed. The coding regions of original plasmids, pBabe.E1.6S (a gift from B.R.G. Williams, Cleveland) and pZC5 (Zhou, A. et al.: Cell (72): 753 (1993), encoding a low molecular weight species of human 2-5A synthetase and human RNase L, respectively, are used to construct a binary plant transformation/expression vector pAM2200. The binary plasmid contains a neomycin phosphotransferase plant selectable marker gene which is driven by the T-DNA gene nopaline synthase promoter. Mitra, A. et al.: Mol. Gen. Genet.. 215:294 (1989). This plasmid is used to produce transgenic tobacco plants by AgroJbacterium-mediated transformation of axenically grown tobacco seedlings. Horsch, R. et al.: Science. 227:1229 (1985). Transformed tobacco plants are selected on MS plates containing about 300 μg/ml kanamycin. See Murasighe, F. et al. : Physiol. Plant.. 15:473 (1962). Young tobacco seedlings (N. tabacum, petit Havana SR-1), Maliga, P. et al. : Plant Sci. Let.. 44:78 (1978), are transformed using the Agrobacterium co- cultivation method. Horsch, R. et al.: Science. 227:1229 (1985). The human 2-5A system cDNAs is believed to have no effect on the transformation frequency or normal growth and development of the transgenic tobacco plants. Primary transformants are grown to maturity and are allowed to self-pollinate. All are believed to produce viable seeds. Kanamycin- resistant Rl seedlings are grown in a greenhouse and are analyzed for transgene expression and virus resistance. Southern blot analysis, Southern, E.M., et al. : J. Mol. Biol.. 98:503 (1985), of the transgenic plants is believed to show that all of the kanamycin- resistant plants contain intact and unmodified inserts, see FIG. 22A, indicating appropriate integration of the transgenes into plant chromosomes. Integration of the plasmid DNA into plant DNA is determined by Southern blot analysis. Southern, E.M. et al.: . Mol. Biol.. 98:503 (1985). Five grams of fresh plant tissue are used to prepare DNA. See Guillemaut, P. et al. : Plant Mol. Biol. Reptr.. 10:60 (1992). Briefly, plant tissue is ground in liquid nitrogen and is thawed in extraction buffer (about 100 mM sodium acetate, pH about 4.8, about 50 mM EDTA, pH about 8.0, about 500 mM NaCl, about 2% -PVP-40; the mixture adjusted to pH about 5.5, then SDS is added to about 1.4% and cysteine to about 10 mM) , it is then incubated at about 65° C for about 20 minutes, and it is then centrifuged. About one-half volume of about 3 M potassium acetate, pH about 4.8, is added to the supernatant and the mixture is incubated at about 0°C for about 1 hr. The DNA is recovered by ethanol precipitation, which is dissolved in THE and is then centrifuged overnight in a cesium chloride gradient. DNA is digested with Hind III, it is separated on a 1% agarose gel, and it is then transferred to a Zeta-probe membrane (Bio-Rad) according to the manufacturer's recommendations. The membrane is hybridized with a randomly labeled DNA probe, Feinberg, A.P., et al.: Anal. Biochem.. 132:6 (1983), using the human 2-5A synthetase and RNase L cDNAs as templates. In order to determine expression of 2-5A synthetase and RNase L cDNAs in transgenic tobacco plants, total RNA is prepared from fifteen independently transformed plants. See Logemann, J. et al.: Anal Biochem.. 163:16 (1987). RNA extraction buffer contains about 8 M guanidinium chloride, about 20 MM MES, about 20 mM EDTA and about 50 mM B-mercaptoethanol, pH about 7.0. Aliquots of RNA samples are separated on formaldehyde gels and they are transferred to the Zeta- probe membranes and are probed with DNA fragments as in southern blots. Northern blot analysis indicates that most of the transgenic tobacco plants are believed to produce mRNA for both 2-5A synthetase and RNase L, although a few are believed to express only the 2-5A synthetase or the RNase L mRNAs. See FIG. 22B. Expression of RNase L protein in transgenic tobacco is monitored by probing western blots with a monoclonal antibody to human RNase. Dong, B. et al. : J. Biol. Chem.. 269:14153 (1994). A total cellular protein extract is prepared by grinding transformed plant tissue in liquid nitrogen and thawing in protein extraction buffer (about 0.5 M sucrose, about 0.1% ascorbic acid, about 0.1% cysteine- HC1, about 0.01M Tris-HCl, pH about 7.5), Mitra, A. et al.: Mol. Gen. Gene . , 215:294 (1989), in the presence of about 15 μg phenylmethyl sulfonylflouride (PMSF) . The homogenate is centrifuged at about 14,000 X g for about 30 min at about 4° C and the supernatant containing the soluble proteins is recovered and is concentrated using a Microcon (Amicon) concentrator. Protein concentration in the extract is quantified by the Bradford method. Bradford, M. : Anal. Biochem.. 72:248 (1976). Extracts containing about 200 μg of total protein are separated on a 12.5% acrylamide gel, Lamelli, U.K.: Nature, 227:680 (1970), along with about 200 ng recombinant RNase L protein as a standard. The resolved proteins are transferred to a nitrocellulose membrane using a Bio-Rad trans-blot apparatus at about 250 mA for about 1 hr. The membrane is immersed in a blocking solution (about 5% non-fat dry milk in Tris buffered saline) and is incubated at about 28° C for about 1 hr. The membrane is then washed and is incubated with about a 1:5000 dilution of a mouse monoclonal antibody which is prepared against human RNase L antigen. Dong, B. et al. : J. Biol. Chem.. 269:14153 (1994). Following incubation with antibody, the membrane is placed in the biotinylated goat anti- mouse antibody solution for about 1 hr at about 28° C with gentle agitation. The membrane is washed, is incubated in a streptavidin-biotinylated alkaline phosphatase complex for about 1 hr, and is followed by immersion in a color development solution until purple bands become visible. The transgenic plants expressing RNase L mRNA also express the nuclease protein. See FIG. 23. The RNase L which is produced in plants containing both the synthetase and nuclease cDNAs (FIG. 23, lanes T3-T5) as well as in plants containing only the nuclease cDNA (FIG. 23, lane T2) co-migrate with authentic human, recombinant RNase L (FIG. 23, lane RN) . Dong, B. et al.: J. Biol. Chem.. 269:14153 (1994). The immunoblot appears to show a single protein band of about 80 kDa in protein extracts from transgenic plants. Proteins in control plant extracts do not appear to react with the anti-RNase L antibody (FIG. 23, lane TC), which supports the current belief that tobacco plants do not have an RNase L homologue. Functional expression of RNase L in transgenic tobacco plants is detected by 2-5A-induced breakdown of 18S ribosomal RNA (rRNA) in detached leaves that are injected with 2-5A. See FIG. 24. Transgenic leaves are injected with about 2.5 μM p 3 A(2'p5'A) 3 and are incubated for about 3 hrs before total RNA is prepared. Degradation of rRNA is demonstrated by probing the total RNA on a northern blot with a radiolabeled cDNA to 18S rRNA (a gift of John Thaden, Baltimore). Injection of 2-5A appears to result in the degradation of rRNA only in transgenic plants expressing both the 2-5A synthetase and RNase L (FIG. 24, lane 6) or only RNase L (FIG. 24, lane 5), but not in control plants which are transformed with vector along (FIG. 24, lane 1) or plants expressing only 2-5A synthetase (FIG. 24, lane 3). In addition, plants expressing RNase L are believed to have specific 2-5A binding activity that is absent in control, non- transgenic plants. It is therefore surprisingly discovered that introduction of the human RNase L cDNA into transgenic plants leads to production of a functional RNase L enzyme. To determine if 2-5A synthetase is present in the transgenic tobacco plants, functional assays for the enzyme are performed. 2-5A synthetase activity in extracts of transgenic plants is determined by a functional assay for 2-5A. Plants extracts are prepared by homogenizing leaves in NP40 lysis buffer containing: about 0.5% (v/v) Non-idet P-40, about 90 mM KCl, about 5 mM magnesium acetate, about 20 mM Tris-HCl, pH about 7.5, about 5 mM 2-mercaptoethanol, and about 10 μg per ml leupeptin. The total cell lysates are centrifuged at about 10,000 X g for about 10 min at about 4° C, the supernatants are collected and the protein concentration is determined. See Bradford, M. et al. : Anal. Biochem.. 72:248 (1976). Extracts of interferon-treated (about 200 units per ml human interferon alpha for about 18 hr) human HeLa cells are prepared by the same method, except cells are disrupted by vortex mixing. 2-5A synthetase assays are performed by incubating about 200 μg (protein) extract per assay which are adjusted to about 65 μls with NP40 lysis buffer, with about 65 μl (per assay) of about 20 mM Tris-HCl, pH about 7.5, about 50 mM KCl, about 5 mM magnesium acetate, about 4 mM magnesium chloride, about 5 mM 2-mercaptoethanol, about 10% (v/v) glycerol, about 2 mM ATP, about 20 μg per ml poly (I): poly (C) for about 24 hr at about 30° C. Reactions are terminated, and proteins are denatured and removed, by heating reaction mixtures to 100 C for 5 min followed by centrifugation at 10,000 X g for 10 min. Supernatants are removed and concentrated in a speed-vac (Savant) to 20 μl. 2-5A is then assayed by a 2-5A dependent ribonuclease L assay. Concentrated supernatants (about 5 and about 10 μl per plant), or dilutions of authentic 2-5A (pA(2'p5'A) 3 ) , are incubated in a final volume of about 25 μl with about 1 μg of recombinant human RNase L, Dong B. et al. : J. Biol. Chem.. 269:14153 (1994), in buffer (about 90 mM KCl, about 10 mM magnesium acetate, about 20 mM Tris-HCl, pH about 7.5, about 8 mM 2-mercaptoethanol, and about 10 μg per ml leupeptin) containing about 0.2 mM of poly(U) -( 32 P)-pCp which is prepared as described in Silverman, R.H. : Anal. Biochem. , 144:450 (1985), and is incubated at about 30° C for about 2 hr. Reactions are terminated with about 7.5 μl stop buffer, are boiled for about 5 min, are centrifuged briefly, and about 3 μl is loaded to about 6% polyacrylamide/urea gels. After electrophoresis, X-ray film is exposed to the gel. Extracts of leaves are incubated in buffer containing ATP and poly(I) : poly (C), an activator of 2-5A synthetase. Hovanessian, A.G. et al.: Nature, 268:537 (1977); and Marie, I. et al. : J. Biol. Chem.. 267:9933 (1992). After removing the protein from the reaction mixtures, 2-5A is assayed by its ability to activate recombinant human RNase L, which is isolated from transfected insect cells. See Dong, B. et al.: J. Biol. Chem.. 269:14153 (1994) and FIG. 25. For comparison, authentic 2-5A (pA(2'p5'A) 3 ) is incubated with RNase L, resulting in the production of discrete poly (U) cleavage products, see FIG. 25, lanes 1-7. Extracts of plants transgenic for both human 2-5A synthetase and RNase L (FIG. 25, lanes 8-11) or for 2-5A synthetase alone are believed to produce functional 2- 5A. Identical poly(U) cleavage products are observed with authentic 2-5A (FIG. 25, lanes 1-7) and with 2-5A synthetase assays from interferon-treated human HeLa cells (FIG. 25, lanes 16,17). These results appear to demonstrate production of functional 2-5A synthetase in transgenic tobacco plants. In contrast, extracts of control plants which are transformed with vector only do not appear to produce 2-5A, as indicated by the lack of specific poly(U) breakdown products (FIG. 25, lanes 12-15); thereby supporting the belief that 2-5A synthetase is absent in tobacco. See Cayley et al. : Biochem, Biophys. Res. Commun.. 108:1243 (1982). To monitor viral resistance, leaves are manually inoculated with three different types of plant viruses: tobacco etch virus (TEV), a member of the potyvirus group; TMV, a member of the tobamovirus group; and alfalfa mosaic virus (AIMV) , a member of the bromovirus group. See R.E.F. Matthews, Plant Virology, Academic Press Inc., NY, 1991. Transgenic plants are grown in a greenhouse. Leaves from these plants are cut at the petiole and placed in petri dishes on moist filter papers. Leaves are maintained in petri dishes for the incubation period and remain in good physiological condition. The leaves are inoculated with a 1:200, 1:1000 and 1:150 dilution of freshly prepared extracts from tobacco leaves systemically infected with TEV (severe strain), ATCC#PV69, TMV (common strain), and AIMV (Nebraska strain), respectively. Six of six control plants become systemically infected when inoculated with sap diluted 1:10,000, 1:100,000, and 1:15,000, respectively. Following inoculation with virus, the leaves are rinsed with water, petri dishes are sealed with stretched parafilm, and are placed in an incubator at about 22° C for about 7 days under about 18 hr light. Leaves from a total of forty-eight kana ycin-resistant Rl progeny plants expressing both 2-5A synthetase and RNase L, or either proteins alone, are tested. A composite picture from representative plants is shown in FIG. 26. Infection of plants expressing both proteins induce necrotic local lesions (FIG. 26, panels a, c, e), whereas plants expressing only one protein, (FIG. 26, panels g, h) or control plants (FIG. 26, panels b, d, f) produce typical systemic infections. In nature, TEV and AIMV are not believed to produce local lesions in tobacco plants. See R.E.F. Matthews, Plant Virology, Academic Press Inc., NY, 1991. TMV is believed to produce local lesions in tobacco plants containing the N or N' gene. Sela, I. et al. : Adv. Virus Res. , 24:177 (1981). However, the tobacco cultivear that is used (SR-1) does not contain the N gene and hence is a systemic host for TMV. The necrotic lesions that are produced by different viruses are morphologically distinct. Lesions that are produced by AIMV, in addition, are smaller than those of TEV and TMV. Lesions in transgenic plants appear quickly, within about 48 hours, whereas TMV lesions in hypersensitive control plants (N. tabacum, var Samsun NN and Xanthi nc) appear only after about 72 hours. There appears to be a direct correlation between the inoculum concentrations and number of local lesions. Necrotic lesions in transgenic plants are believed to be formed because viral dsRNAs activates the 2-5A synthetase resulting in subsequent RNA decay by RNase L. Activation of the 2-5A system in plants may be achieved either by extensive secondary structure in viral genomic RNAs or by double-stranded replicative intermediates which are formed during viral replication. For all three viruses inoculated, no virus is detected in leaf tissues between lesions by ELISA with virus- specific antibodies. To ascertain that virus in transgenic tobacco plants expressing the human 2-5A system do not undergo alterations or mutation, virus is recovered from single lesions and reinoculated onto control plants. The three recovered viruses produce typical symptoms and systemic infection in control plants. It is therefore believed that transgenic plants expressing a functional 2-5A system selectively destroy a small number of cells that are initially invaded by virus infection, leading to the formation of necrotic lesions. That is, the interferon regulated 2-5A system is believed to induce cell suicide as a defense against viruses. FTL1-1 9709 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Silverman, Robert H. SenGupta, Dibyendu N. (ii) TITLE OF INVENTION: Transgenic Plants Co-Expressing A Functional Human 2-5A System (iii) NUMBER OF SEQUENCES: 11 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Holland & Knight (B) STREET: One E. Broward Boulevard, #1300 (C) CITY: Fort Lauderdale (D) STATE: Florida (E) COUNTRY: USA (F) ZIP: 33301 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: None (B) FILING DATE: 07-JUNE-1995 (C) CLASSIFICATION: 1808 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Manso, Peter J. (B) REGISTRATION NUMBER: 32,264 (C) REFERENCE/DOCKET NUMBER: CL11363-16(C) (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 305/468-7811 (B) TELEFAX: 305/463-2030 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2928 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: * (A) NAME/KEY: CDS (B) LOCATION: 104..2326 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: - 126- AATCCCAACT TACACTCAAA GCTTCTTTGA TTAAGTGCTA GGAGATAAAT TTGCATTTTC 60 TCAAGGAAAλ GGCTAAAAGT GGTAGCAGGT GGCATTTACC GTC ATG GAG AGC AGG 115 Met Glu Ser Arg 1 GAT CAT AAC AAC CCC CAG GAG GGA CCC ACG TCC TCC AGC GGT AGA AGG 163 Asp His Asn Asn Pro Gin Glu Gly Pro Thr Ser Ser Ser Gly Arg Arg 5 10 15 20 GCT GCA GTG GAA GAC AAT CAC TTG CTG ATT AAA GCT GTT CAA AAC GAA 211 Ala Ala Val Glu Asp Asn His Leu Leu He Lye Ala Val Gin Asn Glu 25 30 35 GAT GTT GAC CTG GTC CAG CAA TTG CTG GAA GGT GGA GCC AAT GTT AAT 259 Asp Val Asp Leu Val Gin Gin Leu Leu Glu Gly Gly Ala Asn Val Asn 40 45 50 TTC CAG GAA GAG GAA GGG GGC TGG ACA CCT CTG CAT AAC GCA GTA CAA 307 Phe Gin Glu Glu Glu Gly Gly Trp Thr Pro Leu His Asn Ala Val Gin 55 60 65 ATG AGC AGG GAG GAC ATT GTG GAA CTT CTG CTT CGT CAT GGT GCT GAC 355 Met Ser Arg Glu Asp He Val Glu Leu Leu Leu Arg His Gly Ala Asp 70 75 80 CCT GTT CTG AGG AAG AAG AAT GGG GCC ACG CTT TTT ATC CTC GCA GCG 403 Pro Val Leu Arg Lys Lys Asn Gly Ala Thr Leu Phe He Leu Ala Ala 85 90 95 100 ATT GCG GGG AGC GTG AAG CTG CTG AAA CTT TTC CTT TCT AAA GGA GCA 451 He Ala Gly Ser Val Lys Leu Leu Lys Leu Phe Leu Ser Lys Gly Ala 105 110 115 GAT GTC AAT GAG TGT GAT TTT TAT GGC TTC ACA GCC TTC ATG GAA GCC 499 Asp Val Asn Glu Cys -Asp Phe Tyr Gly Phe Thr Ala Phe Met Glu Ala 120 125 130 GCT GTG TAT GGT AAG GTC AAA GCC CTA AAA TTC CTT TAT AAG AGA GGA 547 Ala Val Tyr Gly Lys Val Lys Ala Leu Lys Phe Leu Tyr Lys Arg Gly 135 140 145 GCA AAT GTG AAT TTG AGG CGA AAG ACA AAG GAG GAT CAA GAG CGG CTG 595 Ala Asn Val Asn Leu Arg Arg Lys Thr Lys Glu Asp G n Glu Arg Leu 150 155 160 AGG AAA GGA GGG GCC ACA GCT CTC ATG GAC GCT GCT GAA AAA GGA CAC 643 Arg Lys Gly Gly Ala Thr Ala Leu Met Asp Ala Ala Glu Lys Gly His 165 170 175 180 GTA GAG GTC TTG AAG ATT CTC CTT GAT GAG ATG GGG GCA GAT GTA AAC 691 Val Glu Val Leu Lys He Leu Leu Asp Glu Met Gly Ala Asp Val Asn 185 190 195 GCC TGT GAC AAT ATG GGC AGA AAT GCC TTG ATC CAT GCT CTC CTG AGC 739 Ala Cys Asp Asn Met Gly Arg Asn Ala Leu He His Ala Leu Leu Ser 200 205 210 TCT GAC GAT AGT GAT GTG GAG GCT ATT ACG CAT CTG CTG CTG GAC CAT 787 - 127- Ser Asp Asp Ser Asp Val Glu Ala He Thr His Leu Leu Leu Asp His 215 220 225 GGG GCT GAT GTC AAT GTG AGG GGA GAA AGA GGG AAG ACT CCC CTG ATC 835 Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lye Thr Pro Leu He 230 235 240 CTG GCA GTG GAG AAG AAG CAC TTG GGT TTG GTG CAG AGG CTT CTG GAG 883 Leu Ala Val Glu Lys Lys His Leu Gly Leu Val Gin Arg Leu Leu Glu 245 250 255 260 CAA GAG CAC ATA GAG ATT AAT GAC ACA GAC AGT GAT GGC AAA ACA GCA 931 Gin Glu His He Glu He Asn Asp Thr Asp Ser Asp Gly Lys Thr Ala 265 270 275 CTG CTG CTT GCT GTT GAA CTC AAA CTG AAG AAA ATC GCC GAG TTG CTG 97S Leu Leu Leu Ala Val Glu Leu Lys Leu Lys Lys He Ala Glu Leu Leu 280 285 290 TGC AAA CGT GGA GCC AGT ACA GAT TGT GGG GAT CTT GTT ATG ACA GCG 1027 Cys Lys Arg Gly Ala Ser Thr Asp Cys Gly Asp Leu Val Met Thr Ala 295 300 305 AGG CGG AAT TAT GAC CAT TCC CTT GTG AAG GTT CTT CTC TCT CAT GGA 1075 Arg Arg Asn Tyr Asp His Ser Leu Val Lys Val Leu Leu Ser His Gly 310 315 320 GCC AAA GAA GAT TTT CAC CCT CCT GCT GAA GAC TGG AAG CCT CAG AGC 1123 Ala Lys Glu Asp Phe His Pro Pro Ala Glu Asp Trp Lys Pro Gin Ser 325 330 335 340 TCA CAC TGG GGG GCA GCC CTG AAG GAT CTC CAC AGA ATA TAC CGC CCT 1171 Ser His Trp Gly Ala Ala Leu Lys Asp Leu His Arg He Tyr Arg Pro 345 350 355 ATG ATT GGC AAA CTC AAG TTC TTT ATT GAT GAA AAA TAC AAA ATT GCT 1219 Met He Gly Lys Leu"Lys Phe Phe He Asp Glu Lys Tyr Lys He Ala 360 365 370 GAT ACT TCA GAA GGA GGC ATC TAC CTG GGG TTC TAT GAG AAG CAA GAA 1267 Asp Thr Ser Glu Gly Gly He Tyr Leu Gly Phe Tyr Glu Lys Gin Glu 375 380 385 GTA GCT GTG AAG ACG TTC TGT GAG GGC AGC CCA CGT GCA CAG CGG GAA 1315 Val Ala Val Lys Thr Phe Cys Glu Gly Ser Pro Arg Ala Gin Arg Glu 390 395 400 GTC TCT TGT CTG CAA AGC AGC CGA GAG AAC AGT CAC TTG GTG ACA TTC 1363 Val Ser Cys Leu Gin Ser Ser Arg Glu Asn Ser His Leu Val Thr Phe 405 410 415 420 TAT GGG AGT GAG AGC CAC AGG GGC CAC TTG TTT GTG TGT GTC ACC CTC 1411 Tyr Gly Ser Glu Ser His Arg Gly His Leu Phe Val Cys Val Thr Leu 425 430 435 TGT GAG CAG ACT CTG GAA GCG TGT TTG GAT GTG CAC AGA GGG GAA GAT 1459 Cys Glu Gin Thr Leu Glu Ala Cys Leu Asp Val His Arg Gly Glu Asp 440 445 450 GTG GAA AAT GAG GAA GAT GAA TTT GCC CGA AAT GTC CTG TCA TCT ATA 1507 - 128- Val Glu Asn Glu Glu Asp Glu Phe Ala Arg Asn Val Leu Ser Ser He 455 460 465 TTT AAG GCT GTT CAA GAA CTA CAC TTG TCC TGT GGA TAC ACC CAC CAG .1555 Phe Lys Ala Val Gin Glu Leu His Leu Ser Cys Gly Tyr Thr His Gin 470 475 480 GAT CTG CAA CCA CAA AAC ATC TTA ATA GAT TCT AAG AAA GCT GCT CAC 1603 Asp Leu Gin Pro Gin Asn He Leu He Asp Ser Lys Lys Ala Ala His 485 490 495 500 CTG GCA GAT TTT GAT AAG AGC ATC AAG TGG GCT GGA GAT CCA CAG GAA 1651 Leu Ala Asp Phe Asp Lys Ser He Lys Trp Ala Gly Asp Pro Gin Glu 505 510 515 GTC AAG AGA GAT CTA GAG GAC CTT GGA CGG CTG GTC CTC TAT GTG GTA 1699 Val Lys Arg Asp Leu Glu Asp Leu Gly Arg Leu Val Leu Tyr Val Val 520 525 530 AAG AAG GGA AGC ATC TCA TTT GAG GAT CTG AAA GCT CAA AGT AAT GAA 1747 Lys Lys Gly Ser He Ser Phe Glu Asp Leu Lys Ala Gin Ser Asn Glu 535 540 545 GAG GTG GTT CAA CTT TCT CCA GAT GAG GAA ACT AAG GAC CTC ATT CAT 1795 Glu Val Val Gin Leu Ser Pro Asp Glu Glu Thr Lys Asp Leu He His 550 555 560 CGT CTC TTC CAT CCT GGG GAA CAT GTG AGG GAC TGT CTG AGT GAC CTG 1843 Arg Leu Phe His Pro Gly Glu His Val Arg Asp Cys Leu Ser Asp Leu 565 570 575 580 CTG GGT CAT CCC TTC TTT TGG ACT TGG GAG AGC CGC TAT AGG ACG CTT 1891 Leu Gly His Pro Phe Phe Trp Thr Trp Glu Ser Arg Tyr Arg Thr Leu 585 590 595 CGG AAT GTG GGA AAT GAA TCC GAC ATC AAA ACA CGA AAA TCT GAA AGT 1939 Arg Asn Val Gly Asn-Glu Ser Asp He Lys Thr Arg Lys Ser Glu Ser 600 605 610 GAG ATC CTC AGA CTA CTG CAA CCT GGG CCT TCT GAA CAT TCC AAA AGT 1987 Glu He Leu Arg Leu Leu Gin Pro Gly Pro Ser Glu His Ser Lys Ser 615 620 625 TTT GAC AAG TGG ACG ACT AAG ATT AAT GAA TGT GTT ATG AAA AAA ATG 2035 Phe Asp Lys Trp Thr Thr Lys He Asn Glu Cys Val Met Lys Lys Met 630 635 640 AAT AAG TTT TAT GAA AAA AGA GGC AAT TTC TAC CAG AAC ACT GTG GGT 2083 Asn Lys Phe Tyr Glu Lys Arg Gly Asn Phe Tyr Gin Asn Thr Val Gly 645 650 655 660 GAT CTG CTA AAG TTC ATC CGG AAT TTG GGA GAA CAC ATT GAT GAA GAA 2131 Asp Leu Leu Lys Phe He Arg Asn Leu Gly Glu His He Asp Glu Glu 665 670 675 AAG CAT AAA AAG ATG AAA TTA AAA ATT GGA GAC CCT TCC CTG TAT TTT 2179 Lys His Lys Lys Met Lys Leu Lys He Gly Asp Pro Ser Leu Tyr Phe 680 685 690 CAG AAG ACA TTT CCA GAT CTG GTG ATC TAT GTC TAC ACA AAA CTA CAG 2227 -129- G n Lys Thr Phe Pro Asp Leu Val He Tyr Val Tyr Thr Lys Leu Gin 695 700 705 AAC ACA GAA TAT AGA AAG CAT TTC CCC CAA ACC CAC AGT CCA AAC AAA 2275 Asn Thr Glu Tyr Arg Lys His Phe Pro Gin Thr His Ser Pro Asn Lys 710 715 720 CCT CAG TGT GAT GGA GCT GGT GGG GCC AGT GGG TTG GCC AGC CCT GGG 2323 Pro Gin Cys Asp Gly Ala Gly Gly Ala Ser Gly Leu Ala Ser Pro Gly 725 730 735 740 TGC TGATGGACTG ATTTGCTGGA GTTCAGGGAA CTACTTATTA GCTGTAGAGT 2376 Cys CCTTGGCAAA TCACAACATT CTGGGCCTTT TAACTCACCA GGTTGCTTGT GAGGGATGAG 2436 TTGCATAGCT GATATGTCAG TCCCTGGCAT CGTGTATTCC ATATGTCTAT AACAAAAGCA 2496 ATATATACCC AGACTACACT AGTCCATAAG CTTTACCCAC TAACTGGGAG GACATTCTGC 2556 TAAGATTCCT TTTGTCAATT GCACCAAAAG AATGAGTGCC TTGACCCCTA ATGCTGCATA 2616 TGTTACAATT CTCTCACTTA ATTTTCCCAA TGATCTTGCA AAACAGGGAT TATCATCCCC 2676 ATTTAAGAAC TGAGGAACCT GAGACTCAGA GAGTGTGAGC TACTGGCCCA AGATTATTCA 2736 ATTTATACCT AGCACTTTAT AAATTTATGT GGTGTTATTG GTACCTCTCA TTTGGGCACC 2796 TTAAAACTTA ACTATCTTCC AGGGCTCTTC CAGATGAGGC CCAAAACATA TATAGGGGTT 2856 CCAGGAATCT CATTCATTCA TTCAGTATTT ATTGAGCATC TAGTATAAGT CTGGGCACTG 2916 GATGCATGAA TT 2928 (2) INFORMATION FO "SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 741 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear . (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Glu Ser Arg Asp His Asn Asn Pro Gin Glu Gly Pro Thr Ser Ser 1 5 10 15 Ser Gly Arg Arg Ala Ala Val Glu Asp Asn His Leu Leu He Lye Ala 20 25 30 Val Gin Asn Glu Asp Val Asp Leu Val Gin G n Leu Leu Glu Gly Gly 35 40 45 Ala Asn Val Asn Phe G n Glu Glu Glu Gly Gly Trp Thr Pro Leu His 50 55 60 Asn Ala Val Gin Met Ser Arg Glu Asp He Val Glu Leu Leu Leu Arg -130- 70 75 80 Ala Asp Pro Val Leu Arg Lys Lys Asn Gly Ala Thr Leu Phe 85 90 95 Ala Ala He Ala Gly Ser Val Lys Leu Leu Lys Leu Phe Leu 100 105 110 Gly Ala Asp Val Asn Glu Cys Asp Phe Tyr Gly Phe Thr Ala 115 120 125 Glu Ala Ala Val Tyr Gly Lys Val Lys Ala Leu Lys Phe Leu 135 140 Arg Gly Ala Asn Val Asn Leu Arg Arg Lys Thr Lys Glu Asp 150 155 160 Arg Leu Arg Lys Gly Gly Ala Thr Ala Leu Met Asp Ala Ala 165 170 175 Gly His Val Glu Val Leu Lys He Leu Leu Asp Glu Met Gly 180 185 190 Val Asn Ala Cys Asp Asn Met Gly Arg Asn Ala Leu He His 195 200 205 Leu Ser Ser Asp Asp Ser Asp Val Glu Ala He Thr His Leu 215 220 Asp His Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lys 230 235 240 Leu He Leu Ala Val Glu Lys Lys His Leu Gly Leu Val Gin 245 250 255 Leu Glu Gin Glu His He Glu He Asn Asp Thr Asp Ser Asp 260 265 270 Thr Ala Leu Leu Leu Ala Val Glu Leu Lys Leu Lys Lys He 275 280 285 Leu Leu Cys Lys Arg Gly Ala Ser Thr Asp Cys Gly Asp Leu 295 300 Thr Ala Arg Arg Asn Tyr Asp His Ser Leu Val Lys Val Leu 310 315 320 His Gly Ala Lys Glu Asp Phe His Pro Pro Ala Glu Asp Trp 325 330 335 Gin Ser Ser His Trp Gly Ala Ala Leu Lys Asp Leu His Arg 340 345 350 Arg Pro Met He Gly Lys Leu Lys Phe Phe He Asp Glu Lys 355 360 365 He Ala Asp Thr Ser Glu Gly Gly He Tyr Leu Gly Phe Tyr 375 380 Glu Lys Gin Glu Val Ala Val Lys Thr Phe Cys Glu Gly Ser Pro Arg -131- 385 390 395 400 Ala Gin Arg Glu Val Ser Cys Leu Gin Ser Ser Arg Glu Asn Ser His 405 410 415 Leu Val Thr Phe Tyr Gly Ser Glu Ser His Arg Gly His Leu Phe Val 420 425 430 Cys Val Thr Leu Cys Glu Gin Thr Leu Glu Ala Cys Leu Asp Val His 435 440 445 Arg Gly Glu Asp Val Glu Asn Glu Glu Asp Glu Phe Ala Arg Asn Val 450 455 460 Leu Ser Ser He Phe Lys Ala Val Gin Glu Leu His Leu Ser Cys Gly 465 470 475 480 Tyr Thr His G n Asp Leu Gin Pro Gin Asn He Leu He Asp Ser Lys 485 490 495 Lys Ala Ala His Leu Ala Asp Phe Asp Lys Ser He Lys Trp Ala Gly 500 505 510 Asp Pro G n Glu Val Lys Arg Asp Leu Glu Asp Leu Gly Arg Leu Val 515 520 525 Leu Tyr Val Val Lys Lys Gly Ser He Ser Phe Glu Asp Leu Lys Ala 530 535 540 Gin Ser Asn Glu Glu Val Val Gin Leu Ser Pro Asp Glu Glu Thr Lys 545 550 555 560 Asp Leu He His Arg Leu Phe His Pro Gly Glu His Val Arg Asp Cys 565 570 575 Leu Ser Asp Leu Leu Gly His Pro Phe Phe Trp Thr Trp Glu Ser Arg 580 " 585 590 Tyr Arg Thr Leu Arg Asn Val Gly Asn Glu Ser Asp He Lys Thr Arg 595 600 605 Lys Ser Glu Ser Glu He Leu Arg Leu Leu Gin Pro Gly Pro Ser Glu 610 615 620 His Ser Lys Ser Phe Asp Lys Trp Thr Thr Lys He Asn Glu Cys Val 625 630 635 640 Met Lys Lys Met Asn Lys Phe Tyr Glu Lys Arg Gly Asn Phe Tyr Gin 645 650 655 Asn Thr Val Gly Asp Leu Leu Lys Phe He Arg Asn Leu Gly Glu His 660 665 670 He Asp Glu Glu Lys His Lys Lys Met Lys Leu Lys He Gly Asp Pro 675 680 685 Ser Leu Tyr Phe Gin Lys Thr Phe Pro Asp Leu Val He Tyr Val Tyr -690 695 700 Thr Lys Leu Gin Asn Thr Glu Tyr Arg Lys His Phe Pro Gin Thr His -132- 705 710 715 720 Ser Pro Asn Lys Pro Gin Cys Asp Gly Ala Gly Gly Ala Ser Gly Leu 725 730 735 Ala Ser Pro Gly Cys 740 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH*. 2928 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 104..2326 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AATCCCAACT TACACTCAAA GCTTCTTTGA TTAAGTGCTA GGAGATAAAT TTGCATTTTC 60 TCAAGGAAAA GGCTAAAAGT GGTAGCAGGT GGCATTTACC GTC ATG GAG AGC AGG 115 Met Glu Ser Arg 1 GAT CAT AAC AAC CCC CAG GAG GGA CCC ACG TCC TCC AGC GGT AGA AGG 163 ASD His Asn Asn Pro Gin Glu Gly Pro Thr Ser Ser Ser Gly Arg Arg 5 10 15 20 GCT GCA GTG GAA GAC"AAT CAC TTG CTG ATT AAA GCT GTT CAA AAC GAA 211 Ala Ala Val Glu Asp Asn His Leu Leu He Lys Ala Val Gin Asn Glu 25 30 35 GAT GTT GAC CTG GTC CAG CAA TTG CTG GAA GGT GGA GCC AAT GTT AAT 259 Asp Val Asp Leu Val Gin Gin Leu Leu Glu Gly Gly Ala Asn Val Asn 40 45 50 TTC CAG GAA GAG GAA GGG GGC TGG ACA CCT CTG CAT AAC GCA GTA CAA 307 Phe Gin Glu Glu Glu Gly Gly Trp Thr Pro Leu His Asn Ala Val Gin 55 60 65 ATG AGC AGG GAG GAC ATT GTG GAA CTT CTG CTT CGT CAT GGT GCT GAC 355 Met Ser Arg Glu Asp He Val Glu Leu Leu Leu Arg His Gly Ala Asp 70 75 80 CCT GTT CTG AGG AAG AAG AAT GGG GCC ACG CCT TTT ATC CTC GCA GCG 403 Pro Val Leu Arg Lys Lys Asn Gly Ala Thr Pro Phe He Leu Ala Ala 85 90 95 100 ATT GCG GGG AGC GTG AAG CTG CTG AAA CTT TTC CTT TCT AAA GGA GCA 451 He Ala Gly Ser Val Lys Leu Leu Lys Leu Phe Leu Ser Lys Gly Ala 105 110 115 -133- GAT GTC AAT GAG TGT GAT TTT TAT " GGC TTC ACA GCC TTC ATG GAA GCC 499 Asp Val Asn Glu Cys Asp Phe Tyr Gly Phe Thr Ala Phe Met Glu Ala 120 125 130 GCT GTG TAT GGT AAG GTC AAA GCC CTA AAA TTC CTT TAT AAG AGA GGA 547 Ala Val Tyr Gly Lys Val Lys Ala Leu Lye Phe Leu Tyr Lys Arg Gly 135 140 145 GCA AAT GTG AAT TTG AGG CGA AAG ACA AAG GAG GAT CAA GAG CGG CTG 595 Ala Asn Val Asn Leu Arg Arg Lys Thr Lys Glu Asp Gin Glu Arg Leu 150 155 160 AGG AAA GGA GGG GCC ACA GCT CTC ATG GAC GCT GCT GAA AAA GGA CAC 643 Arg Lys Gly Gly Ala Thr Ala Leu Met Asp Ala Ala Glu Lys Gly His 165 170 175 180 GTA GAG GTC TTG AAG ATT CTC CTT GAT GAG ATG GGG GCA GAT GTA AAC 691 Val Glu Val Leu Lys He Leu Leu Asp Glu Met Gly Ala Asp Val Asn 185 190 195 GCC TGT GAC AAT ATG GGC AGA AAT GCC TTG ATC CAT GCT CTC CTG AGC 739 Ala Cys Asp Asn Met Gly Arg Asn Ala Leu He His Ala Leu Leu Ser 200 205 210 TCT GAC GAT AGT GAT GTG GAG GCT ATT ACG CAT CTG CTG CTG GAC CAT 787 Ser Asp Asp Ser Asp Val Glu Ala He Thr His Leu Leu Leu Asp His 215 220 225 GGG GCT GAT GTC AAT GTG AGG GGA GAA AGA GGG AAG ACT CCC CTG ATC 835 Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lys Thr Pro Leu He 230 235 240 CTG GCA GTG GAG AAG AAG CAC TTG GGT TTG GTG CAG AGG CTT CTG GAG 883 Leu Ala Val Glu Lys Lys His Leu Gly Leu Val Gin Arg Leu Leu Glu 245 250 255 260 CAA GAG CAC ATA GAG "ATT AAT GAC ACA GAC AGT GAT GGC AAA ACA GCA 931 Gin Glu His He Glu He Asn Asp Thr Asp Ser Asp Gly Lys Thr Ala 265 270 275 CTG CTG CTT GCT GTT GAA CTC AAA CTG AAG AAA ATC GCC GAG TTG CTG 979 Leu Leu Leu Ala Val Glu Leu Lys Leu Lys Lys He Ala Glu Leu Leu 280 285 290 TGC AAA CGT GGA GCC AGT ACA GAT TGT GGG GAT CTT GTT ATG ACA GCG 1027 Cys Lys Arg Gly Ala Ser Thr Asp Cys Gly Asp Leu Val Met Thr Ala 295 300 305 AGG CGG AAT TAT GAC CAT TCC CTT GTG AAG GTT CTT CTC TCT CAT GGA 1075 Arg Arg Asn Tyr Asp His Ser Leu Val Lys Val Leu Leu Ser His Gly 310 315 320 GCC AAA GAA GAT TTT CAC CCT CCT GCT GAA GAC TGG AAG CCT CAG AGC 1123 Ala Lys Glu Asp Phe His Pro Pro Ala Glu Asp Trp Lys Pro G n Ser 325 330 335 340 TCA CAC TGG GGG GCA GCC CTG AAG GAT CTC CAC AGA ATA TAC CGC CCT 1171 Ser His Trp Gly Ala Ala Leu Lys Asp Leu His Arg He Tyr Arg Pro 345 350 355 -134- ATG ATT GGC AAA CTC AAG TTC TTT ATT GAT GAA AAA TAC AAA ATT GCT 1219 Met He Gly Lys Leu Lys Phe Phe He Asp Glu Lys Tyr Lys He Ala 360 365 370 GAT ACT TCA GAA GGA GGC ATC TAC CTG GGG TTC TAT GAG AAG CAA GAA 1267 Asp Thr Ser Glu Gly Gly He Tyr Leu Gly Phe Tyr Glu Lys Gin Glu 375 380 385 GTA GCT GTG AAG ACG TTC TGT GAG GGC AGC CCA CGT GCA CAG CGG GAA 1315 Val Ala Val Lys Thr Phe Cys Glu Gly Ser Pro Arg Ala Gin Arg Glu 390 395 400 GTC TCT TGT CTG CAA AGC AGC CGA GAG AAC AGT CAC TTG GTG ACA TTC 1363 Val Ser Cys Leu Gin Ser Ser Arg Glu Asn Ser His Leu Val Thr Phe 405 410 415 420 TAT GGG AGT GAG AGC CAC AGG GGC CAC TTG TTT GTG TGT GTC ACC CTC 1411 Tyr Gly Ser Glu Ser His Arg Gly His Leu Phe Val Cys Val Thr Leu 425 430 435 TGT GAG CAG ACT CTG GAA GCG TGT TTG GAT GTG CAC AGA GGG GAA GAT 1459 Cys Glu Gin Thr Leu Glu Ala Cys Leu Asp Val His Arg Gly Glu Asp 440 445 450 GTG GAA AAT GAG GAA GAT GAA TTT GCC CGA AAT GTC CTG TCA TCT ATA 1507 Val Glu Asn Glu Glu Asp Glu Phe Ala Arg Asn Val Leu Ser Ser He 455 460 465 TTT AAG GCT GTT CAA GAA CTA CAC TTG TCC TGT GGA TAC ACC CAC CAG 1555 Phe Lys Ala Val Gin Glu Leu His Leu Ser Cys Gly Tyr Thr His Gin 470 475 480 GAT CTG CAA CCA CAA AAC ATC TTA ATA GAT TCT AAG AAA GCT GCT CAC 1603 Asp Leu Gin Pro Gin Asn He Leu He Asp Ser Lys Lys Ala Ala His 485 490 495 500 CTG GCA GAT TTT GAT-AAG AGC ATC AAG TGG GCT GGA GAT CCA CAG GAA 1651 Leu Ala Asp Phe Asp Lys Ser He Lys Trp Ala Gly Asp Pro Gin Glu 505 510 515 GTC AAG AGA GAT CTA GAG GAC CTT GGA CGG CTG GTC CTC TAT GTG GTA 1699 Val Lys Arg Asp Leu Glu Asp Leu Gly Arg Leu Val Leu Tyr Val Val 520 525 530 AAG AAG GGA AGC ATC TCA TTT GAG GAT CTG AAA GCT CAA AGT AAT GAA 1747 Lys Lys Gly Ser He Ser Phe Glu Asp Leu Lys Ala Gin Ser Asn Glu 535 540 545 GAG GTG GTT CAA CTT TCT CCA GAT GAG GAA ACT AAG GAC CTC ATT CAT 1795' Glu Val Val Gin Leu Ser Pro Asp Glu Glu Thr Lys Asp Leu He His 550 555 560 CGT CTCVTTC CAT CCT GGG GAA CAT GTG AGG GAC TGT CTG AGT GAC CTG 1843 Arg Leu Phe His Pro Gly Glu His Val Arg Asp Cys Leu Ser Asp Leu 565 570 575 580 CTG GGT CAT CCC TTC TTT TGG ACT TGG GAG AGC CGC TAT AGG ACG CTT 1891 Leu Gly His Pro Phe Phe Trp Thr Trp Glu Ser Arg Tyr Arg Thr Leu 585 590 595 -135- CGG AAT GTG GGA AAT GAA TCC GAC ATC AAA ACA CGA AAA TCT GAA AGT 1939 Arg Asn Val Gly Asn Glu Ser Asp He Lys Thr Arg Lys Ser Glu Ser 600 605 610 GAG ATC CTC AGA CTA CTG CAA CCT GGG CCT TCT GAA CAT TCC AAA AGT 1987 Glu He Leu Arg Leu Leu Gin Pro Gly Pro Ser Glu His Ser Lys Ser 615 620 625 TTT GAC AAG TGG ACG ACT AAG ATT AAT GAA TGT GTT ATG AAA AAA ATG 2035 Phe Asp Lys Trp Thr Thr Lys He Asn Glu Cys Val Met Lys Lys Met 630 635 640 AAT AAG TTT TAT GAA AAA AGA GGC AAT TTC TAC CAG AAC ACT GTG GGT 2083 Asn Lys Phe Tyr Glu Lys Arg Gly Asn Phe Tyr Gin Asn Thr Val Gly 645 650 655 660 GAT CTG CTA AAG TTC ATC CGG AAT TTG GGA GAA CAC ATT GAT GAA GAA 2131 Asp Leu Leu Lys Phe He Arg Asn Leu Gly Glu His He Asp Glu Glu 665 670 675 AAG CAT AAA AAG ATG AAA TTA AAA ATT GGA GAC CCT TCC CTG TAT TTT 2179 Lys His Lys Lys Met Lys Leu Lys He Gly Asp Pro Ser Leu Tyr Phe 680 685 690 CAG AAG ACA TTT CCA GAT CTG GTG ATC TAT GTC TAC ACA AAA CTA CAG 2227 Gin Lys Thr Phe Pro Asp Leu Val He Tyr Val Tyr Thr Lys Leu Gin 695 700 705 AAC ACA GAA TAT AGA AAG CAT TTC CCC CAA ACC CAC AGT CCA AAC AAA 2275 Asn Thr Glu Tyr Arg Lys His Phe Pro Gin Thr His Ser Pro Asn Lys 710 715 720 CCT CAG TGT GAT GGA GCT GGT GGG GCC AGT GGG TTG GCC AGC CCT GGG 2323 Pro Gin Cys Asp Gly Ala Gly Gly Ala Ser Gly Leu Ala Ser Pro Gly 725 730 735 740 TGC TGATGGACTG ATTTGCTGGA GTTCAGGGAA CTACTTATTA GCTGTAGAGT 2376 Cys CCTTGGCAAA TCACAACATT CTGGGCCTTT TAACTCACCA GGTTGCTTGT GAGGGATGAG 2436 TTGCATAGCT GATATGTCAG TCCCTGGCAT CGTGTATTCC ATATGTCTAT AACAAAAGCA 2496 ATATATACCC AGACTACACT AGTCCATAAG CTTTACCCAC TAACTGGGAG GACATTCTGC 2556 TAAGATTCCT TTTGTCAATT GCACCAAAAG AATGAGTGCC TTGACCCCTA ATGCTGCATA 2616 TGTTACAATT CTCTCACTTA ATTTTCCCAA TGATCTTGCA AAACAGGGAT TATCATCCCC 2676 ATTTAAGAAC TGAGGAACCT GAGACTCAGA GAGTGTGAGC TACTGGCCCA AGATTATTCA 2736 ATTTATACCT AGCACTTTAT AAATTTATGT GGTGTTATTG GTACCTCTCA TTTGGGCACC 2796 TTAAAACTTA ACTATCTTCC AGGGCTCTTC CAGATGAGGC CCAAAACATA TATAGGGGTT 2856 CCAGGAATCT CATTCATTCA TTCAGTATTT ATTGAGCATC TAGTATAAGT CTGGGCACTG 2916 GATGCATGAA TT 2928 -136- (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 741 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Glu Ser Arg Asp His Asn Asn Pro G n Glu Gly Pro Thr Ser Ser 1 5 10 15 Ser' Gly Arg Arg Ala Ala Val Glu Asp Asn His Leu Leu He Lys Ala 20 25 30 Val Gin Asn Glu Asp Val Asp Leu Val Gin Gin Leu Leu Glu Gly Gly 35 40 45 Ala Asn Val Asn Phe Gin Glu Glu Glu Gly Gly Trp Thr Pro Leu His 50 55 60 Asn Ala Val Gin Met Ser Arg Glu Asp He Val Glu Leu Leu Leu Arg 65 70 75 80 His Gly £la Asp Pro. Val Leu Arg Lys Lys Asn Gly Ala Thr Pro Phe 85 90 95 He Leu Ala Ala He Ala Gly Ser Val Lys Leu Leu Lys Leu Phe Leu 100 105 110 Ser Lys Gly Ala Asp Val Asn Glu Cys Asp Phe Tyr Gly Phe Thr Ala 115 120 125 Phe Met Glu Ala Ala-Val Tyr Gly Lys Val Lys Ala Leu Lys Phe Leu 130 135 140 Tyr Lys Arg Gly Ala Asn Val Asn Leu Arg Arg Lys Thr Lys Glu Asp 145 150 155 160 Gin Glu Arg Leu Arg Lys Gly Gly Ala Thr Ala Leu Met Asp Ala Ala 165 170 175 Glu Lys Gly His Val Glu Val Leu Lys He Leu Leu Asp Glu Met Gly 180 185 190 Ala Asp Val Asn Ala Cys Asp Asn Met Gly Arg Asn Ala Leu He His 195 200 205 Ala Leu Leu Ser Ser Asp Asp Ser Asp Val Glu Ala He Thr His Leu 210 215 220 Leu Leu Asp His Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lys 225 230 235 240 Thr Pro Leu He Leu Ala Val Glu Lys Lys His Leu Gly Leu Val ' Gin 245 250 255 -137- Arg Leu Leu Glu Gin Glu His He Glu He λan Asp Thr Asp Ser Asp 260 265 270 Gly Lys Thr Ala Leu Leu Leu Ala Val Glu Leu Lys Leu Lys Lys He 275 280 285 Ala Glu Leu Leu Cys Lys Arg Gly Ala Ser Thr Asp Cys Gly Asp Leu 290 295 300 Val Met Thr Ala Arg Arg Asn Tyr Asp His Ser Leu Val Lys Val Leu 305 310 315 320 Leu Ser His Gly Ala Lys Glu Asp Phe His Pro Pro Ala Glu Asp Trp 325 330 335 Lys Pro Gin Ser Ser His Trp Gly Ala Ala Leu Lys Asp Leu His Arg 340 345 350 He Tyr Arg Pro Met He Gly Lys Leu Lys Phe Phe He Asp Glu Lys 355 360 365 Tyr Lys He Ala Asp Thr Ser Glu Gly Gly He Tyr Leu Gly Phe Tyr 370 375 380 Glu Lys Gin Glu Val Ala Val Lys Thr Phe Cys Glu Gly Ser Pro Arg 385 390 395 400 Ala Gin Arg Glu Val Ser Cys Leu Gin Ser Ser Arg Glu Asn Ser His 405 410 415 Leu Val Thr Phe Tyr Gly Ser Glu Ser His Arg Gly His Leu Phe Val 420 425 430 Cys Val Thr Leu Cys Glu Gin Thr Leu Glu Ala Cys Leu Asp Val His 435 440 445 Arg Gly Glu Asp Val"Glu Asn Glu Glu Asp Glu Phe Ala Arg Asn Val 450 455 460 Leu Ser Ser He Phe Lys Ala Val Gin Glu Leu His Leu Ser Cys Gly 465 470 475 480 Tyr Thr His Gin Asp Leu Gin Pro Gin Asn He Leu He Asp Ser Lys 485 490 495 Lys Ala Ala His Leu Ala Asp Phe Asp Lys Ser He Lys Trp Ala Gly 500 505 510 Asp Pro Gin Glu Val Lys Arg Asp Leu Glu Asp Leu Gly Arg Leu Val 515 520 525 Leu Tyr Val Val Lys Lys Gly Ser He Ser Phe Glu Asp Leu Lys Ala 530 535 540 Gin Ser Asn Glu Glu Val Val Gin Leu Ser Pro Asp Glu Glu Thr Lys 545 550 555 560 Asp Leu He His Arg Leu Phe His Pro Gly Glu His Val Arg Asp Cys 565 570 575 -138- Leu Ser Asp Leu Leu Gly His Pro Phe Phe Trp Thr Trp Glu Ser Arg 580 585 590 Tyr Arg Thr Leu Arg Asn Val Gly Asn Glu Ser Asp He Lys Thr Arg 595 600 605 Lys Ser Glu Ser Glu He Leu Arg Leu Leu Gin Pro Gly Pro Ser Glu 610 615 620 His Ser Lys Ser Phe Asp Lys Trp Thr Thr Lys He Asn Glu Cys Val 625 630 635 640 Met Lys Lys Met Asn Lys Phe Tyr Glu Lys Arg Gly Asn Phe Tyr Gin 645 650 655 Asn Thr Val Gly Asp Leu Leu Lys Phe He Arg Asn Leu Gly Glu His 660 665 670 He Asp Glu Glu Lys His Lys Lys Met Lys Leu Lys He Gly Asp Pro 675 680 685 Ser Leu Tyr Phe Gin Lys Thr Phe Pro Asp Leu Val He Tyr Val Tyr 690 695 700 Thr Lys Leu Gin Asn Thr Glu Tyr Arg Lys His Phe Pro Gin Thr His 705 710 715 720 Ser Pro Asn Lys Pro Gin Cys Asp Gly Ala Gly Gly Ala Ser Gly Leu 725 730 735 Ala Ser Pro Gly Cys 740 (2) INFORMATION FOR SEQ ID NO:5: . (i) SEQUENCE CHARACTERISTICS: (A) LENGTH-: 2200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 164..2200 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATTCGGCACG AGGAAGGTGC CAATTACTAG CTCCCTTCTT TATTCGTGTA CTGATGAGAT 60 GTCAGAAGAC AGAACATAAT CAGCCCAATC CCTACTCCAA GACTCTCATT GTGTCCCAAA 120 GAAλCACACG TGTGCATTTC CCAAGGAAAA GGCATTGAGG ACC ATG GAG ACC CCG 175 Met Glu Thr Pro 1 GAT TAT AAC ACA CCT CAG GGT GGA ACC CCA TCA GCG GGAΑGT CAG AGG 223 -139- Asp Tyr Asn Thr Pro Gin Gly Gly Thr Pro Ser Ala Gly Ser Gin Arg 5 10 15 20 ACC GTT GTC GAA GAT GAT TCT TCG TTG ATC AAA GCT GTT CAG AAG GGA 271 Thr Val Val Glu Asp Asp Ser Ser Leu He Lys Ala Val Gin Lys Gly 25 30 35 GAT GTT GTC AGG GTC CAG CAA TTG TTA GAA AAA GGG GCT GAT GCC AAT 319 Asp Val Val Arg Val Gin Gin Leu Leu Glu Lys Gly Ala Asp Ala Asn 40 45 50 GCC TGT GAA GAC ACC TGG GGC TGG ACA CCT TTG CAC AAC GCA GTG CAA 367 Ala Cys Glu Asp Thr Trp Gly Trp Thr Pro Leu His Asn Ala Val Gin 55 60 65 GCT GGC AGG GTA GAC ATT GTG AAC CTC CTG CTT AGT CAT GGT GCT GAC 415 Ala Gly Arg Val Asp He Val Asn Leu Leu Leu Ser His Gly Ala Asp 70 75 80 CCT CAT CGG AGG AAG AAG AAT GGG GCC ACC CCC TTC ATC ATT GCT GGG 463 Pro His Arg Arg Lys Lys Asn Gly Ala Thr Pro Phe He He Ala Gly 85 90 95 100 ATC CAG GGA GAT GTG AAA CTG CTC GAG ATT CTC CTC TCT TGT GGT GCA 511 He Gin Gly Asp Val Lys Leu Leu Glu He Leu Leu Ser Cys Gly Ala 105 110 115 GAC GTC AAT GAG TGT GAC GAG AAC GGA TTC ACG GCT TTC ATG GAA GCT 559 Asp Val Asn Glu Cys Asp Glu Asn Gly Phe Thr Ala Phe Met Glu Ala 120 125 130 GCT GAG CGT GGT AAC GCT GAA GCC TTA AGA TTC CTT TTT GCT AAG GGA 607 Ala Glu Arg Gly Asn Ala Glu Ala Leu Arg Phe Leu Phe Ala Lys Gly 135 140 145 GCC AAT GTG AAT TTG CGA CGA CAG ACA ACG AAG GAC AAA AGG CGA TTG 655 Ala Asn Val Asn Leu "Arg Arg Gin Thr Thr Lys Asp Lys Arg Arg Leu 150 155 160 AAG CAA GGA GGC GCC ACA GCT CTC ATG AGC GCT GCT GAG AAG GGC CAC 703 Lys G n Gly Gly Ala Thr Ala Leu Met Ser Ala Ala Glu Lys Gly His 165 170 175 180 CTG GAA GTC CTG AGA ATT CTC CTC AAT GAC ATG AAG GCA GAA GTC GAT 751 Leu Glu Val Leu Arg He Leu Leu Asn Asp Met Lys Ala Glu Val Asp 185 190 195 GCT CGG GAC AAC ATG GGC AGA AAT GCC CTG ATC CGT ACT CTG CTG AAC 799 Ala Arg Asp Asn Met Gly Arg Asn Ala Leu He Arg Thr Leu Leu Asn 200 205 210 TGG GAT-"TGT GAA AAT GTG GAG GAG ATT ACT TCA ATC CTG ATT CAG CAC 847 Trp Asp Cys Glu Asn Val Glu Glu He Thr Ser He Leu He Gin His 215 220 225 GGG GCT GAT GTT AAC GTG AGA- GGA GAA AGA GGG AAA ACA CCC CTC ATC 895 Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lys Thr Pro Leu He 230 235 240 GCA GCA GTG GAG AGG AAG CAC ACA GGC TTG GTG CAG ATG CTC CTG AGT 943 - 140- Ala Ala Val Glu Arg Lys His Thr Gly Leu Val Gin Met Leu Leu Ser 245 250 255 260 CGG GAA GGC ATA AAC ATA GAT GCC AGG GAT AAC GAG GGC AAG ACA GCT 991 Arg Glu Gly He Asn He Asp Ala Arg Asp Asn Glu Gly Lys Thr Ala 265 270 275 CTG CTA ATT GCT GTT GAT AAA CAA CTG AAG GAA ATT GTC CAG TTG CTT 1039 Leu Leu He Ala Val Asp Lys Gn Leu Lys Glu He Val Gin Leu Leu 280 285 290 CTT GAA AAG GGA GCT GAT AAG TGT GAC GAT CTT GTT TGG ATA GCC AGG 1087 Leu Glu Lys Gly Ala Asp Lys Cys Asp Asp Leu Val Trp He Ala Arg 295 300 305 AGG AAT CAT GAC TAT CAC CTT GTA AAG CTT CTC CTC CCT TAT GTA GCT 1135 Arg Asn His Asp Tyr His Leu Val Lys Leu Leu Leu Pro Tyr Val Ala 310 315 320 AAT CCT GAC ACC GAC CCT CCT GCT GGA GAC TGG TCG CCT CAC AGT TCA 1183 Asn Pro Asp Thr Asp Pro Pro Ala Gly Asp Trp Ser Pro His Ser Ser 325 330 335 340 CGT TGG GGG ACA GCC TTG AAA AGC CTC CAC AGT ATG ACT CGA CCC ATG 1231 Arg Trp Gly Thr Ala Leu Lys Ser Leu His Ser Met Thr Arg Pro Met 345 350 355 ATT GGC AAA CTC AAG ATC TTC ATT CAT GAT GAC TAT AAA ATT GCT GGC 1279 He Gly Lys. Leu Lys He Phe He His Asp Asp Tyr Lys He Ala Gly 360 365 370 ACT TCC GAA GGG GCT GTC TAC CTA GGG ATC TAT GAC AAT CGA GAA GTG 1327 Thr Ser Glu Gly Ala Val Tyr Leu Gly He Tyr Asp Asn Arg Glu Val 375 380 385 GCT GTG AAG GTC TTC CGT GAG AAT AGC CCA CGT GGA TGT AAG GAA GTC 1375 Ala Val Lys Val Phe -Arg Glu Asn Ser Pro Arg Gly Cys Lys Glu Val 390 395 400 TCT TGT CTG CGG GAC TGC GGT GAC CAC AGT AAC TTA GTG GCT TTC TAT 1423 Ser Cys Leu Arg Asp Cys Gly Asp His Ser Asn Leu Val Ala Phe Tyr 405 410 415 420 GGA AGA GAG GAC GAT AAG GGC TGT TTA TAT GTG TGT GTG TCC CTG TGT 1471 Gly Arg Glu Asp Asp Lys Gly Cys Leu Tyr Val Cys Val Ser Leu Cys 425 430 435 GAG TGG ACA CTG GAA GAG TTC CTG AGG TTG CCC AGA GAG GAA CCT GTG 1519 Glu Trp Thr Leu Glu Glu Phe Leu Arg Leu Pro Arg Glu Glu Pro Val 440 445 450 GAG AAC GGG GAA GAT AAG TTT GCC CAC AGC ATC CTA TTA TCT ATA TTT 1567 Glu Asn Gly Glu Asp Lys Phe Ala His Ser He Leu Leu Ser He Phe 455 460 465 GAG GGT GTT CAA AAA CTA CAC TTG CAT GGA TAT TCC CAT CAG GAC CTG 1615 Glu Gly Val Gin Lys Leu His Leu His Gly Tyr Ser His Gin Asp Leu 470 475 480 CAA CCA CAA AAC ATC TTA ATA GAT TCC AAG AAA GCT GTC CGG CTG GCA 1663 - 141- G n Pro G n Asn He Leu He Asp Ser Lye Lys Ala Val Arg Leu Ala 485 490 495 500 GAT TTT GAT CAG AGC ATC CGA TGG ATG GGA GAG TCA CAG ATG GTC AGG 1711 Asp Phe Asp Gin Ser He Arg Trp Met Gly Glu Ser Gin Met Val Arg 505 510 515 AGA GAC TTG GAG GAT CTT GGA CGG CTG GTT CTC TAC GTG GTA ATG AAA 1759 Arg Asp Leu Glu Asp Leu Gly Arg Leu Val Leu Tyr Val Val Met Lys 520 525 530 GGT GAG ATC CCC TTT GAG ACA CTA AAG ACT CAG AAT GAT GAA GTG CTG 1807 Gly Glu He Pro Phe Glu Thr Leu Lys Thr Gin Asn Asp Glu Val Leu 535 540 545 CTT ACA ATG TCT CCA GAT GAG GAG ACT AAG GAC CTC ATT CAT TGC CTG 1855 Leu Thr Met Ser Pro Asp Glu Glu Thr Lys Asp Leu He His Cys Leu 550 555 560 TTT TCT CCT GGA GAA AAT GTC AAG AAC TGC CTG GTA GAC CTG CTT GGC 1903 Phe Ser Pro Gly Glu Asn Val Lys Asn Cys Leu Val Asp Leu Leu Gly 565 570 575 580 CAT CCT TTC TTT TGG ACT TGG GAG AAC CGC TAT AGA ACA CTC CGG AAT 1951 His Pro Phe Phe Trp Thr Trp Glu Asn Arg Tyr Arg Thr Leu Arg Asn 585 590 595 GTG GGA AAT GAA TCT GAC ATC AAA GTA CGG AAA TGT AAA AGT GAT CTT 1999 Val Gly Asn Glu Ser Asp He Lys Val Arg Lys Cys Lys Ser Asp Leu 600 605 610 CTC AGA CTA CTG CAG CAT CAG ACA CTT GAG CCT CCC AGA AGC TTT GAC 2047 Leu Arg Leu Leu Gin His Gin Thr Leu Glu Pro Pro Arg Ser Phe Asp 615 620 625 CAG TGG ACA TCT AAG ATC GAC AAA AAT GTT ATG GAT GAA ATG AAT CAT 2095 Gin Trp Thr Ser Lys -He Asp Lys Asn Val Met Asp Glu Met Asn His 630 635 640 TTC TAC GAA AAG AGA AAA AAA AAC CCT TAT CAG GAT ACT GTA GGT GAT 2143 Phe Tyr Glu Lys Arg Lys Lys Asn Pro Tyr Gin Asp Thr Val Gly Asp 645 650 655 660 CTG CTG AAG TTT ATT CGG AAT ATA GGC GAA CAC ATC AAT GAG GAA AAA 2191 Leu Leu Lys Phe He Arg Asn He Gly Glu His He Asn Glu Glu Lys 665 670 675 AAG CGG GGG 2200 Lys Arg Gly (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 679 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein -142- (xi) SEQUENCE DESCRIPTION: SEQ IS NO:6: Met Glu Thr Pro Asp Tyr Asn Thr Pro Gin Gly Gly Thr Pro Ser Ala 1 5 10 15 Gly Ser Gin Arg Thr Val Val Glu Asp Asp Ser Ser Leu He Lys Ala 20 25 30 Val Gin Lys Gly Asp Val Val Arg Val Gn Gin Leu Leu Glu Lys Gly 35 40 45 Ala Asp Ala Asn Ala Cys Glu Asp Thr Trp Gly Trp Thr Pro Leu His 50 55 60 Asn Ala Val Gin Ala Gly Arg Val Asp He Val Asn Leu Leu Leu Ser 65 70 75 80 His Gly Ala Asp Pro His Arg Arg Lys Lys Asn Gly Ala Thr Pro Phe 85 90 95 He He Ala Gly He Gin Gly Asp Val Lys Leu Leu Glu He Leu Leu 100 105 110 Ser Cys Gly Ala Asp Val Asn Glu Cys Asp Glu Asn Gly Phe Thr Ala 115 120 125 Phe Met Glu Ala Ala Glu Arg Gly Asn Ala Glu Ala Leu Arg Phe Leu 130 135 140 Phe Ala Lys Gly Ala Asn Val Asn Leu Arg Arg Gin Thr Thr Lys Asp 145 150 155 160 Lys Arg Arg Leu Lys Gin Gly Gly Ala Thr Ala Leu Met Ser Ala Ala 165 170 175 Glu Lys Gly His Leu-Glu Val Leu Arg He Leu Leu Asn Asp Met Lys 180 185 190 Ala Glu Val Asp Ala Arg Asp Asn Met Gly Arg Asn Ala Leu He Arg 195 200 205 Thr Leu Leu Asn Trp Asp Cys Glu Asn Val Glu Glu He Thr Ser He 210 215 220 Leu He Gin His Gly Ala Asp Val Asn Val Arg Gly Glu Arg Gly Lys 225 230 235 240 Thr Pro Leu He Ala Ala Val Glu Arg Lys His Thr Gly Leu Val G n 245 250 255 Met Leu Leu Ser Arg Glu Gly He Asn He Asp Ala Arg Asp Asn Glu 260 265 270 Gly Lys Thr Ala Leu Leu He Ala Val Asp Lys G n Leu Lys Glu He 275 280 285 Val Gin Leu Leu Leu Glu Lys Gly Ala Asp Lys Cys Asp Asp Leu'Val 290 295 300 -143- Trp He Ala Arg Arg Asn His Asp Tyr His Leu Val Lys Leu Leu Leu 305 310 315 320 Pro Tyr Val Ala Asn Pro Asp Thr Asp Pro Pro Ala Gly Asp Trp Ser 325 330 335 Pro His Ser Ser Arg Trp Gly Thr Ala Leu Lys Ser Leu His Ser Met 340 345 350 Thr Arg Pro Met He Gly Lys Leu Lys He Phe He His Asp Asp Tyr 355 360 365 Lys He Ala Gly Thr Ser Glu Gly Ala Val Tyr Leu Gly He Tyr Asp 370 375 380 Asn Arg Glu Val Ala Val Lys Val Phe Arg Glu Asn Ser Pro Arg Gly 385 390 395 400 Cys Lys Glu Val Ser Cys Leu Arg Asp Cys Gly Asp His Ser Asn Leu 405 410 415 Val Ala Phe Tyr Gly Arg Glu Asp Asp Lys Gly Cys Leu Tyr Val Cys 420 425 430 Val Ser Leu Cys Glu Trp Thr Leu Glu Glu Phe Leu Arg Leu Pro Arg 435 440 445 Glu Glu Pro Val Glu Asn Gly Glu Asp Lys Phe Ala His Ser He Leu 450 455 460 Leu Ser He Phe Glu Gly Val Gin Lys Leu His Leu His Gly Tyr Ser 465 470 475 480 His Gin Asp Leu Gin Pro Gin Asn He Leu He Asp -Ser Lys Lys Ala 485 490 495 Val Arg Leu Ala Asp "Phe Asp Gin Ser He Arg Trp Met Gly Glu Ser 500 505 510 Gin Met Val Arg Arg Asp Leu Glu Asp Leu Gly Arg Leu Val Leu Tyr 515 520 525 Val Val Met Lys Gly Glu He Pro Phe Glu Thr Leu Lys Thr Gin Asn 530 535 540 Asp Glu Val Leu Leu Thr Met Ser Pro Asp Glu Glu Thr Lys Asp Leu 545 550 555 560 He His Cys Leu Phe Ser Pro Gly Glu Asn Val Lys Asn Cys Leu Val 565 570 575 Asp Le Leu Gly His Pro Phe Phe Trp Thr Trp Glu Asn Arg Tyr Arg 580 585 590 Thr Leu Arg Asn Val Gly Aan Glu Ser Asp He Lys Val Arg Lys Cys 595 600 605 Lys Ser Asp Leu Leu Arg Leu Leu G n His G n Thr Leu Glu Pro Pro 610 615 620 -144- Arg Ser Phe Asp Gin Trp Thr Ser Lys He Asp Lys Asn Val Met Asp 625 630 635 640 Glu Met Asn His Phe Tyr Glu Lys Arg Lys Lys Asn Pro Tyr Gin Asp 645 650 655 Thr Val Gly Asp Leu Leu Lys Phe He Arg Asn He Gly Glu His He 660 665 670 Asn Glu Glu Lys Lye Arg Gly 675 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 190 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein \ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Asp Arg Arg Lys Pro Arg Gin Asn Asn Arg Arg Asp Arg Asn Glu Arg 1 5 10 15 Arg Asp Thr Arg Ser Glu Arg Thr Glu Gly Ser Asp Asn Arg Glu Glu 20 25 30 Asn Arg Arg Asn Arg Arg Gin Ala Gin Gin Gin Thr Ala Glu Thr Arg 35 40 45 Glu Ser Arg Gin Gin Ala Glu Val Thr Glu Lyε Ala Arg Thr Ala Asp 50 55 60 Glu Gin Gin Ala Pro Arg Arg Glu Arg Ser Arg Arg Arg Asn Asp Asp 65 70 75 80 Lys Arg Gin Ala Gin Gin Glu Ala Lys Ala Leu Asn Val Glu Glu Gin 85 90 95 Ser Val Gin Glu Thr Glu Gin Glu Glu Arg Val Arg Pro Val Gin Pro 100 105 110 Arg Arg Lys Gin Arg Gin Leu Asn Gin Lys Val Arg Tyr Glu Gin Ser 115 120 125 Val Ala Glu Glu Ala Val Val Ala Pro Val Val Glu Glu Thr Val Ala 130 135 140 Ala Glu Pro He Val Gin Glu Ala Pro Ala Pro Arg Thr Glu Leu Val 145 150 155 160 Lyε Val Pro Leu Pro Val Val Ala Gin Thr Ala Pro Glu Gin Gin Glu 165 170 175 Glu Asn Asn Ala Asp Asn Arg Asp Asn Gly Gly Met Pro Ser -145- 180 185 190 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2562 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CAGTTTCTGG AGCAAATTCA GTTTGCCTTC CTGGATTTGT CTTTAGCAGT TCTTCCATCT GACTCAGGTT TGCTTCTCTG CCACACTTCC GTGATTATCT GCGTGCATTT TGGACAAAGC GAAGAAATGG CTGGTGATCT TTCAGCAGGT TTCTTCATGG CAGAAGCAGG GAGTAGTACT TAAATATCAA GAACTGCCTA AGGAGGTTTA CATTTCAAGT TATAATAGAT GGAAGAGAAT TCAAAGAAGG AAGCAAAAAA TGCCGCAGCC AAATTAGCTG AAGAAGGCAG TTAGTCCTTT ATTATTGACA ACAACGAATT GGGAATTACA TAGGCCTTAT CAATAGAATT GCCCAGAAGA GAACAGTGTG CATCGGGGGT GCATGGGCCA GAAGGATTTC CAGAAAGAAT ATAGTATTGG TACAGGTTCT ACTAAACAGG AAACTTGCAT ATCTTCAGAT ATTATCAGAA GAAACCTCAG TCTGGTTCTT TTGCTACTAC GTGTGAGTCC CAAAGCAACT GCTTCTGAAT CATCATCTGA AGGTGACTTC CAGCAGATA AGTGACAGTT TAAACAGTTC TTCGTTGCTT ATGAATGGTC GCAAAAAGAT CTTTGGCACC CAGATTTGAC CTTCCTGACA GTGGACAAGA GGTTTGGCAT GGATTTTAAA GAAATAGAAT GGCCAAGTTT TCAAAGCAAA ACACAGAATT GACGGAAAGA AAATATAATA ACGAGAAGGC GGAGCGTGAA GTAAAAGCAT AATATTGTTC ACTACAATGG CTGTTGGGAT GGATTTGATT GATTCTCTTG AGAGCAGTGA TTATGATCCT GAGAACAGCA ACTAAGTGCC TTTTCATCCA AATGGAATTC TGTGATAAAG -146- GAAAAAAGAA GAGGCGAGAA ACTAGACAAA GTTTTGGCTT ACAAAAGGGG TGGATTATAT ACATTCAAAA AAATTAATTC AATATATTCT TAGTAGATAC AAAACAAGTA AAGATTGGAG CTGAAAAATG ATGGAAAGCG AACAAGGAGT AGGGGAACTT CAGATTTCTT CGCAAGACTA TGGAAAGGAA GTGGACCTCT GCTGAACTTC TTCATGTATG TGACACTGCT TTTGAAACAT CGGGATGGCA TCATCTCAGA TATATTTGAT AAAAAAGAAA CTCTCAAAGA AACCTGAGGA TCGACCTAAC ACATCTGAAA TGGAAGAAAA GCCCAGAGAA AAATGAACGA CACACATGTT TCCTGCTTCT GATATGCAGT TTTCCTTAAA TTATCTAAAA GATATTTACC TTTTATTTTA ATGTTTCCTT TAATTTTTTA GCAGAAACAG AAAGGTTTTC TTCTTTTTGC TTCAAAAACA CTGGCTCATC TCTTTATTTT Tl'iΥllΥiΥΪ TTTTAAAGAC AGGCTGGAGT GCAATGACAC AGTCTTGGCT CACTGCAACT GATTCTCCTG CCTCAGCCTC CTGAGTAGCT GGATTACAGG AATTTTTGTG TTTTTAATAA AGACAGGGTT TCACCATGTT CCTGACCTCA AGTAATCCAC CTGCCTCGGC CTCCCAAAGT CCACCGCGCC CAGCCTCATC TCTTTGTTCT AAAGATGGAA TTTTATACTA TTAATGAATC AATCAATTCA TATCTATTTA GGCCAAAAAA ATGTAAGATC GTTCTCTGCC TCACATAGCT ATGGTACTCA TTAAAAAAAA AAAAAAAAAG TGATGTACAA (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 551 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Ala Gly Asp Leu Ser Ala Gly Phe Phe Met Glu Glu Leu Asn Thr 1 5 10 15 Tyr Arg Gin Lys Gin Gly Val Val Leu Lys Tyr Gin Glu Leu Pro Asn -147- 20 25 30 Ser Gly Pro Pro His Asp Arg Arg Phe Thr Phe G n Val He He Asp 35 40 45 Gly Arg Glu Phe Pro Glu Gly Glu Gly Arg Ser Lys Lys Glu Ala Lys 50 55 60 Asn Ala Ala Ala Lys Leu Ala Val Glu He Leu Asn Lys Glu Lys Lys 65 70 75 80 Ala Val Ser Pro Leu Leu Leu Thr Thr Thr Asn Ser Ser Glu Gly Leu 85 90 95 Ser Met Gly Asn Tyr He Gly Leu He Asn Arg He Ala Gin Lyε Lys 100 105 110 Arg Leu Thr Val Asn Tyr Glu Gin Cys Ala Ser Gly Val His Gly Pro 115 120 125 Glu Gly Phe His Tyr Lys Cys Lys Met Gly Gin Lys Glu Tyr Ser He 130 135 140 Gly Thr Gly Ser Thr Lys Gin Glu Ala Lys Gin Leu Ala Ala Lys Leu 145 150 155 160 Ala Tyr Leu Gin He Leu Ser Glu Glu Thr Ser Val Lys Ser Asp Tyr 165 170 175 Leu Ser Ser Gly Ser Phe Ala Thr Thr Cyε Glu Ser Gin Ser Asn Ser 180 185 190 Leu Val Thr Ser Thr Leu Ala Ser Glu Ser Ser Ser Glu Gly Asp Phe 195 200 205 Ser Ala Asp Thr Ser Glu He Asn Ser Asn Ser Asp Ser Leu Asn Ser 210 215 220 Ser Ser Leu Leu Met Asn Gly Leu Arg Asn Asn Gin Arg Lyε Ala Lys 225 230 235 240 Arg Ser Leu Ala Pro Arg Phe Asp Leu Pro Asp Met Lyε Glu Thr Lyε 245 250 255 Tyr Thr Val Asp Lys Arg Phe Gly Met Asp Phe Lys Glu He Glu Leu 260 265 270 He Gly Ser Gly Gly Phe Gly Gin Val Phe Lys Ala Lys His Arg He 275 280 285 Asp Gly Lys Thr Tyr Val He Lys Arg Val Lys Tyr Asn Asn Glu Lys 290 295 300 la Glu Arg Glu Val Lys Ala Leu Ala Lys Leu Asp His Val Asn He 305 310 315 320 Val His Tyr Asn Gly Cys Trp Asp Gly Phe Asp Tyr Asp Pro Glu Thr 325 330 335 Ser Asp Asp Ser Leu Glu Ser Ser Asp Tyr Asp-Pro Glu Asn Ser Lys -148- 340 345 350 Asn Ser Ser Arg Ser Lys Thr Lye Cys Leu Phe He G n Met Glu Phe 355 360 365 Cys Asp Lys Gly Thr Leu Glu G n Trp He Glu Lys Arg Arg Gly Glu 370 375 380 Lys Leu Asp Lys Val Leu Ala Leu Glu Leu Phe Glu G n He Thr Lys 385 390 395 400 Gly Val Asp Tyr He His Ser Lys Lys Leu He His Arg Asp Leu Lyε 405 410 415 Pro Ser Asn He Phe Leu Val Asp Thr Lys Gin Val Lys He Gly Asp 420 425 430 Phe Gly Leu Val Thr Ser Leu Lys Asn Asp Gly Lys Arg Thr Arg Ser 435 440 445 Lys Gly Thr Leu Arg Tyr Met Ser Pro Glu Gin He Ser Ser Gin Asp 450 455 460 Tyr Gly Lys Glu Val Asp Leu Tyr Ala Leu Gly Leu He Leu Ala Glu 465 470 475 480 Leu Leu His Val Cys Asp Thr Ala Phe Glu Thr Ser Lys Phe Phe Thr 485 490 495 Asp Leu Arg Asp Gly He He Ser Asp He Phe Asp Lys Lyε Glu Lys 500 505 510 Thr Leu Leu Gin Lyε Leu Leu Ser Lys Lyε Pro Glu Asp Arg Pro Asn 515 520 525 Thr Ser Glu He Leu Arg Thr Leu Thr Val Trp Lys Lyε Ser Pro Glu 530 535 540 Lys Asn Glu Arg His Thr Cys 545 550 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1650 base pairs (B) TYPE*, nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: AACTGAAACC AACAGCAGTC CAAGCTCAGT CAGCAGAAGA GATAAAAGCA AACAGGTCTG 60 GGAGGCAGTT CTGTTGCCAC TCTCTCTCCT ' GTCAATGATG GATCTCAGAA ATACCCCAGC 120 CAAATCTCTG GACAAGTTCA TTGAAGACTA TCTCTTGCCA GACACGTGTT TCCGCATGCA 180 -149- AATCGACCAT GCCATTGACA TCATCTGTGG GTTCCTGAAG GAAAGGTGCT TCCGAGGTAG 240 CTCCTACCCT GTGTGTGTGT CCAAGGTGGT AAAGGGTGGC TCCTCAGGCA AGGGCACCAC 300 CCTCAGAGGC CGATCTGACG CTGACCTGGT TGTCTTCCTC AGTCCTCTCA GCACTTTTCA 360 GGATCAGTTA AATCGCCGGG GAGAGTTCAT CCAGGAAATT AGGAGACAGC TGGAAGCCTG 420 TCAAAGAGAG AGAGCACTTT CCGTGAAGTT TGAGGTCCAG GCTCCACGCT GGGGCAACCC 480 CCGTGCGCTC AGCTTCGTAC TGAGTTCGCT CCAGCTCGGG GAGGGGGTGG AGTTCGATGT 540 GCTGCCTGCC TTTGATGCCC TGGGTCAGTT GACTGGCAGC TATAAACCTA ACCCCCAAAT 600 CTATGTCAAG CTCATCGAGG AGTGCACCGA CCTβCAGAAA GAGGGCGAGT TCTCCACCTG 660 CTTCACAGAA CTACAGAGAG ACTTCCTGAA GCAGCGCCCC ACCAAGCTCA AGAGCCTCAT 720 CCGCCTAGTC AAGCACTGGT ACCAAAATTG TAAGAAGAAG CTTGGGAAGC TGCCACCTCA 780 GTATGCCCTG GAGCTCCTGA CGGTCTATGC TTGGGAGCGA GGGAGCATGA AAACACATTT 840 CAACACAGCC CAAGGATTTC GGACGGTCTT GGAATTAGTC ATAAACTACC AGCAACTCTG 900 CATCTACTGG ACAAAGTATT ATGACTTTAA AAACCCCATT ATTGAAAAGT ACCTGAGAAG 960 GCAGCTCACσ AAACCCAGGC CTGTGATCCT GGACCCGGCG GACCCTACAG GAAACTTGGG 1020 TGGTGGAGAC CCAAAGGGTT GGAGGCAGCT GGCACAAGAG GCTGAGGCCT GGCTGAATTA 1080 CCCATGCTTT AAGAATTGGG ATGGGTCCCC AGTGAGCTCC TGGATTCTGC TGGCTGAAAG 1140 CAACAGTACA GACGATGAGA CCGACGATCC CAGGACGTAT CAGAAATATG GTTACATTGG 1200 AACACATGAG TACCCTCATT TCTCTCATAG ACCCAGCACG CTCCAGGCAG CATCCACCCC 1260 ACAGGCAGAA GAGGACTGGA CCTGCACCAT CCTCTGAATG CCAGTGCATC TTGGGGGAAA 1320 GGGCTCCAGT GTTATCTGGA CCAGTTCCTT CATTTTCAGG TGGGACTCTT GATCCAGAGA 1380 AGACAAAGCT CCTCAGTGAG CTGGTGTATA ATCCAAQACA GAACCCAAGT CTCCTGACTC 1440 CTGGCCTTCT ATGCCCTCTA TCCTATCATA GATAACATTC TCCACAGCCT CACTTCATTC 1500 CACCTATTCT CTGAAAATAT TCCCTGAGAG AGAACAGAGA GATTTAGATA AGAGAATGAA 1560 ATTCCAGCCT TGACTTTCTT CTGTGCACCT GATGGGAGGG TAATGTCTAA TGTATTATCA 1620 ATAACAATAA AAATAAAGCA AATACCAAAA 1650 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 amino acids (B) TYPE*, amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein -150- (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Met Asp Leu Arg Asn Thr Pro Ala Lys Ser Leu Asp Lys Phe He 1 5 10 15 Glu Asp Tyr Leu Leu Pro Asp Thr Cys Phe Arg Met Gin He Asp His 20 25 30 Ala He Asp He He Cys Gly Phe Leu Lys Glu Arg Cys Phe Arg Gly 35 40 45 Ser Ser Tyr Pro Val Cys Val Ser Lys Val Val Lys Gly Gly Ser Ser 50 55 60 Gly Lys Gly Thr Thr Leu Arg Gly Arg Ser Asp Ala Asp Leu Val Val 65 70 75 80 Phe Leu Ser Pro Leu Thr Thr Phe Gin Asp Gin Leu Asn Arg Arg Gly 85 90 95 Glu Phe Thr Gin Glu He Arg Arg Gin Leu Glu Ala Cys Gin Arg Glu 100 • 105 110 Arg Ala Leu Ser Val Lys Phe Glu Val Gin Ala Pro Arg Trp Gly Asn 115 120 125 Pro Arg Ala Leu Ser Phe Val Leu Ser Ser Leu Gin Leu Gly Glu Gly 130 135 140 Val Glu Phe Asp Val Leu Pro Ala Phe Asp Ala Leu Gly Gin Leu Thr 145 150 155 160 Gly Ser Tyr Lyε Pro Asn Pro Gin He Tyr Val Lys Leu He Glu Glu -165 170 175 Cys Thr Asp Leu Gin Lys Glu Gly Glu Phe Ser Thr Cyε Gly Thr Glu 180 185 190 Leu Gin Arg Asp Phe Leu Lyε Gin Arg Pro Thr Lyε Leu Lys Ser Leu 195 200 205 He Arg Leu Val Lyε His Trp Thr Gin Asn Cys Lys Lyε Lys Leu Gly 210 215 220 Lyε Leu Pro Pro Gin Tyr Ala Leu Glu Leu Leu Thr Val Tyr Ala Trp 225 230 235 240 Glu Arg Gly Ser Met Lys Thr His Phe Asn Thr Ala Gin Gly Phe Arg 245 250 255 Thr Val Leu Glu Leu Val He Asn Tyr Gin Gin Leu Cys He Tyr Trp 260 265 270 He Lys Tyr Tyr Asp Phe Lys Asn Pro He He Glu Lys Tyr Leu Arg 275 280 285 Arg Gin Leu Thr Lys Pro Arg Pro Val He Leu Lys Pro Ala Asp Pro 290 295 300 Thr Gly Asn Leu Gly Gly Gly Asp Pro Lys Gly Trp Arg Gin Leu Ala 305 310 315 320 Gin Glu Ala Glu Ala Trp Leu Asn Tyr Pro Cys Phe Lys Asn Trp Asp 325 330 335 Gly Ser Pro Val Ser Ser Trp He Leu Leu Ala Glu Ser Asn Ser Thr 340 345 350 Asp Asp Glu Thr Asp Asp Pro Arg Thr Tyr Gin Lys Tyr Gly Tyr He 355 360 365 Gly Thr His Glu Tyr Pro His Phe Ser His Arg Pro Ser Thr Leu Gin 370 375 380 Ala Ala Ser Thr Pro G n Ala Glu Glu Asp Trp Thr Cyε Thr He Leu 385 390 395 400 -152- The present invention may, of course, be carried out in other specific ways than those herein set forth without departing from the spirit and essential characteristics of the invention. For example, the nucleotide sequences disclosed herein may be combined with other nucleotide sequences to generate heterologous nucleotide sequences for introduction into the genomes of plants to form transgenic plants. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive and all changes co ing within the meaning and equivalency range of ~~ the appended claims are intended to be embraced herein. Having described our invention, we claim:

Claims: 1. A transgenic plant all of whose cells contain: a.) a first exogenous nucleotide sequence encoding an amino acid sequence having activity identical or equivalent to 2-5A-dependent RNase; b.) a second exogenous nucleotide sequence encoding an amino acid sequence having activity identical or equivalent to 2-5A synthetase; said transgenic plant being more resistant against viral infection than a similar plant which does not contain said first and second exogenous nucleotide sequences. 2. A transgenic plant of claim 1, said transgenic plant being a tobacco plant. 3. A transgenic plant of claim 2, said transgenic tobacco plant being more resistant against the tobacco mosaic virus, the tobacco etch virus and the alfalfa mosaic virus than a similar tobacco plant which does not contain said first and second exogenous nucleotide sequences. 4. A transgenic plant of claim 1, said transgenic plant being selected from the group consisting of vegetable, fruit, grain, tree, flower, grass, weed, and shrub transgenic plants. 5. A transgenic plant of claim 1, said first exogenous nucleotide sequence includes nucleotides designated as 1-2223 in Table 1 or any part of this nucleotide sequence which contains the complete or partial coding sequence for 2-5A-dependent RNase, and said second exogenous nucleotide sequence includes nucleotides designated as 1-1650 in FIG. 20 or any part of this nucleotide sequence which contains the complete or partial coding sequence for 2-5A-synthetase on the double stranded RNA binding domain of 2-5A-synthetase. 6. A transgenic plant of claim 1, said first exogenous nucleotide sequence includes nucleotides designated as 1-2037 in Table 2 or any part of this nucleotide sequence which contains the complete or partial coding sequence for 2-5A-dependent RNase, and said second exogenous nucleotide sequence includes nucleotides designated as 1-1650 in FIG. 20 or any part of this nucleotide sequence which contains the complete or partial coding sequence for 2-5A-synthetase on the double stranded RNA binding domain of 2-5A-synthetase. 7. A transgenic plant of claim 1, said first and second exogenous nucleotide sequence being introduced into said plant via pAM2200 vector. 8. A vector for introduction into a plant for transferring the plant such that the plant expresses a functional 2-5A system, said vector being pAM2200.

Inventors: MITRA AMITAVA, SILVERMAN ROBERT H, MITRA, AMITAVA, SILVERMAN, ROBERT, H.
Applicants: CLEVELAND CLINIC FOUNDATION
Application year: 1996
Main classification: A01H5
IPC codes: A01H5, C12N9, C12N15